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Zusammenfassung 
Sepsis entsteht durch eine Infektion, der oft eine unkontrollierte Entzündungsreaktion folgt 
und die letztendlich in Schock, Organversagen oder Tod münden kann. Jedes Jahr sterben 
allein in Deutschland bis zu 60.000 Menschen an einer Sepsis. Vieles weist darauf hin, dass 
die Sepsis in Zusammenhang mit dem Versagen der Hypothalamus-Hypophysen-
Nebennierenrinden-Achse steht. Es ist bekannt, dass bei septischen Patienten die von den 
Nebennieren freigesetzten Glukokortikoide (Kortisol, Kortikosteron) eine wesentliche Rolle 
während der Unterdrückung einer exzessiven proinflammatorischen Reaktion spielen. Die 
Nebenniereninsuffizienz tritt in großer Anzahl bei Patienten im septischen Schock auf und ist 
verantwortlich für die erhöhte Sterblichkeit der an Sepsis Erkrankten. Im Rahmen des 
angeborenen Immunsystems spielen die sogenannten Toll-like Rezeptoren (TLRs) eine 
bedeutende Rolle bei der Erkennung von pathogen-assoziierten Molekülen. Interaktionen 
zwischen dem Immunsystem und dem endokrinen Stresssystem sind bekannt. Demzufolge ist 
eine gut aufeinander abgestimmte Antwort des adrenalen Systems und des Immunsystems für 
das Überleben während einer schweren Entzündungsreaktion von besonderer Bedeutung. 
 
Die vorliegende Arbeit befasst sich mit der Rolle von TLR-2, TLR-4 und TLR-9 während 
adrenalem Stress. Die Ergebnisse zeigen, dass das Fehlen von TLR-2 oder TLR-4, aber nicht 
TLR-9 zur Änderung der Morphologie der Nebennieren, bezüglich ihrer Größe und zellulären 
Struktur, bei den Mäusen führt. Dennoch scheint diese Änderung den Phänotyp der TLR 
knock-out Mäuse nicht zu beeinträchtigen. Mäuse mit fehlendem TLR-2, 4 oder 9 sind 
unfähig, sich adäquat auf einen inflammatorischen Stress, der durch die entsprechenden 
Liganden Lipopolysaccharid (LPS, TLR-4), Lipoteichonsäure (LTA, TLR-2) oder Cytidin-
Phosphat-Guanosin-Oligodeoxynucleotid (CpG-ODN, TLR-9) hervorgerufen wird, zu 
antworten. Diese verminderte adrenale Stressantwort scheint mit der Abschwächung der 
systemischen und auch der intra-adrenalen Zytokin-Expressionen einherzugehen.  
Zusammenfassend deuten diese Ergebnisse darauf hin, dass TLR-2, 4 und 9 
Schlüsselrezeptoren in der immun-adrenalen Antwort bei Entzündung und SIRS sind. Das 
enge funktionale Verhältnis zwischen den beiden Systemen sollte im Rahmen der Behandlung 
von entzündlichen Krankheiten, bei denen eine intakte adrenale Stressantwort erforderlich ist, 
berücksichtigt werden. Darüber hinaus könnten TLR Polymorphismen zu den zugrunde 
liegenden Mechanismen der beeinträchtigten adrenalen Stressantwort bei Patienten mit 
bakterieller Sepsis beigetragen haben. 3 
Abstract 
Sepsis is caused by infection and often followed by an overwhelming inflammatory response. 
This can lead to shock, organ failure and even death. Each year approximately 60,000 people 
die in Germany due to sepsis. There is good evidence that sepsis is associated with failure of 
the hypothalamic-pituitary-adrenal-axis. In patients with sepsis, glucocorticoids (e.g. 
corticosterone, cortisol) released from adrenal glands play an essential role in preventing an 
excessive pro-inflammatory response. Adrenal insufficiency occurs in a large number of 
patients with septic shock and is associated with an increased mortality. In the innate immune 
system, Toll-like receptors (TLRs) play a crucial role in its onset by recognizing pathogen-
associated molecules. It is well known that there are interactions between the immune and 
endocrine stress systems; glucocorticoids and TLRs regulate each other in a bi-directional 
way. Therefore, a coordinated response of the adrenal and immune system is of vital 
importance for survival during severe inflammation.  
This experimental study focuses on the role of TLR-2, TLR-4 and TLR-9 during adrenal 
stress. The results show that in mice, the absence of TLR-2 and TLR-4, but not TLR-9 leads 
to altered adrenal morphology, relating to size and cellular structure. However, this alteration 
does not appear to compromise the phenotype of TLR knock-out mice. Mice deficient of 
TLR-2, 4 and 9 are not able to respond adequately to inflammatory stress induced by their 
potential ligands lipopolysaccharide (LPS), lipoteichoic acid (LTA) or cytidine phosphate 
guanosine-oligodeoxynucleotides (CpG-ODN). This impaired adrenal stress response appears 
to be associated with a decrease in systemic and intra-adrenal cytokine expressions. Taken 
together, these results suggest that TLR-2, 4 and 9 are key players in the immuno-endocrine 
response during inflammation and SIRS. In conclusion, TLRs play a crucial role in the 
immune-adrenal crosstalk. This close functional relationship needs to be considered in the 
treatment of inflammatory diseases where an intact adrenal stress response is required. 
Furthermore, TLR polymorphisms could contribute to the underlying mechanisms of 
impaired adrenal stress response in patients with bacterial sepsis. 4 
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1 Introduction 
1.1 Background 
Sepsis is one of the major clinical and economic burdens of the world and a leading cause of 
death in intensive care units (ICU). An epidemiological study of the United States showed 
that severe sepsis (sepsis with associated acute organ failure) affects approximately 750,000 
people every year (1995) and accounts for more than 210,000 deaths annually (Angus et al. 
2001). A study by Watson and his co-workers, based on the paediatric hospital discharge 
records in the US, revealed 42,365 cases of paediatric severe sepsis per year (Watson et al. 
2003). Effective prevention and treatments are urgently needed, since the death rate from 
sepsis has climbed more than 90% over the last two decades (Murphy 2000). In the United 
States, the incidence of sepsis increased on average by 9% per year in the last 20 years 
(Martin et al. 2003). From an economic point of view, the annual costs caused by sepsis were 
estimated at $16.7 billion in the US, with the highest costs due to infants, non-survivors, ICU 
patients, surgical patients and those with failure of more than one organ (Angus et al. 2001). 
 
A recent epidemiological study by Engel and co-workers has documented that 154,000 new 
cases of sepsis and severe sepsis occur annually in Germany, an incidence of 226 per 100,000 
inhabitants. This equates to an estimated nation-wide prevalence of 12.4% for sepsis and 
11.0% for severe sepsis. The mortality rates remain high. In Germany, severe sepsis and 
septic shock result in ICU mortality of 48.4% and a remaining hospital mortality of 55.2% 
(Engel et al. 2007). With more than 59,000 deaths, sepsis is the third most frequent cause of 
death in Germany, behind coronary artery disease and cancer. The economic burden of sepsis 
is considerable with average costs per patient of about €25,000 at daily costs of approximately 
€1,500. In Germany, €1.7 billion are spent on the intensive care of sepsis patients annually. 
This accounts for about 32% of the budget of intensive care medicine in Germany [source 
from German Competence Network Sepsis (SepNet) in newsletter no. 17 (Dec.2004): 
Gesundheitsforschung: Forschung für den Menschen. Sepsis fordert viel mehr Todesopfer als 
gedacht. From the German Ministry of Education and Science (BMBF)]. 
In sepsis, increases in rates of morbidity and mortality are due to aging populations. The 
widening use of aggressive and invasive medical procedures and the growth of antimicrobial 
resistance (caused by overuse of antibiotics) make the disease harder to manage (Alarcon et 
al. 2004;Birtles et al. 2004;Johnson et al. 2004;Thongpiyapoom et al. 2004). Sepsis can strike 17 
anyone at anytime, developing from infections associated with for e.g. pneumonia, trauma, 
surgery, burns or cancer. In fact, deaths that are attributed to complications from pneumonia 
or cancer are often actually caused by severe sepsis. An epidemiological study by Williams 
revealed a prevalence of 16.4 cases of severe sepsis per 1000 cancer patients per year in the 
US. Furthermore, the mortality rate for cancer patients with severe sepsis was 37.8% 
(Williams et al. 2004b). Although gram-negative infections (e.g. Escherichia coli, Klebsiella 
species and Pseudomonas aeruginosa) were predominant in the 1960s and early 1970s gram-
positive infections (mainly Staphylococci and Streptococci) have increased in the past two 
decades and now account for about half of cases of severe sepsis (Bochud et al. 2001). In the 
study from Engel et al. (2007), among patients with a microbiologically proven infection, the 
numbers of gram-positive and gram-negative isolates were comparable (55.7 and 54.1%, 
respectively). 
 
Adrenal insufficiency is recognized in 60% of patients with sepsis (Annane et al. 2006) and 
can be absolute or relative. Either of these conditions can be permanent or transient. Absolute 
adrenal insuffiency, as defined by low basal and stimulated cortisol level (usually basal and 
stimulated cortisol concentrations < 560 nM/l), seems to be extremely uncommon in critically 
ill patients (0-3%). In contrast, plasma cortisol levels are usually elevated in patients with 
septic shock. The blunted response to stimulation has been refered to as ‘relative adrenal 
insufficiency’ (Matot and Sprung 1998;Rothwell et al. 1991). This causes adrenergic receptor 
desensitization, a decreased number of both α- and β-adrenergic receptors. This is either 
related to sepsis itself or to the use of vasopressors for long periods of time. Relative adrenal 
insufficiency is probably the most common and most difficult to diagnose and treat in 
critically ill patients. During septic shock, replacement therapy with low ‘physiological’ doses 
of steroid (hydrocortisone and fludrocortisone) showed improved survival (Annane et al. 
2002;Bornstein and Briegel 2003;Burry and Wax 2004). The main effect of low-dose 
glucocorticoids is due to the reversal of suppression of the hypothalamic-pituitary-adrenal 
(HPA)-axis. However, the efficacy of glucocorticoids is related to their endogenous 
catecholamine-enhancing effects (Williamson and Lapointe 2003). 
 
There is evidence to suggest that intact adrenal stress response is very important for a host’s 
defence to infections (Chrousos 1995;Webster and Sternberg 2004). Furthermore, there are 
bi-directional communications between the immune and endocrine systems. Cytokines 
produced by an inflammatory response cause changes in the endocrine system, which include 18 
activation of the HPA-axis. Hormones produced in the endocrine system, especially 
glucocorticoids, affect the immune responses. In addition to hypothalamic hormones 
(corticotrophin releasing hormone (CRH) and vasopressin), inflammatory cytokines such as 
interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-α have been identified as important 
modulators of HPA-axis function (Bornstein and Chrousos 1999;Chrousos 1995). During 
inflammation, these cytokines are capable of maintaining high glucocorticoid output, 
suggesting a shift from neuro-endocrine to immune-endocrine regulation of the adrenal 
(Bornstein et al. 2004a). Therefore, a coordinated response of the adrenal and immune system 
is of vital importance for survival during severe inflammation (Galon et al. 2002;McEwen and 
Seeman 1999;Sapolsky et al. 2000). Moreover, there is evidence that impaired innate immune 
responses mediated by Toll-like receptors (TLRs) may lead to sepsis including multiple organ 
failure (Cook et al. 2004;Li 2004), immunodeficiency (Decker 2004), atherosclerosis (de and 
Pasterkamp 2003) in humans. The initial host defence against bacterial infection by the innate 
immune system essentially requires TLRs, which belong to family of pattern recognition 
receptors (PRRs). They are responsible for the detection and response to conserved microbial 
components by activating an inflammatory signal cascade.  
 
This study investigates whether interactions between the innate immune system and the HPA-
axis exist. Therefore, this study focuses on the signalling pathway of TLR-2, 4 and 9 in 
mediating responses of the adrenal stress system. The role of these three TLRs in the adrenal 
gland during development and progression of inflammatory conditions has not been 
investigated to date. 19 
1.2 Aims of this Study 
This thesis focuses on the following aims:  
1.  Expression of TLR-2, 4 and 9 in murine adrenal glands.  
2.  Expression pattern of these TLRs in adrenals after treatment with a non-lethal dose of 
their potential ligand lipopolysaccharide (LPS), lipoteichoic acid (LTA) or cytidine 
phosphate guanosine-oligodeoxynucleotides (CpG-ODN).  
3.  Alterations in adrenal morphology and function in TLR-2, 4 and 9 deficient mice.  
4.  Effects of the potential ligands on the release of adrenal corticosterone and 
adrenocorticotropic hormone (ACTH) in wild-type (WT) and TLR-2, 4 and 9 deficient 
mice.  
5.  Activation of the transcription factor NF-κB in murine adrenal glands after potential 
ligand stimulation.  
6.  Effects on several inflammatory cytokines during an intra-adrenal stress response 
induced by the potential ligands and in the absence of the respective TLR gene. 20 
2 Review of the Literature 
2.1 Innate Immune System  
The immune system is a large and complex defence network of widely distributed elements in 
the body. The immune system can recognize, control and kill pathogens that gain successful 
entry into the body. There are two types of immunity: innate (natural) and adaptive (specific) 
immunity. 
Although not pathogen specific, the innate immunity is largly responsible for containing and 
limiting the spread of infection. The first line of defence against invading microorganisms is 
the physical barriers, like skin or self-cleaning processes (e.g. sneezing and mucous flow) 
(Tizard 2000). The second line of defence is the inflammatory response, which results in 
increased vascular permeability and increased blood flow in affected tissues followed by an 
accumulation of leukocytes and certain soluble factors. Neutrophils, monocytes and natural 
killer cells migrate to affected areas guided by chemotactic factors, like complement factor 
C5a and IL-8 (Paape et al. 2002). The innate immunity distinguishes self from non-self 
(pathogens) through pattern recognition receptors (PRRs) by recognizing the conserved 
structures of invading microorganisms called pathogen-associated molecular patterns 
(PAMPs) (Aderem and Underhill 1999;Janeway, Jr. 1992). After recognition of transformed 
or infected cells, natural killer cells and T-cells secrete cytokines that play a critical role in 
coordinating the early defence by innate and later by the acquired immune system. In 
addition, evidence in the literature shows that the activation of innate immunity plays a key 
role in stimulating the adaptive immune response (Hoffmann et al. 1999).  
 
Adaptive immunity develops later than the innate immunity and consists of lymphocytes 
activation and their products, including antibodies and cytokines (Vitetta et al. 1991). The 
important difference between innate and adaptive immune system is that the adaptive immune 
response is highly specific to pathogens. Moreover, the response improves with each 
successive encounter of the same pathogen due to the establishment of long-term memory of 
the antigen. The adaptive immunity can be divided into humoral and cell-mediated responses 
and becomes effective only after several days. This is the time required for lymphocytes to 
recognize specific antigens and to proliferate and differentiate into effector cells and finally to 
eradicate the pathogen. In contrast, the innate immunity which consists of antimicrobial 21 
peptides, phagocytes, and complement system is activated immediately after infection and 
controls the replication of the pathogen (Medzhitov and Janeway, Jr. 2000).  
 
 
 
2.2 PRRs and PAMPs 
Innate immune responses are activated rapidly after the introduction of inflammatory stimuli 
to the host. Microbes contain highly conserved molecular structures called PAMPs, including 
cell wall components LPS (Poltorak et al. 1998b), LTA (Lien et al. 1999), peptidoglycan 
(Lien et al. 1999), mannan (starie-Dequeker et al. 1999), glycans (Ozinsky et al. 2000) as well 
as foreign DNA (Hemmi et al. 2000) and double-stranded ribonucleic acid (Alexopoulou et 
al. 2001). Other examples of PAMPs are bacterial lipoproteins and lipoarabinomannan of 
mycobacteria (Medzhitov and Janeway, Jr. 1997b). PAMPs are recognized as ‘foreign’ by 
specific PRRs which are preferentially expressed in monocytes and macrophages as well as in 
other cell types. The receptors can be structurally divided into those containing a leucine-rich 
repeat domain, a calcium-dependent lectin domain or a scavenger receptor protein domain. 
Furthermore, PRRs characterized so far include cluster of differentiation (CD)14 (Viriyakosol 
and Kirkland 1995), β2-integrins (CD11/CD18) (Ehlers 2000), C-type lectins (Keler et al. 
2004;McGreal et al. 2004), macrophage scavenger receptors (Ramet et al. 2001;van der Laan 
et al. 1999) and complement receptors (Humbles et al. 2000). Functionally, they are divided 
into secreted or endocytic proteins or signalling molecules (Medzhitov and Janeway, Jr. 
1997a). Secreted PRRs serve as opsonins and bind to the cell wall of a microbe, tagging it for 
recognition by the complement system. Endocytic PRRs are expressed on the surface of 
phagocytes and mediate phagocytosis and delivery of microbes to lysosomes for degradation. 
Signalling PRRs induce the expression of a variety of acute-phase reaction products. In 
mammals, PAMPs activate the production of bioactive lipids (e.g. platelet-activating factor) 
and cytokines (e.g. IL-1, IL-6 and TNF-α), which all are important in the response to infection 
(Hallman et al. 2001;Janeway, Jr. and Medzhitov 1998;Janeway, Jr. and Medzhitov 
2002;Zhang and Ghosh 2001). 
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2.2.1 LTA 
The cell wall of gram-positive bacteria is structurally simpler than the cell wall of gram-
negative bacteria. No outer lipid layer exists and up to 90% of the cell wall of gram-positive 
bacteria may consist of peptidoglycan. LTA molecules are composed of a repeating glycerol 
phosphate backbone that is substituted with D-alanine, sugars (e.g. glucose) and a single lipid 
side chain, which intercalates into the cytoplasmic membrane (Fischer et al. 1990). The 
chemical structure of LTA derived from Staphylococcus aureus is shown in Fig. 1. LTA 
appears to be crucial for the vital function of the bacteria because their biosynthesis is not 
halted in the absence of phosphate. The biological functions of LTA include binding of metal 
cations by the negatively charged polysaccharide chains (Rose and Hogg 1995) and regulation 
of the activity of autolytic enzymes (Fischer 1988;Fischer 1994). To the host, they represent 
patterns for immune recognition similar to LPS. The amphiphlic LTA molecule resembles 
LPS, in that it forms micelles; it is lipid anchored and carries phosphate as well as repetitive 
subunits of carbohydrates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic structure of LTA derived from Staphylococcus aureus. D-Ala, D-alanine; NAG, N-acetyl-
glucosamine. Modified from http://www3.imperial.ac.uk/cmmi/research/angelikagrundling. 
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2.2.2 LPS 
LPS represents the main outer membrane component of gram-negative bacteria and plays a 
key role in mediating severe gram-negative infection, sepsis and septic shock (Rietschel and 
Brade 1992;Rietschel et al. 1994;Schletter et al. 1995). LPS is now used as a synonym for 
endotoxin since it was discovered in the late 19th century by Richard Pfeiffer (Pfeiffer 1892). 
In contrast to secreted exotoxins of cholera bacteria, this heat stable toxin was found to be a 
constituent of the bacterial cell, thus Pfeiffer named it endotoxin. Although there is a great 
variation between endotoxins (derived from different bacterial serotypes), they all share a 
common structural. A schematic of the structure of LPS is shown in Fig. 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Schematic structure of LPS derived from E. coli (O111:B4). Hep, L-glycerol-D-manno-heptose; Gal, galactose; 
Glc, glucose; KDO, 2-keto-3-deoxyoctonic acid; NGa, N-acetyl-galactosamine; NGc, N-acetyl-glucosamine (Magalhaes et 
al. 2007). 24 
LPS consists of a sugar portion with varying length of polysaccharide chains. The sugar part 
is covalently linked to the hydrophobic part of LPS, lipid A, which anchors the LPS molecule 
to the outer membrane (Schletter et al. 1995). The complex structure of LPS can be further 
divided into the O-specific chain and lipid A. The O-specific chain is the part of LPS that 
shows the largest variation between species and the part that evokes a specific immune 
response. It stimulates the production of antibodies which are able to recognize that particular 
O-chain. The O-chain consists of repeated oligosaccharide units and is attached to the core. 
The core oligosaccharide is divided into outer (linked to the O-chain) and inner core (linked 
to lipid A). The core has a complex structure: It is joined to the lipid A region by 3-deoxy-D-
manno-octulosonic acid, which is an eight carbon sugar. The core structure is conserved for 
each type of bacteria and its biological function is not clear. The structure of lipid A is more 
conserved than that of the core. The lipid A part is responsible for endotoxic properties, 
complement activation and B lymphocyte mitogenicity (Galanos et al. 1985).  
 
 
 
2.2.3 CpG-DNA  
CpG sites are regions of DNA where a cytosine nucleotide occurs next to a guanine 
nucleotide. ‘CpG’ stands for cytosine and guanine separated by a phosphate, which links the 
two nucleosides together in DNA. CpG dinucleotides are more frequent in the genomes of 
bacteria and viruses than of vertebrates. In addition, the cytosines in CpG dinucleotides are 
highly methylated in vertebrates. It can be noted that in mammals, 70-80% of CpG cytosines 
are methylated by DNA methyltransferases (Jabbari and Bernardi 2004). A decreased in CpG 
frequency and cytosine methylation leads to abrogation of the immunostimulatory activity in 
vertebrates. Therefore, unmethylated CpG sites can be used to detect DNA from pathogens. 
 
There are two different subtypes of CpG-DNA: A/D-type CpG-DNA (CpG-A) and B/K-type 
CpG-DNA (CpG-B) (Klinman 2004). CpG-A is characterized by a phosphodiester backbone 
CpG motif and phosphorothioate-modified poly G stretches at the 5′ and 3′ ends. As a TLR-9 
ligand, CpG-A strongly induces interferon (IFN)-α production from plasmacytoid dendritic 
cells (DC) and co-localizes with TLR-9, myeloid differentiation factor 88 (MyD88) and 
interferon regulatory factor (IRF)7 in endosomes in plasmacytoid DC (Hemmi et al. 
2003;Krug et al. 2001). By contrast, CpG-A is rapidly transferred and degraded in the 25 
lysosome in conventional DC and macrophages. However, when CpG-A is relocalized to the 
endosome in conventional DC using a cationic lipid, these cells can produce IFN-α as a 
consequence of activation of the MyD88-IRF7 pathway. On the other hand, CpG-B is 
phosphorothioate-modified throughout the sequence and is known to induce DC maturation 
and B cell proliferation. CpG-B poorly induces type I IFN, but induces inflammatory 
cytokines, also elicits IFN-α induction if it is manipulated to stay longer in the endosome of 
conventional DC (Honda et al. 2005). These findings suggest that retention of the CpG-
DNA/TLR-9 complex in the endosome might cause the induction of robust IFN-α production.  
Furthermore, several reports have shown that DNA without CpG motifs can be a biologically 
active ligand for TLR-9. Oligodeoxynucleotides containing nucleotide derivatives or the 
phosphorothioate backbone along with a bicyclic heterobase structure have immuno-
stimulatory activity through TLR-9 (Kandimalla et al. 2005;Roberts et al. 2005;Vollmer et al. 
2004). Thus, TLR-9 recognizes not just CpG motifs, but DNA itself with certain structures. 
 
 
 
2.3 TLRs 
TLRs are evolutionarily conserved and have been found in insects, plants and mammals. The 
discovery of TLRs was based on identification of Drosophila Toll, which was initially 
characterized as a developmental protein governing the formation of the dorsal-ventral axis in 
Drosophila melanogaster (Anderson et al. 1985;Hashimoto et al. 1988;Morisato and 
Anderson 1995). However, a subsequent study revealed that Drosophila Toll also plays a key 
role in triggering innate immune responses against fungal infection in adult flies (Anderson 
2000;Belvin and Anderson 1996). The first characterized mammalian TLR (first named Toll 
and now termed TLR-4) was found in 1997 by Charles Janeway Jr. and his co-workers 
(Medzhitov et al. 1997). Since then, several proteins structurally related to TLR-4 were 
identified and named TLRs (Rock et al. 1998). To date, 11 TLRs in humans and 13 in mice 
have been identified (Akira 2004;Beutler 2004;Verstak et al. 2007). TLRs 1-9 are conserved 
in humans and mice. TLR-10 is present only in humans and TLR-11 is functional only in 
mice and is silenced by a stop codon in humans. The biological roles, expression patterns, 
ligands and modes of signalling of TLR-10, 12 and 13 remain to be defined. The known 
ligands recognized by these different receptors are summarized in Table 1. 
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TLR Microbial  Ligand  Endogenous  Ligand 
TLR-1/TLR-2  triacyl lipopeptides (bacteria and 
mycobacteria) 
 
TLR-2 
PG (gram-positive bacteria); 
porins (Neisseria); 
lipoarabinomannan (mycobacteria); 
phospholipomannan (Candida albicans); 
glucoronoxylomannan (Cryptococcus 
neoformans); 
tGPI-mutin (Trypanosoma); 
haemagglutinin protein (Measles virus); 
HCMV; 
HSV1 
 
necrotic cells (cellular injury); 
HSP60, HSP70 (cellular injury; 
controversial!); 
gp96 (cellular injury); 
HMGB1 (damaged cells); 
hyaluronate (degradation of extracellular 
matrix); 
fibronectin (release from cells in response to 
tissue damage); 
minimally modified LDL (atherosclerotic 
lesion); 
heparin sulphate (plasma membrane or 
extracellular matrix in injury or 
inflammation); 
HSPB8 (synovial tissue); 
αA crystallin 
TLR-3  dsRNA (viruses)  dsRNA (necrotic cells) 
TLR-4 
LPS (gram-negative bacteria); 
glucuronoxylomannan (Cryptococcus 
neoformans); 
glucoinositolphospholipids (Trypanosoma); 
envelope proteins (RSV, MMTV) 
same ligands as for TLR-2 
TLR-5 flagellin  (flagellated  bacteria)   
TLR-6/TLR-2 
diacyl lipopeptides (Mycoplasma); 
LTA (Group B Streptococcus); 
zymosan (Saccharomyces cerevisiae) 
 
TLR-7 ssRNA  (RNA  viruses) 
ssRNA (dead or dying cells); 
purified snRNPs 
TLR-8 ssRNA  (RNA  viruses) 
ssRNA (dead or dying cells); 
purified snRNPs 
TLR-9 
CpG-DNA (bacteria and mycobacteria); 
haemozoin (Plasmodium); 
DNA (viruses) 
DNA (dead or dying cells) 
TLR-11 
unknown component from uropathogenic 
bacteria; 
profiling-like molecule (Toxoplasma gondii) 
 
 
Table 1: Microbial and endogenous ligands of TLRs. HCMV, human cytomegalovirus; HMGB1, high-mobility group box 
1; HSP, heat shock protein; HSPB8, heat shock 22kDa protein 8; HSV1, herpes simplex virus 1; LDL, low-density 
lipoprotein; LPS, lipopolysaccharide; LTA, lipotechoic acid; MMTV, mouse mammary tumor virus; PG, peptidoglycan; 
RSV, respiratory syncytial virus; snRNPs, small nuclear ribonucleoproteins; tGPI-mucin, glycosylphosphatidylinositol-
anchored mucin-like glycoprotein. Information adapted from Akira et al. 2006;Marshak-Rothstein 2006;Tian et al. 2007. 
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All TLRs share the same structure: a ligand binding extracellular domain (ectodomain) 
consisting of leucine-rich repeats, a single transmembrane α-helix (transmembrane domain), 
and the cytoplasmic domain, known as the Toll/IL-1 receptor (TIR) domain, which couples 
downstream signal transduction to receptor engagement (see Fig. 3). A comparison of the 
sequences of the TLR members reveals five sub-families: TLR-2, 3, 4, 5, and 9. The TLR-2 
subfamily is composed of TLR-1, 2, 6, and 10, while the TLR-9 subfamily is composed of 
TLR-7, 8, and 9 (Takeda et al. 2003). TLRs are PRRs that function as a CD14-associated 
signal inducers, helping cells to recognize and distinguish between pathogens. They also help 
to bridge innate and adaptive immunity by inducing various co-stimulatory and effector 
molecules (Zhang and Ghosh 2001). TLRs sense microbial products (PAMPs) as well as 
endogenous ligands (Tsan and Gao 2004). 
Consistent with their role in pathogen recognition and host defence, TLRs are expressed on 
monocytes/macrophages, neutrophils, dentritic cells, intestinal epithelial cells and endothelial 
cells. These cell types are immediately accessible to microorganisms upon infection (Muzio et 
al. 2000). There are two different mechanisms by which activation of TLRs can contribute to 
host defence. First, activation of TLRs can directly mediate innate responses by regulating 
phagocytosis and triggering anti-microbial activity (Blander and Medzhitov 2004). Second, 
activation of TLRs can trigger the release of cytokines and the differentiation of immature to 
mature dendritic cells, enabling the innate immune system to instruct the adaptive immune 
response (Medzhitov and Janeway, Jr. 1997a). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The structure of TLR-3. A diagram showing the extracellular, transmembrane and cytoplasmic domains of the 
receptor. Toll/IL-1–receptor-containing (TIR) domain.  
Modified from: http://www.bio.indiana.edu/facultyresearch/faculty/Kao.html. 
extracellular domain 
transmembrane domain 
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2.3.1 TLR-2 
TLR-2 distinguishes a variety of microbial components such as lipoproteins from different 
pathogens, peptidoglycans and LTA from gram-positive bacteria (Takeda et al. 2003). 
Furthermore, TLR-2 has been shown to recognize LPS from non-enterobacteria such as 
Leptospira interrogans, Phorphyromonas gingivalis and Helicobacter pyroli (Hirschfeld et al. 
2001;Smith, Jr. et al. 2003;Werts et al. 2001). This LPS structurally differ from the typical 
LPS of gram-negative bacteria (recognized by TLR-4) in the number of acyl chains in the 
lipid A component which presumably confers to differential recognition (Netea et al. 2002). 
One aspect that could explain why TLR-2 recognizes a wide spectrum of microbial 
components is that TLR-2 forms heterophilic dimers with other TLRs such as TLR-1 and 
TLR-6, both are structurally related to TLR-2.  
Studies on TLR-1 and TLR-6 deficient mice have shown the important role of these receptors 
in the recognition of structural differences between lipopeptides. Macrophages from TLR-6 
deficient mice did not produce any inflammatory cytokines in response to lipopetides derived 
from gram-positive bacteria. However, these cells have normal production of inflammatory 
cytokines in response to lipopeptides derived from gram-negative bacteria (Takeuchi et al. 
2001). In contrast, TLR-1 has an impaired response to wall fragments of gram-negative 
bacteria and a normal response to wall fragments of gram-positive bacteria (Takeuchi et al. 
2002). Therefore, TLR-1 and TLR-6 associate with TLR-2 and participate in the recognition 
of different lipopetides. 
 
 
2.3.2 TLR-4 
TLR-4 was in fact the first TLR to be described and was originally named human Toll. LPS is 
an agonist for TLR-4. The discovery that this receptor is necessary for LPS signalling was 
confirmed in TLR-4 knock out (TLR-4
-/-) mice (Hoshino et al. 1999). The recognition of LPS 
by TLR-4 requires several additional molecules. LPS binds to LPS-binding protein, an acute 
phase protein which circulates in the bloodstream, there it recognizes and forms a high-
affinity complex with the lipid A part of LPS (Schumann et al. 1990). LPS-binding protein 
helps LPS to dock on the receptor by binding and then forming a ternary complex with CD14, 
enabling LPS to be transferred to the receptor complex of TLR-4 (Viriyakosol and Kirkland 
1995). The glycoprotein MD-2 acts as an extracellular adaptor protein in the activation of 29 
TLR-4 by LPS and is necessary for LPS signalling (Shimazu et al. 1999;Yang et al. 2000). 
Visintin and colleagues demonstrated that LPS binds to MD-2 and induces subsequently 
TLR-4 signalling (Visintin et al. 2003). It has been demonstrated that MD-2 is indispensable 
for LPS responses, because MD-2 deficient mice are unresponsive to LPS (Nagai et al. 2002). 
In addition to recognizing LPS, TLR-4 mediates signals induced by exogenous compounds 
like taxol (Byrd-Leifer et al. 2001), several endogenous ligands such as heat shock proteins 
HSP60 and HSP70 (Gao and Tsan 2003), the extra domain A of fibronectins (Termeer et al. 
2002), oligosaccharides of hyaluronic acid (Ohashi et al. 2000), heparin sulphate and 
fibrinogen (Johnson et al. 2002). 
 
 
2.3.3 TLR-9 
TLR-9 recognizes unmethylated CpG sites on DNA molecules and is hence the receptor for 
bacterial and viral CpG-DNA, as well as non-nucleic acids such as haemozoin from the 
malaria parasite (Akira et al. 2006;Hemmi et al. 2000). Upon Mycobacterium tuberculosis 
infection, TLR-9 cooperates with TLR-2 to induce innate and adaptive immune responses 
against the bacterium (Bafica et al. 2005). TLR-9 also plays an important role in the fight 
against infection with Brucella (Copin et al. 2007) and Streptococcus pneumoniae (Lee et al. 
2007). Polymorphisms in TLR-9 have been reported to be associated with an increased 
susceptibility for Helicobacter pylori infection, suggesting that TLR-9 is involved in 
recognition and clearance of Helicobacter (Anderson et al. 2007). Genomes of DNA viruses 
often have unmethylated CpG motifs, and therefore act as a ligand for TLR-9. Mouse 
cytomegalovirus (Krug et al. 2004a), herpes simplex virus type 1 (Krug et al. 2004b) and type 
2 (Lund et al. 2003) and adenovirus (Zhu et al. 2007) are recognized by TLR-9 on 
plasmacytoid DC, and the resulting activated plasmacytoid DC produce IFN-α and other 
cytokines. 
TLR-9 is localized intracellularly in late endosomes or lysosomes, where it detects 
unmethylated CpG-DNA (Latz et al. 2004;Leifer et al. 2004). It has been suggested that the 
intracellular localization of TLR-9 is important to enable discrimination of foreign-derived 
DNA and self-DNA. Barton et al. (2006) demonstrated that when the transmembrane and 
cytoplasmic region of TLR-9 is replaced to that of TLR-4, the chimeric protein (TLR9N4C) is 
trafficked to the plasma membrane. Whereas TLR9N4C responds to CpG-DNA, it has no 
ability to sense viral DNA. More importantly, when TLR9N4C is expressed on the cell 30 
surface of macrophages, these cells respond to self-DNA. As abnormal recognition of self-
DNA is associated with the pathogenesis of autoimmune diseases, intracellular localization of 
TLR-9 might safeguard against contact with self-DNA. 
 
 
 
2.4 TLR Signalling Pathways 
Upon binding
 to specific ligands via pattern recognition, TLRs recruit
 and activate various 
downstream kinases such as IL-1 receptor-associated
  kinase (IRAK)-1, IRAK-4 and TNF 
receptor-associated factor (TRAF) family member-associated NF-κB activator binding kinase
 
1 (TBK1) via a specific set of adaptors. There are
 five Toll/IL-1 receptor-containing (TIR) 
domain-containing adaptors, namely myeloid differentiation factor 88 (MyD88), MyD88 
adaptor-like protein (Mal), TIR domain-containing
 adaptor protein inducing IFN-β-mediated 
transcription factor
  (TRIF), TRIF-related adaptor molecule (TRAM) and a sterile
  α- and 
armadillo-motif-containing protein (O'Neill and Bowie 2007). TLRs
  interact with their 
respective adaptor(s) via the homologous
 binding of their unique TIR domains present in 
both, the receptors
 and the adaptor molecules. Based on the specific adaptors recruited
 to 
TLRs, TLR signalling can be divided into two general pathways,
 namely MyD88-dependent 
and MyD88-independent pathway.
  The two distinct signalling pathways lead to the 
production of
 pro-inflammatory cytokines and type 1 IFN, respectively (O'Neill and Bowie 
2007). Recently, a novel pathway of TLR signalling has been discovered, which involves 
phosphoinisitide-3-kinase (PI3K) and protein kinases B which is also called as Akt, leading to 
activation of nuclear factor-κB (NF-κB). An overview of the TLR signalling pathways is 
shown in Fig. 4. 
 
 
2.4.1 MyD88-dependent Pathway 
Upon recognition of PAMPs through TLRs, the adaptor molecule MyD88 interacts with the 
transmembrane receptor through the C-terminal TIR domain. MyD88 then recruits IRAK-4 (a 
serine threonine kinase) to TLRs through interaction of the death domain of both molecules 
and facilitates IRAK-4-mediated phosphorylation of IRAK-1. Phosphorylated IRAK-1 
associates with TRAF-6 (Cao et al. 1996;Wesche et al. 1997), leading to the activation of two 31 
distinct signalling pathways.  One pathway leads to activation of the transcription factor 
activator protein-1 (AP-1) through activation of mitogen-activated protein kinases (MAPKs). 
On the other pathway, the IRAK-1/TRAF-6
  complex then activates transforming growth 
factor-β-activated
  protein kinase-1 (TAK-1) through a process involving the cytosol
 
translocation of TAK-1 and two TAK-1-binding proteins (TAB) from membrane
 to cytosol 
and the ubiquitination of TRAF-6 (Jiang et al. 2002;Takaesu et al. 2001). Activated TAK-1 
then enhances activity of the IκB kinase (IKK) complex as well as c-Jun N-terminal kinase 
(JNK)/p38 kinases (Wang et al. 2001).  Once activated, the IKK complex induces 
phosphorylation and degradation of the inhibitor of NF-κB (IκB), which leads to subsequent 
translocation of NF-κB to the nucleus and finally transcription of pro-inflammatory genes 
(Akira and Takeda 2004;Dunne and O'Neill 2003;Janeway, Jr. and Medzhitov 2002).  
As stated above, MyD88 is one of the five TIR domain-containing
 adaptors in TLR signalling 
(O'Neill and Bowie 2007) and plays a critical role in
 the signalling of all TLRs except TLR-3 
(Janssens and Beyaert 2002;Medzhitov et al. 1998;Muzio et al. 1997). 
 
 
2.4.2 MyD88-independent Pathway 
In MyD88-deficient macrophages, TLR-4 activation of inflammatory cytokines does not 
occur. However, activation of NF-κB is observed with delayed kinetics (Kawai et al. 1999). 
This indicates that although TLR-4 activation of inflammatory cytokines depends on the 
MyD88-dependent pathway, a MyD88-independent component exists in TLR-4 signalling. 
Subsequent studies have shown that TLR-4 stimulation leads to activation of IRF-3 as well as 
the late phase of NF-κB activation in a MyD88-independent pathway (Kawai et al. 2001). 
TLR-4 activation of IRF-3 leads then to the production of IFN-β. A previous study proved 
that viral infection or double stranded RNA may activate IRF-3 (Yoneyama et al. 1998). 
Accordingly, the TLR-3-mediated pathway also activates IRF-3 and thereby induces IFN-β in 
a MyD88-independent way. Hence, TLR-3 and TLR-4 use the MyD88-independent signalling 
pathway to induce IFN-β.  
TRIF has been demonstrated to be essential for TLR-3 and TLR-4 mediated MyD88-
independent pathways. TRIF deficient mice generated by gene targeting showed no activation 
of IRF-3 and have impaired expression of IFN-β and IFN-inducible genes in response to 
TLR-3 and TLR-4 ligands (Diebold et al. 2004). IRF-3 binds to the IFN-stimulated response 
element and leads to induction of type-1 IFNs (Au et al. 1995).  32 
Studies with TRAM deficient mice showed that TRAM is involved in TLR-4-mediated, but 
not TLR-3-mediated activation of IRF-3 and induction of IFN-β and IFN-inducible genes 
(Fitzgerald et al. 2003;Oshiumi et al. 2003;Yamamoto et al. 2003). Thus, TRAM is an adaptor 
molecule that provides specificity for the MyD88-independent pathway of TLR-4 signalling. 
 
 
2.4.3 PI3K Properties in TLR-mediated Signalling 
In vitro studies using pharmacological inhibitory compounds of PI3K, e.g. the fungal 
metabolite wortmannin or the synthetic inhibitor LY294002 suggested an involvement of 
PI3K in the modulation of innate immune responses, though the role of PI3K still remained 
controversial. Some studies showed direct or indirect TLR-mediated activation of IKK/NF-κB 
signaling via PI3K/Akt. Inhibition of PI3K by pharmacological inhibitors or dominant 
negative PI3K constructs led to diminished NF-κB activation and reduced inflammatory gene 
expression (Arbibe et al. 2000;Ojaniemi et al. 2003;Rhee et al. 2006). In contrast, others 
could show an enhancing effect of pharmacological inhibition of PI3K on pro-inflammatory 
gene expression, which was dependent on a number of signalling pathways such as p38, JNK, 
extracellular signal-regulated kinases and IKK (Aksoy et al. 2005;az-Guerra et al. 1999;Guha 
and Mackman 2002) Furthermore, several studies provide in vivo evidence for a down-
regulatory role on innate immunity of PI3K in models of acute inflammation and sepsis, using 
the potent PI3K inhibitor wortmannin (Schabbauer et al. 2004;Williams et al. 2004a;Zhang et 
al. 2007). 
 
The first genetic reports on the role of PI3K in the regulation of innate immune responses 
were published by the group of Fukao. It could be shown in vitro that ablation or down-
modulation of PI3K activity had strong impact on the innate immune response in DCs. In 
particular, IL-12 expression upon PAMP stimulation (TLR-2, 4 and 9) was elevated in p85α-
deficient cells (Fukao et al. 2002). Another study could show in vivo that p85α deficiency led 
to an enhanced response of gene-deficient mice to the TLR-5 agonist flagellin (Yu et al. 
2006). These data indicate that PI3K is involved in the down-regulation of pro-inflammatory 
responses. More recently, Luyendyk and colleagues showed evidence for a role of PI3K in the 
modulation of the amplitude of inflammatory signals. Several pro-inflammatory signalling 
pathways activated by TLR-4, such as the MAP kinases p38, JNK and extracellular signal-
regulated kinase 1 and 2 are affected by p85α deficiency in macrophages. Activation of 33 
MAPKs upon LPS/TLR-4 activation was enhanced and persisted over a prolonged period of 
time in p85α-deficient macrophages, as compared to WT control cells (Luyendyk et al. 2008).  
Furthermore, one study found direct effects of Akt and glycogen synthase kinase 3β (GSK3β) 
on NF-κB activity (Martin et al. 2005). Downstream of Akt, GSK3β is a crucial target in the 
PI3K signalling cascade. GSK3β is important for a variety of cellular processes, such as 
glucose/glycogen metabolism, protein synthesis and apoptosis (Frame and Cohen 2001). 
Recently, Martin and colleagues proved that Akt-mediated GSK3β inhibition led to down-
modulation of TLR-2, 4, 5 and 9 mediated inflammation both in vitro and in vivo (Martin et 
al. 2005).  34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: TLR signalling pathways. A schematic of TLR signalling initiated by various TLR ligands. On MyD88-
dependent pathway, MyD88 serves as the central adapter protein associating with IRAK4 which in turn recruits and 
phosphorylates IRAK1. Following interaction with TRAF6, the activated IRAK complex phosphorylates TAB1 and TAK1, 
and activates the NF-κB and MAPK pathways. On MyD88-independent pathway, TLRs (only TLR-3 and TLR-4) interact 
with TRIF, thereby activating a complex of IKKε, TRAF3 and TBK1 that phosphorylates IRF3 and IRF7. A noveau 
discovered pathway of TLRs involving PI3K and Akt, which finally leads to activation of NF-κB. 
Activation of IRF3 results in the induction of genes (CD40, CD80 and CD86) that stimulate T cell immunogenic responses. 
IRF7 promotes an antiviral immune response by the induction of IFN-α and -β gene expression. AP-1 and NF-κB mediate 
inflammatory responses through the expression of different cytokines (e.g. ILs, RANTES and TNF-α) and macrophage 
inflammatory proteins (MIP-1α and MIP-1β). 
 
AP-1, activator protein-1; ERK, extracellular signal-regulated kinase; IFN, interferon; IκB, inhibitor of NF-κB; IKK, IκB 
kinase; IRAK, IL-1 receptor-associated kinase; IRF, interferon regulatory factor; JNK, c-Jun N-terminal kinase; Mal, MyD88 
adaptor-like protein; MAPK, mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase; MIP, 
macrophage inflammatory protein; MKK, MAP kinase kinase; MyD88, myeloid differentiation factor88; NF-κB, nuclear 
factor-κB; PI3K, phosphoinisitide-3-kinase; RANTES, regulated upon activation, normal T-cell expressed and secreted; 
TAB, TAK1-binding protein; TAK1, transforming growth factor-β-activated protein kinase 1; TBK1, TRAF-family member-
associated NF-κB activator-binding kinase 1; TRAF6, TNF receptor-associated factor 6; TRAM, TRIF-related adaptor 
molecule; TRIF, TIR-domain-containing adaptor protein inducing INF-β-mediated transcription factor.  
Obtained from http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cell-and-Tissue Analysis/ 
Signaling-Pathways/Toll-like-Receptor-TLR.html. 
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2.4.4 TLR Polymorphisms 
Many years ago, the mouse strains C3H/HeJ and C57BL/10ScCr were found not to respond to 
bacterial endotoxin (Coutinho et al. 1977;Sultzer 1968). These mouse strains could tolerate 
high doses of LPS without manifesting any lethal effects. However, they were highly 
susceptible to gram-negative bacterial infection. Genetic studies identified a single LPS locus 
on chromosome 4, which was responsible for this hyporesponsiveness. In the late 90´s, this 
locus was mapped as the TLR-4 gene (Poltorak et al. 1998a;Poltorak et al. 1998b;Qureshi et 
al. 1999). The C3H/HeJ mouse strain has single co-dominant missense mutation on the third 
exon of the TLR-4 gene, which causes a replacement of proline with histidine at position 712 
of the polypeptide. The strain C57BL/10ScCr is homozygous for a null mutation of TLR-4, 
which is caused by a deletion of about 75 kb on chromosome 4. The TLR-4 knock-out mouse 
generated by Hoshino and his co-workers had the same phenotype as naturally occurring 
TLR-4 mutant mice (Hoshino et al. 1999). The animals developed normally, however showed 
no response to LPS or synthetic lipid A. The hyporesponsiveness was later suggested to be 
due to a disruption of the TLR-4-mediated signalling pathway resulting from the inability of 
mutant TLR-4 to interact with the second messenger MyD88 (Rhee and Hwang 2000). In 
addition to interrupted LPS signalling, the ‘loss-of-function’ mutation in TLR-4 has been 
shown to be beneficial in preventing for instance neurodegeneration and artherogenesis 
(Kiechl et al. 2003;Lehnardt et al. 2003).  
The importance of TLRs in human diseases has been identified in studies of polymorphisms 
in TLR genes. The first identified TLR polymorphism encodes a missense mutation 
Asp299Gly (an A →G substitution at nucleotide 896 from the start codon of the TLR-4 gene, 
which results in an aspartic acid - glycine substitution at position 299 of the amino-acid 
sequence) in TLR-4 (Arbour et al. 2000). Thus far, the most extensively studied 
polymorphism is the Asp299Gly mutation. The incidence of heterozygosity of the mutant 
allele in the Caucasian population is 9.4% (Feterowski et al. 2003).  This polymorphism 
affects the extracellular domain of human TLR-4 and is associated with hyporesponsiveness 
to inhaled LPS or endotoxin (Arbour et al. 2000). While it was shown that the Asp299Gly 
polymorphism increased the susceptibility to gram-negative infections (Agnese et al. 
2002;Lorenz et al. 2002), no correlation of this polymorphism to pre- or post-operative LPS-
induced cytokine release could be demonstrated (Kumpf et al. 2006). Furthermore, during 
post-operative sepsis induced by mixed-bacterial infections, a correlation between the 
incidence of sepsis and mortality could not be demonstrated (Feterowski et al. 2003). Several 36 
recent studies suggest an association between TLR-4 polymorphisms and the development 
and progression of atherosclerosis. The Asp299Gly mutation is associated with a reduced risk 
for carotid artery atherosclerosis (Kiechl et al. 2003), acute coronary events (Ameziane et al. 
2003;Boekholdt et al. 2003) and asthma (Werner et al. 2003;Yang et al. 2004). There are 
other rare TLR-4 polymorphisms, which lead to missense mutations and influence 
meningococcal infections (Smirnova et al. 2003).  
 
Among the TLRs, TLR-2 recognizes the broad variety of pathogens, including bacteria, 
parasites, viruses and fungi. Several studies described the existence of TLR-2 mutations in 
humans: The Arg753Gln polymorphism in TLR-2 is associated with a decreased response to 
bacterial peptides from Borrelia burgdorferi and Treponema pallidum (Schroder et al. 2005). 
This polymorphism may predispose people to staphylococcal infections (Lorenz et al. 2000) 
or to tuberculosis (Ben-Ali et al. 2004;Ogus et al. 2004). Schroder and co-workers reported a 
rate of 9.4 % heterozygosity for this Arg753Gln polymorphism (Schroder et al. 2003). 
Another mutation in the intracellular domain of human TLR-2 protein, the Arg677Trp 
polymorphism, is associated with lepromatous leprosy in the Korean population (Kang and 
Chae 2001;Kang et al. 2002).  
Other subtypes, in particular TLR-9, have recently started to be characterized and their 
functional importance elucidated. Among these, the most studied is T1237C, a polymorphism 
located within the putative promoter region that may influence transcriptional regulation of 
the TLR-9 gene. The variation T1237C has been shown to be associated with an increased 
risk for asthma among European Americans (Lazarus et al. 2003) and preliminary data 
regarding a possible positive association with Crohn's disease was also reported (Torok et al. 
2004). Three studies conducted in the UK, Korea and Hong Kong
  investigated possible 
associations of genetic variations of
 TLR-9 with systemic lupus erythematosus (De Jager et al. 
2006;Hur et al. 2005;Ng et al. 2005), but they did not detect an association
 between TLR-9 
gene variations and susceptibility to systemic lupus erythematosus. However in a recent 
study, Tao and co-workers found that the presence of a G1174A polymorphism is associated 
with an increased
 risk of systemic lupus erythematosus in the Japanese population. The C 
allele at position –1486 (T1486C) was also closely
 correlated with the risk of systemic lupus 
erythematosus. The combination of both alleles
 down-regulated the transcription of TLR-9 
(Tao et al. 2007). Moreover, Bochud et al. showed that the polymorphisms G1174A and 
G1635A in TLR-9 are associated with rapid progression in human immunodeficiency virus 
(Bochud et al. 2007).  37 
2.5 Sepsis  
2.5.1 Definition of Sepsis 
For many years clinicians used a variety of terms to describe illnesses associated with 
infection or what looked like infection. These terms included sepsis, septicaemia, 
bacteraemia, infection, sepsis shock, toxic shock, etc. Unfortunately, problems arose with the 
use of these terms: First, there were no strict definitions for the terms used and often these 
words were used incorrectly. Second, emerging evidence arose which led to the belief that 
systemic inflammation (rather than infection) was responsible for multiple organ failure. 
Since the 1992 consensus conference between the American College of Chest Physicians 
(ACCP) and the Society of Critical Care Medicine (SCCM), new definitions and criteria for 
the diagnostics of sepsis were created. Although lacking specificity (particularly for paediatric 
patients) these definitions (see below) have enabled medical professionals to be unified in the 
definitions of such conditions and allowed comparisons of clinical data (Levy et al. 2003).  
 
Infection  
A host response to the invasion of microorganisms.  
 
Bacteraemia  
The presence of viable bacteria in circulating blood.  
 
Systemic Inflammatory Response Syndrome (SIRS)  
A systemic inflammatory response to a wide variety of severe clinical insults (e.g. infection, 
burns, trauma, etc.), manifested by two or more of the following conditions: 
•  Temperature > 38°C or < 36°C  
•  Heart rate > 90 beats/min  
•  Respiratory rate > 20 breaths/min or Pa CO2 < 32 mm Hg  
•  White blood cell count > 12,000/mm
2, < 4000/mm
3, or 10% immature (band) forms. 
 
Sepsis  
Infection plus systemic manifestations of infection. 
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Severe sepsis  
Sepsis associated with organ failure, hypoperfusion or hypotension. Hypoperfusion and 
perfusion abnormalities may include -but are not limited to- lactic acidosis, oliguria or an 
acute alteration in mental status.  
 
Septic shock 
A subset of severe sepsis and defined as sepsis associated with hypoperfusion (alterations), 
but with persistent hypotension even after suitable treatment (vasopressures or volumes).  
 
Multiple organ dysfunction syndrome (MODS) 
The presence of altered organ functions in an acutely ill patient, such that homeostasis can not 
be maintained without intervention. MODS may represent the final stage of sepsis.  
 
 
2.5.2 Diagnosis and Therapy in Adults 
The symptoms, which separate sepsis from severe sepsis and septic shock are not easily 
detected in ICU or even from a conceptual point of view (Bone 1996;Proulx et al. 1996). In 
2001, the International Sepsis Definitions Conference of researchers and experts opted to 
increase the first of signs and symptoms of sepsis (Tab. 2), thus valuing the clinical 
experience of medical professionals (Levy et al. 2003). 
 
 
Documented or suspected infection with some of the following conditions: 
General variables: 
Fever (core temperature > 38.3°C)  
Hypothermia (core temperature < 36°C)  
Heart rate >90 bpm or > 2 SD above the normal value for age  
Altered mental status  
Hyperglycaemia (plasma glucose > 110 mg/dl or 7.7 mM/l) in absence of diabetes 
Inflammatory variables: 
Leukocytosis (WBC > 12,000/µl)  
Leukopenia (WBC < 4,000/µl)  
Normal WBC count with > 10% immature forms  
Plasma C reactive protein > 2 SD above normal value  
Plasma procalcitonin > 2 SD above normal value 39 
Haemodynamic variables: 
Arterial hypotension (SBP < 90 mmHg, mean arterial pressure < 70, or SBP decrease > 40 mmHg in adults or  
< 2 SD below normal for age)  
Mixed venous oxygen saturation > 70%  
Cardiac index > 3.51 min
-1 m
-2 
Organ dysfunction variables: 
Acute oliguria (urine output < 0.5 ml kg
-1h
-1 or 45 mM/l for at least 2 h) 
 
Coagulation abnormalities (international normalised ratio > 1.5 or activated partial thromboplastin time > 60 s)  
Thrombocytopenia (platelet count < 100,000/µl) 
Tissue perfusion variables: 
Hyperlactatemia (> 3 mmol/l)  
Decreased capillary refill or mottling 
 
Table 2: Diagnostic criteria for sepsis. SBP, systolic blood pressure; SD, standard deviation; WBC, white blood cells. 
Modified from Levy et al. 2003.  
 
 
Despite encouraging pre-clinical data, the majority of clinical trials in sepsis showed 
disappointing results (Polderman and Girbes 2004). One of the possible explanations for the 
failure of clinical trials (investigating sepsis) is that the current definitions, although important 
for clinical purposes, are too general and do not allow for precise characterization and staging 
of patients with sepsis. A possible approach to this problem is the development of a system 
for the stages of sepsis, which would allow classification of patients by both their ‘baseline 
risk’ of an adverse outcome and their potential to respond to therapy. This is why a new 
concept Predisposition-Infection-Response-Organ (PIRO) dysfunction is being proposed that 
can better characterize sepsis on the basis of predisposition factors, the nature of the 
underlying infection, the characteristics of the host response and the extent of resultant organ 
dysfunction (Levy et al. 2003). This means that beside the current criteria (see Tab. 2), genetic 
predisposition and specific response, as reflected by laboratory parameters, should be 
included in the diagnostics. Recently, the latest international guidelines for the management 
of severe sepsis and septic shock of the Surviving Sepsis Campaign are published in Critical 
Care Medicine (Dellinger et al. 2008), which provide an update to the guidelines of 2004. 
These guidelines represented phase II of the Surviving Sepsis Campaign, increasing 
awareness and improving the outcome of severe sepsis (Dellinger et al. 2004b;Dellinger et al. 
2004a). The revised guidelines are based on the Grades of Recommendation, Assessment, 
Development and Evaluation (GRADE), which is a structured system for rating quality of 
evidence and the strength of grading recommendations in clinical practice (Guyatt et al. 40 
2006;Schunemann et al. 2006). The GRADE system classifies the quality of evidence from 
high (A) to very low (D) and determines recommendations as strong (grade 1) or weak (grade 
2). A strong recommendation implies that the desirable effect of an intervention (e.g. 
beneficial health outcomes, fewer burdens on staff and patients, and cost savings) clearly 
outweighs it undesirable effects (e.g. risk, harm, more burden and greater costs). A weak 
recommendation reflects that the trade-off between desirable and undesirable effects is less 
clear. The following tables 3-5 summarize issues of initial resuscitation and infection, 
haemodynamic support and adjunctive therapy, as well as other supportive therapies of severe 
sepsis. 
 
  Strong recommendation 
or “we recommend” 
Weak recommendation 
or “we suggest” 
Initial 
resuscitation 
(first 6 h) 
Begin resuscitation immediately in patients 
with hypotension or elevated serum lactate 
<4 mmol/l; do not delay pending ICU 
admission (1C) 
 
Resuscitation goals (1C): 
•  CVP 8-12 mm Hg
a 
•  Mean arterial pressure ≥ 65 mm Hg 
•  Urine output ≥ 0.5 ml/kg/h 
•  Central venous (superior vena 
cava) oxygen saturation ≥ 70% or 
mixed venous ≥ 65% 
If venous oxygen saturation target is not 
achieved (2C): 
•  Consider further fluid 
•  Transfuse packed red blood cells if 
required to haematocrit of ≥ 30% 
and/or 
•  Start dobutamine infusion, 
maximum 20 µg/kg/min 
Diagnosis 
Obtain appropriate cultures before starting 
antibiotics provided this does not signi-
ficantly delay antimicrobial administration 
(1C): 
•  Obtain two or more BCs 
•  One or more BCs should be 
percutaneous 
•  One BC from each vascular access 
device in place >48 h 
•  Culture other sites as clinically 
indicated 
 
Perform imaging studies promptly to 
confirm and sample any source of infection, 
if safe to do so (1C)  
 
Antibiotic 
therapy 
Begin intravenous antibiotics as early as 
possible and always within the first hour of 
recognizing severe sepsis (1D) and septic 
shock (1B) 
 
 
Combination therapy in Pseudosomas 
infections (2D) 
 
Combination empiric therapy in neutropenic 
patients (2D) 
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Broad-spectrum: one or more agents active 
against likely bacterial/fungal pathogens and 
with good penetration into presumed source 
(1B) 
 
Reassess antimicrobial regimen daily to 
optimize efficacy, prevent resistance, avoid 
toxicity and minimize costs (1C) 
 
Duration of therapy typically limited to 7-10 
days; longer if response is slow or there are 
undrainable foci of infection or immuno-
logic deficiencies (1D) 
 
Stop antimicrobial therapy if cause is found 
to be non-infectious (1D) 
 
Combination therapy ≤3-5 days and de-
escalation following susceptibilities (2D) 
Source 
identification 
and control 
A specific anatomic site of infection should 
be established as rapidly as possible (1C) 
and within first 6 h of presentation (1D) 
 
Formally evaluate patient for a focus of 
infection amenable to source control 
measures (e.g. abscess drainage, tissue 
debridement) (1C) 
 
Implement source control measures as soon 
as possible following successful initial 
resuscitation (1C) (exception: infected pan-
creatic necrosis, where surgical intervention 
is best delayed) (2B) 
 
Choose source control measure with 
maximum efficacy and minimal physiologic 
upset (1D) 
 
Remove intravascular access devices if 
potentially infected (1C) 
 
 
Table 3: Initial resuscitation and infection issues. Strength of recommendation and quality of evidence have been assessed 
using the GRADE criteria, presented in parentheses after each guideline.
 a A higher target CVP of 12-15 mm Hg is 
recommended in the presence of mechanical ventilation or pre-existing decreased ventricular compliance. BC, blood culture; 
CVP, central venous pressure; GRADE, Grades of Recommendation, Assessment, Development and Evaluation; ICU, 
intensive care unit. Modified from Dellinger et al. 2008. 
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  Strong recommendation 
or “we recommend” 
Weak recommendation 
or “we suggest” 
Fluid therapy 
Fluid-resuscitate using crystalloids or 
colloids (1B) 
 
Target a CVP ≥8 mm Hg (≥12 mm Hg if 
mechanically ventilated) (1C) 
 
Fluid challenge technique while associated 
with a haemodynamic improvement (1D) 
 
Fluid challenge of 1000 ml of crystalloids or 
300-500 ml colloids over 30 min. More 
rapid and larger volumes required in sepsis-
induced tissue hypoperfusion (1D) 
 
Reduce rate of fluid administration if 
cardiac filling pressures increase without 
concurrent haemodymanic improvement 
(1D) 
 
Vasopressors 
Maintain MAP ≥65 mm Hg (1C) 
 
Norepinephrine and dopamine centrally 
administered as the initial vasopressors of 
choice (1C) 
 
Do not use low-dose dopamine for renal 
protection (1A) 
 
In patients requiring vasopressors, insert an 
arterial catheter as soon as practical (1D) 
No epinephrine, phenylephrine or vaso-
pressin as the initial vasopressor in septic 
shock (2C). Vasopressin 0.03 units/min may 
be subsequently added to norepinephrine 
with anticipation of an effect equivalent to 
norepinephrine alone 
 
Use epinephrine as the first alternative agent 
in septic shock when blood pressure is 
poorly responsive to norepinephrine or 
dopamine (2B) 
Inotropic 
therapy 
Use dobutamine in patients with myocardial 
dysfunction as supported by elevated 
cardiac filling pressures and low cardiac 
output (1C) 
 
Do not increase cardiac index to 
predetermined supranormal levels (1B) 
 
Steroids 
Hydrocortisone dose should be ≤300 
mg/day (1A) 
 
No corticosteroids to treat sepsis in the 
absence of shock unless the patient’s 
endocrine or corticosteroid history warrants 
it (1D) 
Intravenous hydrocortisone for adult septic 
shock when hypotension responds poorly to 
adequate fluid resuscitation and vasopressors 
(2C) 
 
No ACTH stimulation test recommended to 
identify subset of adults with septic shock 
who should receive hydrocortisone (2B) 
 
Hydrocortisone is preferred to dexa-
methasone (2B) 
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Fludrocortisone (50 µg/day; orally) if an 
alternative to hydrocortisone is being used 
that lacks significant mineralcorticoid 
activity. Fludrocortisone if optional if 
hydrocortisone is used (2C) 
 
Wean steroid therapy once vasopressors are 
no longer required (2D) 
Recombinant 
human 
activated 
protein C 
No rhAPC for adult patients with severe 
sepsis and low risk of death (typically 
APACHE II <20 or one organ failure) (1A) 
rhAPC in adult patients with sepsis-induced 
organ dysfunction with clinical assessment 
of high risk of death (typically APACHE II 
≥25 or multiple organ failure) if no contra-
indications (2B, 2C for postoperative 
patients) 
 
Table 4: Haemodynamic support and adjunctive therapy. Strength of recommendation and quality of evidence have been 
assessed using the GRADE criteria, presented in parentheses after each guideline. ACTH, adrenocorticotropic hormone; 
APACHE, Acute Physiology and Chronic Health Evaluation; CVP, central venous pressure; GRADE, Grades of 
Recommendation, Assessment, Development and Evaluation; MAP, mean arterial pressure; rhAPC, recombinant human 
activated protein C. Modified from Dellinger et al. 2008. 
 
 
  Strong recommendation 
or “we recommend” 
Weak recommendation 
or “we suggest” 
Blood product 
administration 
Give red blood cells when haemoglobin 
decreases to <7.0 g/dl (<70g/l) to target a 
haemoglobin of 7.0-9.0 g/dl in adults (1B). 
A higher haemoglobin level may be 
required in special circumstances (e.g. 
myocardial ischeamia, severe hypoxemia, 
acute haemorrhage, cyanotic heart disease 
or lactic acidosis) 
 
No antithrombin therapy (1B) 
No erythropoietin to treat sepsis-related 
anemia (1B) 
 
No fresh frozen plasma to correct laboratory 
clotting abnormalities unless there is 
bleeding or planned invasive procedures 
(2D) 
 
Administer platelets when (2D): 
•  counts are <5000/mm
3 (5 x 10
9/l) 
regardless of bleeding 
•  counts are 5000-30,000/mm
3 (5-30 
x 10
9/l) and there is significant 
bleeding risk 
•  higher platelet counts 
(≥50,000/mm
3 [50 x 10
9/l]) are 
required for surgery or invasive 
procedures 
Mechanical 
ventilation of 
sepsis-induced 
ALI/ARDS 
Target a tidal volume of 6 ml/g (predicted) 
body weight in patients with ALI/ARDS 
(1B) 
Target an initial upper limit plateau 
pressure ≤30 cm H2O. Consider chest wall 
compliance when assessing plateau 
pressure (1C) 
Allow PaCO2 to increase above normal if 
needed to minimize plateau pressures and 
tidal volumes (1C) 
Consider using the prone position for ARDS 
patients requiring potentially injurious levels 
of FIO2 or plateau pressure, provided they 
are not put at risk from positional changes 
(2C) 
 
Consider non-invasive ventilation in the 
minority of ALI/ARDS patients with mild to 
moderate hypoxemic respiratory failure.  44 
 
Set PEEP to avoid extensive lung collapse 
at end-expiration (1C) 
Maintain mechanically ventilated patients 
in a semirecumbent position (head of the 
bed raised to 45°) unless contra-indicated 
(1B), between 30° and 45° (2C) 
Use a weaning protocol and an SBT 
regularly to evaluate the potential for 
discontinuing mechanical ventilation (1A): 
SBT options include a low level of 
pressure support with continuous positive 
airway pressure 5 cm H2O or a T piece 
Before the SBT, patients should: 
•  be arousable 
•  be haemodynamically stable 
without vasopressors 
•  have no new potentially serious 
conditions 
•  have low ventilatory and end-
expiratory pressure requirement 
•  require FIO2 levels that can e 
safely delivered with a face mask 
or nasal cannula 
 
No pulmonary artery catheter for the 
routine monitoring of patients with 
ALI/ARDS (1A) 
 
Use a conservative fluid strategy for 
patients with established ALI who do not 
have evidence of tissue hypoperfusion (1C) 
 
Patients need to be haemodynamically stable, 
comfortable, easily arousable, able to 
protect/clear their airway and expected to 
recover rapidly (2B) 
Sedation, 
anlagesia and 
neuro-muscular 
blockade in 
sepsis 
Use sedation protocols with a sedation goal 
for critically ill mechanically ventilated 
patients (1B) 
 
Use either intermittent bolus sedation or 
continuous infusion sedation to 
predetermined end points (sedation scales), 
with daily interruption/lightening to 
produce awakening. Re-titrate if necessary 
(1B) 
 
Avoid neuromuscular blockers where 
possible. Monitor depth of block with 
train-of-four when using continuous 
infusions (1B) 
 
Glucose control 
Use intravenous insulin to control 
hyperglycemia in patients with severe 
sepsis following stabilization in the ICU 
(1B) 
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Keep blood glucose <150 mg/dl (8.3 
mmol/l) using a validated protocol for 
insulin dose adjustment (2C) 
Provide a glucose calorie source and 
monitor blood glucose values every 1-2 h 
(4 h when stable) in patients receiving 
intravenous insulin (1C) 
 
Interpret with caution low glucose levels 
obtained with point of care testing, as these 
techniques may overestimate arterial blood 
or plasma glucose values (1B) 
Renal 
replacement 
  Intermittent haemodialysis and CVVH are 
considered equivalent (2B) 
 
CVVH offers easier management in 
haemodynamically unstable patients (2D) 
Bicarbonate 
thearapy 
No bicarbonate therapy for the purpose of 
improving haemodynamics or reducing 
vasopressor requirements when treating 
hypoperfusion-induced lactic acidemia 
with pH≥7.15 (1B) 
 
Deep vein 
thrombosis 
prophylaxis 
Use either low-dose UFH or LMWH, 
unless contra-indicated (1A) 
 
Use a mechanical prophylactic device such 
as compression stockings or an intermittent 
compression device, when heparin is 
contra-indicated (1A) 
Use a combination of pharmacologic and 
mechanical therapy for patients who are at 
very high risk for deep vein thrombosis (2C) 
 
Use LMWH rather than UFH in patients at 
very high risk (2C) 
Stress ulcer 
prophylaxis 
Provide stress ulcer prophylaxis using H2 
blocker (1A) or proton pump inhibitor 
(1B). Benefits of prevention of upper 
gastrointestinal bleed must be weighed 
against the potential for development of 
ventilator-acquired pneumonia 
 
Consideration 
for limitation of 
support 
Discuss advance care planning with 
patients and families. Describe likely 
outcomes and set realistic expectations 
(1D) 
 
 
Table 5: Other supportive therapy of severe sepsis. Strenght of recommendation and quality of evidence have been 
assessed using the GRADE criteria, presented in parentheses after each guideline. ALI, acute lung injury; ARDS, acute 
respiratory distress syndrome; CVVH, continuous veno-venous haemofiltration; GRADE, Grades of Recommendation, 
Assessment, Development and Evaluation; ICU, intensive care unit; LMWH, low-molecular weight heparin; PEEP, positive 
end-expiratory pressure; SBT, spontaneous breathing trial; UFH, unfractionated heparin. Modified from Dellinger et al. 2008. 
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2.5.3 Diagnosis and Therapy in Infants 
Sepsis in children is a major cause of mortality, estimated at about 10% in the United States, 
although the overall mortality from severe sepsis in infants is much lower than that in adults 
(Watson et al. 2003). It is important to note that the definitions for severe sepsis and septic 
shock in children are not identical to those in adults (Goldstein et al. 2005). Apart from age-
appropriate differences in vital signs, the definition of SIRS obligates the presence of either 
temperature or leukocyte abnormalities. Severe sepsis in children is defined as sepsis plus 
cardiovascular dysfunction or acute respiratory distress syndrome or two or more other organ 
dysfunctions (Goldstein et al. 2005). Table 6 shows a summary of therapies of pediatric 
severe sepsis. 
 
  Strong recommendation 
or “we recommend” 
Weak recommendation 
or “we suggest” 
Antibiotics 
Administer antibiotics within 1 h of the 
identification of severe sepsis, after 
appropriate cultures have been obtained 
(1D) 
 
Mechanical ventilation  No graded recommendations   
Fluid therapy 
  Initial resuscitation begin with infusion 
of crystalloids 20 ml/kg over 5-10 min, 
titrated to clinical monitors of cardiac 
output, capillary refill, and level of 
consciousness (2C) 
Vasopressors/Inotropic 
therapy 
  Dopamine as the first choice of support 
for pediatric patient with hypotension 
refractory to fluid resuscitation (2C) 
 
Use dobutamine in patients with low 
cardiac output and elevated systemic 
vascular resistance stated (cool 
extremities, prolonged capillary refill, 
decreased urine output but normal blood 
pressure following fluid resuscitation) 
(2C) 
Therapeutic end points 
  Normalization of the heart rate, capillary 
refill of <2 s, normal pulses with no 
differential between peripheral and 
central pulses, warm extremities, urine 
output <1 ml/kg/h, and normal mental 
status (2C) 
Steroids 
  Use hydrocortisone therapy in children 
with catecholamine resistance and 
suspected or proven adrenal insufficiency 
(50 mg/m
2/24 h (2C) 
Recombinant human 
activated protein C 
No rhAPC in children (1B)   47 
DVT prophylaxis    Use DVT prophylaxis in postpubertal 
children with severe sepsis (2C) 
Stress ulcer 
prophylaxis 
No graded recommendations   
Renal replacement 
therapy 
No graded recommendations   
Glycemic control  No graded recommendations   
Sedation/Analgesia 
Sedation protocols with a sedation goal 
when sedation of critically ill 
mechanically ventilated patients with 
sepsis is required (1D) 
 
Blood products  No graded recommendations   
Intravenous 
immunoglobulin 
  Consider immunoglobulin in children 
with severe sepsis (2C) 
Extracorporeal 
membrane 
oxygenation (ECMO) 
  Limit use of ECMO to refractory 
pediatric septic shock and/or respiratory 
failure that cannot be supported by 
conventional therapies (2C) 
 
Table 6: Therapies of pediatric severe sepsis. Strength of recommendation and quality of evidence have been assessed 
using the GRADE criteria, presented in parentheses after each guideline. DVT, deep vein thrombosis; ECMO, extracorporeal 
membrane oxygenation; GRADE, Grades of Recommendation, Assessment, Development and Evaluation; rhAPC, 
recombinant human activated protein C. Sources from Dellinger et al. 2008. 
 
 
 
2.5.4 The Role of Cytokines in Inflammatory Reaction 
The inflammatory reaction is a defensive response, which is directed against injury and 
infection. The innate immune system recognizes PAMPs and reacts with the release of 
mediators including anti-inflammatory cytokines, which protect against injury and infection 
(Gerard 2003). However, the extensive release of inflammatory mediators can cause excessive 
tissue injury and can have adverse effects toward the host itself. Ongoing activation of 
inflammation can result in MODS and frequently death (Munford and Pugin 2001). 
Additional syndromes such as compensatory anti-inflammatory response syndrome (CARS) 
and mixed antagonists response syndrome (MARS) have been described (Bone et al. 1997).  
In the end, anti-inflammatory cytokines play a significant role in the outcome of patients with 
sepsis by counteracting ongoing inflammation. In Table 7, pro- and anti-inflammatory 
mediators are listed. 
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Pro-inflammatory Anti-inflammatory 
•  TNF-α 
•  IL-1β, 2, 6, 8, 12, 15, 18 
•  IFN-γ 
•  Nitric oxide 
•  Inducible nitric oxide synthase 
•  Neutrophil elastase 
•  Thromboxane 
•  Platelet activating factor 
•  Granulocyte macrophage-colony stimulating 
factor 
•  Vasoactive neuropeptides 
•  Phospholipase A2 
•  Plasminogen activator inhibitor-1 
•  Prostaglandins 
•  Prostacyclin 
•  IL-1 receptor antagonist 
•  IL-4, 10, 13 
•  Type II IL-1 receptor 
•  Transforming growth factor-β 
•  Adrenaline 
•  Soluble TNF-α receptors 
•  Leukotriene B4-receptor antagonist 
•  LPS-binding protein 
 
Table 7: Pro-inflammatory and anti-inflammatory mediators. IFN-γ, interferon-γ; IL, interleukin; TNF-α, tumor 
necrosis factor-α. 
 
 
While anti-inflammatory cytokines are a prerequisite for controlling the inflammatory 
response, they also can lead to a depression of the immune system in patients. The condition 
in which these anti-inflammatory cytokines are produced in excess and become dominant 
systemically is called CARS or ‘immunoparalysis’ (Bone et al. 1997). Hartemink et al. (2003) 
described a ‘biphasic immunological pattern’ during sepsis, where an ‘early hyper-
inflammatory phase (SIRS)’ followed by an anti-inflammatory response leads to a ‘hypo-
inflammatory state (CARS)’. The spectrum of the responses to sepsis is illustrated in Fig. 5 
(Bone et al. 1997). This diagram shows the five stages of sepsis leading to MODS: Stage 1 is 
the initial insult producing local inflammation. Stage 2 is when severe insults lead to a 
systemic spillover of inflammatory mediators with few clinical signs or symptoms. When 
macrophages were primed for intense cytokine release, this amplified response is most likely 
the result of a second insult. In stage 3, the systemic reaction becomes apparent, leading to the 
clinical signs of SIRS and early organ dysfunction. Stage 4 is characterized by inappropriate 
immunosuppression or CARS overreaction with increased susceptibility to new infection. The 
last stage is characterized by an inappropriate, imbalance response and either excessive SIRS 
or CARS along with severe MODS.  49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Progression of sepsis from the initial insult with local pro- and anti-inflammatory responses through the 
systemic spillover of mediators. The systemic reaction may have the features of an excess of either pro-inflammatory and 
anti-inflammatory mediators or a mixed pattern. The clinical sequelae of sepsis may vary depending on the balance of 
mediators. Excessive inflammatory response (SIRS) may produce shock and organ dysfunction. Excessive anti-inflammatory 
response (CARS) suppresses the immune system. A balanced response of inflammatory mediators produces homeostasis. 
CARS, compensatory anti-inflammatory response syndrome; MARS, mixed antagonists response syndrome; SIRS, systemic 
inflammatory response syndrome. From Bone et al. 1997. 
 
 
 
2.5.5 The Role of Adrenal Gland during Sepsis 
Adrenal insufficiency in patients with sepsis has gained more attention over the last few 
years. Absolute and relative adrenal insufficiency can be distinguished by using laboratory 
investigations. In most cases, testing the basal level of cortisol is able to identify the problem. 
In patients with critical illnesses, however, it is difficult to diagnose adrenal insufficiency. 
Although absolute adrenal insufficiency occurs only in a minority (1-3%) of critically ill 
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patients (Matot and Sprung 1998), relative adrenal insufficiency was found in up to 80% 
among those patients (Annane et al. 2000). During sepsis, subnormal adrenal corticosteroid 
production can occur without any obvious structural defects in the HPA-axis (Burchard 
2001). Functional adrenal insufficiency can develop during the illness and is usually transient 
(Cooper and Stewart 2003). The major cause of relative adrenal insufficiency is an 
insufficient synthesis of cortisol due to cellular dysfunction. In contrast to absolute adrenal 
insufficiency, the morphological changes in relative adrenal insufficiency may be minor and 
sometimes are characterized by cellular hyperplasia within the adrenal cortex. This is often 
associated with a peripheral glucocorticoid resistance of the target cells caused by 
inflammatory conditions, although the absolute levels of cortisol might be normal (Meduri 
and Chrousos 1998). In septic shock, relative adrenal insufficiency may be due to impaired 
pituitary corticotropin release, attenuated adrenal response to corticotropin and reduced 
cortisol synthesis (Cooper and Stewart 2003). In patients with severe acute respiratory distress 
syndrome, it has been demonstrated that methylprednisolone treatment improved the 
decreased glucocorticoid response by reduction of NF-κB-mediated DNA binding and 
transcription of pro-inflammatory cytokines (Meduri et al. 2002). Therefore, if adrenal 
insufficiency can be identified, treatment with corticosteroids may be of benefit (Cooper and 
Stewart 2003). In critically ill patients, primary causes of adrenal insufficiency are often not 
detectable, if no specific hypothesis exists. In patients with sepsis and septic shock, the 
individual clinical course is different. Furthermore, dynamic testing is not always possible in 
ICU, which makes it difficult for the physician to consider glucocorticoids therapy due to the 
fact that decisions have to be made immediately in severe forms of sepsis in order to improve 
prognosis. Recently, Annane and co-workers tried to research more accurate diagnostic 
criteria for adrenal insufficiency in patients with severe sepsis or septic shock (Annane et al. 
2006). They found that patients were very likely to have adrenal insufficiency when a 
baseline total cortisol was less than 10 µg/dl or a change in cortisol of less than 9 µg/dl (after 
cosyntropin) was observed. Conversely, adrenal insufficiency can be ruled out when patients 
after cosyntropin stimulation exhibited levels of total cortisol of 44 µg/dl or greater or a 
change in cortisol of 16.8 µg/dl or greater. When baseline cortisol level is between 10-44 
µg/dl and the cortisol increment after cosyntropin stimulation is between 9-16.8 µg/dl, 
assessment of adrenal function requires metyrapone testing. 
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2.5.6 Corticosteroid Treatment 
Administration of high doses of corticosteroids (e.g. 30 mg/kg of methylprednisolone) did not 
improve survival of patients with sepsis and worsens their outcomes by increasing the risk of 
secondary infections (Cronin et al. 1995). Despite the negative effects associated with the use 
of high-dose corticosteroids, a study by Annane and colleagues indicated that extremely ill 
patients with sepsis, who have persistent shock requiring vasopressors and prolonged 
ventilation may benefit from ‘physiological’ doses of corticosteroids (Annane 2001). It is 
postulated, that such patients may have ‘relative’ adrenal insufficiency, despite having 
elevated levels of circulating cortisol (Marik and Zaloga 2003;Shenker and Skatrud 2001). 
Annane and co-workers found that in the majority of critically ill patients, the body fails to 
mount an adequate stress response with respect to cortisol even with normal pre-existing 
adrenal function. The anti-inflammatory effects of corticosteroids include inhibition of pro-
inflammatory cytokine synthesis, free radicals, prostaglandins, nitric oxide synthase and up-
regulation of the vascular responsiveness to catecholamines (Annane et al. 2000;Annane and 
Cavaillon 2003). A study also by Annane and colleagues demonstrated that hydrocortisone 
(50 mg intravenous bolus, 4 times per day) and fludrocortisone (50 µg per day) administered 
for seven days to patients with sepsis shock improves survival. Combination therapy was 
beneficial even in patients, where baseline plasma cortisol did not increase by < 9 µg/dl when 
stimulated with ACTH (Annane et al. 2002). Meta-analysis of the trials conducted after 1997 
as compared to those before 1989 (Annane et al. 2004;Minneci et al. 2004) showed a 
consistent improvement in overall mortality and shock reversal, whether they were 
‘responders’ or ‘non-responders’. The premise, on which earlier studies had administered 
high dose steroids, was that immunosuppression could alter the course of septic shock. 
However, this could have led to the harmful effects by for e.g. increasing the incidence of 
secondary infections (Minneci et al. 2004). In contrast, later studies were based on correcting 
the relative insufficiency of cortisol and to attenuate rather than suppress inflammation. This 
modified approach led to a lower dose of hydrocortisone (200-300 mg/daily) and over a 
longer duration of 5 days with tapering over 5-7 days (Keh and Sprung 2004;Minneci et al. 
2004). A previous study demonstrated that corticosteroids in low doses only attenuate but do 
not suppress inflammatory responses (Keh et al. 2003). A large European multicentre trial 
(CORTICUS) tested the hypothesis that low dose steroids improves 28-day mortality in 
patients with septic shock, whose cortisol levels did not increase by more than 9 µg/dl in 
response to ACTH stimulation (Annane et al. 2003). Unfortunately, this trial failed to prove a 52 
benefit in mortality using hydrocortisone therapy for septic shock. CORTICUS did 
demonstrate a faster resolution of septic shock in patients, who received steroids, but the use 
of the ACTH test (responders and non-responders) did not predict the faster resolution of 
shock (Sprung et al. 2008). Although corticosteroids seem to promote shock reversal, a lack 
of clear improvement in mortality, generally tempered the enthusiasm for their broad use, 
which is also due to the coupled side effects of corticosteroids, such as increased risk of 
infection and myopathy, immunosuppression, hypertension and metabolic disturbances (Rhen 
and Cidlowski 2005). 
 
 
 
2.6 The Adrenal Gland 
The adrenal gland is an endocrine organ that is essential for life. It secretes several 
glucocorticoids and mineralocorticoids that regulate both metabolism and electrolytes. The 
adrenal gland is located near the upper portion of the kidney (Fig. 6). Each gland is composed 
of two embryonic distinct regions, the adrenal cortex and the adrenal medulla.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Location of the adrenal glands. 
Obtained from http://jcsurgery.com/lap%20adrenal.htm. 
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The adrenal medulla, which arises from neuroectodermal cells, is located within the centre of 
the gland and ultimately gives rise to both the noradrenaline/adrenaline-secreting chromaffin 
cells and ganglia (James 1992;Parmer and Zinder 2002). The adrenal cortex, which will be the 
focus hereafter, is mesoderm-derived and comprises of three zones of anatomical and 
physiological distinct cells: the zona glomerulosa, zona fasciculata and zona reticularis (Fig. 
7). The division of the mammalian adrenal cortex into these three distinct concentric zones 
was first described by Harley in 1858. The terms zona glomerulosa, zona fasciculata and zona 
reticularis were introduced by Arnold in 1866 (Neville and O’Hare 1982). 
 
Zona glomerulosa cells reside in the outermost zone of the adrenal cortex. In response to 
increased potassium levels or decreased renal blood flow, cells of the zona glomerulosa 
secrete mineralocorticoids (primarily aldosterone) into the blood and therefore play a part in 
the renin-angiotensin system. Aldosterone regulates the body’s concentration of electrolytes, 
primarily sodium and potassium. Immediately beneath the zona glomerulosa is the zona 
fasciculata. The cells of this zone produce glucocorticoids, such as corticosterone or cortisol. 
The primary glucocorticoid of the adrenal gland is cortisol. Upon binding to its target, cortisol 
enhances metabolism in several ways: stimulating the release of amino acids from the body, 
stimulating lipolysis (the breakdown of fat), stimulating gluconeogenesis (the production of 
glucose from newly released amino acids and lipids) and conserving glucose by inhibiting 
uptake into muscle and fat cells (Ehrenreich 1999;Ehrhart-Bornstein et al. 1998;Holmes et al. 
2001). The third and innermost zone of the adrenal cortex is the zona reticularis. Cells of this 
zone provide a secondary source of androgens, such as testosterone, dihydrotestosterone, 
androstenedione and dehydroepiandrosterone. These androgens enhance muscle mass, 
stimulate cell growth and aid in the development of the secondary sexual characteristics 
(Rainey 1999;Rainey et al. 2002). 
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Figure 7: Histology of the adrenal gland. Illustrated are the diversity of the cells of the adrenal cortex and part of the 
adrenal medulla. Beneath the adrenal capsule are the three adrenal cortical zones: the zona glomerulosa, zona fasciculata, 
zona reticularis and their distinct morphology is apparent. The outermost zone is the zona glomerulosa. Cells within this zone 
tend to be columnar in shape and are arranged in irregular cords. The zona fasiculata is the middle and largest of the three 
zones in the cortex. Cells in the fasiculata are polyhedral and usually have a foamy appearance due to abundant lipid droplets. 
They also are arranged in distinctively straight cords that radiate toward the medulla. The innermost zone of the cortex is the 
zona reticularis. Cells within this zone are arranged in cords that project in many different directions and anastomose with 
one another. Obtained from http://academic.kellogg.cc.mi.us/herbrandsonc/bio201_McKinley/Endocrine%20System.htm. 
 
 
 
2.7 The HPA-Axis 
The HPA-axis is a major part of the neuroendocrine system that is activated in response to 
severe illness and stress situations (pain, fever, tissue damage, surgery, hypoxaemia, 
hypotension or hypoglycaemia). Under normal healthy conditions, the HPA-axis contributes 
to the maintenance of cellular and organ homeostasis. The hypothalamus releases CRH and 
vasopressin from an area along the median eminence. The hormones are then transported to 
the anterior lobe of the pituitary through the portal blood vessel system of the hypophyseal 
stalk, which descends from the hypothalamus. In the anterior pituitary gland, these hormones 
stimulate release of stored ACTH (also known as corticotrophin) which is transported by the 
blood to the cortex of the adrenal glands, where it rapidly stimulates the synthesis and 
secretion of glucocorticoids (Jurney et al. 1987;Reincke et al. 1993). Liberated 
glucocorticoids in turn will act on the HPA-axis, establishing a negative feedback mechanism 
with a resultant reduction in the release of CRH and ACTH (Fig. 8). Through the mechanism 
described, the body can control the secretion of glucocorticoids within relatively narrow 
limits and can respond with increased secretion of glucocorticoids to a variety of stresses and 
other signals (cytokines, endogenous peptides and other hormones). 
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Figure 8: The HPA-axis. The hypothalamus releases CRH from an area along the median eminence. Release of this 
hormone is influenced by stress, by blood levels of cortisol and by the sleep/wake cycle. In the anterior pituitary gland, CRH 
stimulates release of ACTH, which is then transported to the cortex of the adrenal glands. Subsequent, cortisol is synthesized 
and secreted rapidly. Increased production of this glucocorticoid mediates alarm reactions to stress. Furthermore, cortisol 
exerts a negative feedback influence on the pituitary and the hypothalamus by inhibiting the synthesis and release of CRH 
and ACTH. ACTH adrenocorticotropic hormone; CRH, corticotropin-releasing hormone. Green arrow: stimulation; red 
arrow: inhibition. 
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3 Materials and Methods 
3.1 Equipment and Materials 
3.1.1 Chemicals 
 
30% Acrylamide/Bis Solution      Bio-Rad, Munich, Germany 
Albumin fraction V (Bovine; BSA)    Merck-Schuchardt,  Hohenbrunn, 
       G e r m a n y  
Ammonium  chloride        Sigma-Aldrich,  Taufkirchen,  Germany 
(NH4Cl; MW:53.49 g/mol) 
Ammonium  persulfate  (APS)     Sigma-Aldrich, Taufkirchen, Germany 
((NH4)2S2O8; MW: 228.2 g/mol)     
Aprotinin  (Trypsin  inhibitor)     Sigma-Aldrich,  Taufkirchen,  Germany 
(C284H432N84O79S7; MW: 6511.4 g/mol) 
Ascorbic acid (Vitamin C)        Sigma-Aldrich, Taufkirchen, Germany 
(cell culture tested) 
Boric  acid       Sigma-Aldrich,  Taufkirchen,  Germany 
(H3BO3; MW: 61.8 g/mol) 
Bradford reagent (Protein dye reagent)    Sigma-Aldrich, Taufkirchen, Germany 
Bromophenol  blue      Merck,  Darmstadt,  Germany 
(C19H9Br4NaO5S; MW: 691.9 g/mol) 
CpG-ODN  (Thioat  1668)     TibMolBiol, Berlin, Germany 
Deoxycholic  acid      Sigma-Aldrich,  Taufkirchen,  Germany 
(C24H40O4; MW: 392.5 g/mol) 
D-galactosamine  (D-GalN)     Roth,  Karlsruhe,  Germany 
Dimethyl sulfoxide (DMSO)       Sigma-Aldrich, Taufkirchen, Germany 
(C2H6OS; MW: 78.1 g/mol) 
Di-sodium hydrogen phosphate dihydrate    Merck, Darmstadt, Germany 
(Na2HPO4 ⋅ 2 H2O; MW: 178.0 g/mol) 
DL-Dithiothreitol  (DTT)     Sigma-Aldrich, Taufkirchen, Germany 
(C4H10O2S2; MW: 154.3 g/mol)       57 
Entellan
® (mounting medium)      Merck, Darmstadt, Germany 
β-Estradiol (cell culture tested)      Sigma-Aldrich, Taufkirchen, Germany 
Ethanol  (absolute)      Merck,  Darmstadt,  Germany 
(C2H5OH; MW: 46.1 g/mol) 
Ethylenediaminetetraacetic acid (EDTA)    Sigma-Aldrich, Taufkirchen, Germany 
(C10H16N2O8; MW: 292.2 g/mol) 
Ethylene Glycol-bis (β-Aminoethylether)-   Sigma-Aldrich, Taufkirchen, Germany 
N,N,N’,N’-Tetraacetic acid (EGTA) 
(C14H24N2O10; MW: 380.4 g/mol) 
Ficoll  400       Sigma-Aldrich,  Taufkirchen,  Germany 
Foetal bovine serum (FBS)        Gibco, Invitrogen GmbH, Karlsruhe, 
       G e r m a n y  
Foetal  calf  serum      PAA Laboratories, Pasching, 
       A u s t r i a  
Forskolin         Sigma-Aldrich,  Taufkirchen,  Germany 
Glycerol       Sigma-Aldrich,  Taufkirchen,  Germany 
(C3H8O3; MW: 92.1 g/mol) 
Glycine       Fluka,  Buchs,  Switzerland 
(C2H5NO2; MW: 75.1 g/mol) 
Haematoxylin (modified acc. to Gill II)    Merck, Darmstadt, Germany 
HEPES (N-2-hydroxymethylpiperazine-    Gibco Life Technologies, 
N’-2-ethanesulfonic  acid)     Eggenstein,  Germany 
Leupeptin Hemisulfate Salt        Sigma-Aldrich, Steinheim, Germany 
(C20H38N6O4⋅ ½ H2SO4; MW: 475.6 g/mol) 
Lipopolysaccharides  (LPS)     Sigma-Aldrich,  Taufkirchen,  Germany 
(Escherichia coli 0111:B4) 
Lipopolysaccharides  (LPS)     Prof. Zähringer, Borstel, Germany 
(Escherichia coli F515 LPS SB III,66) 
Magnesium  chloride      Merck,  Darmstadt,  Germany 
(MgCl2; MW: 95.2 g/mol) 
2-Mercaptoethanol      Merck,  Darmstadt,  Germany 
(HSCH2CH2OH; MW: 78.1 g/mol)     
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Methanol       Merck,  Darmstadt,  Germany 
(CH3OH; MW: 32.0 g/mol) 
Nonidet P40 Substitute        Fluka, Buchs, Switzerland 
(Nonylphenylpolyethylene glycol) 
Paraffin (Paraplast tissue embedding media) Fisher  Scientific, Pittsburgh, PA 
Paraformaldehyde      Merck,  Darmstadt,  Germany 
((CH2O)n; MW: 30.0 g/mol) 
Phenylmethylsulfonyl fluoride (PMSF)   Sigma-Aldrich,  Steinheim, 
(C7H7O2SF; MW: 174.2 g/mol)      Germany; 
Phosphate buffered saline (PBS) tablets    Sigma-Aldrich, Taufkirchen, Germany 
Poly  dI-dC       Sigma  Chemical,  St.  Louis,  USA. 
(poly desoxyinosin-desoxycytidin) 
Potassium  chloride      Fluka,  Buchs,  Switzerland 
(KCl; MW: 74.6 g/mol) 
Roti®-Histol       Carl  Roth  GmbH,  Karlsruhe,  Germany 
Skimmed  milk  powder     Fluka,  Buchs,  Switzerland 
Sodium  chloride      Merck,  Darmstadt,  Germany 
(NaCl; MWT: 58.4 g/mol) 
Sodium  deoxycholate      Sigma-Aldrich, Taufkirchen, Germany 
(C24H39NaO4; MW: 414.6 g/mol) 
Sodium dihydrogen phosphate monohydrate  Merck, Darmstadt, Germany 
(NaH2PO4 ⋅ H2O; MW: 138.0 g/mol) 
Sodium dodecyl sulfate (SDS)      Merck, Darmstadt, Germany 
(C12H25NaO4S; MW: 288.4 g/mol) 
Sodium  orthovanadate    Sigma-Aldrich, Taufkirchen, Germany 
(Na3VO4; MWT: 183.9 g/mol) 
Sodium  pentobarbital      University  Pharmacy  of  Dusseldorf, 
       G e r m a n y  
Sodium selenite (cell culture tested)   Sigma-Aldrich,  Taufkirchen,  Germany 
N,N,N’,N’-Tetramethyl ethylenediamine    Merck, Darmstadt, Germany 
(TEMED) (C6H16N2; MW: 116.2 g/mol) 
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Tris(hydroxymethyl)-aminomethane    Roth,  Karlsruhe,  Germany 
(Sigma 7-9
®) (C4H11NO3; MW: 121.1 g/mol) 
Triton
®X-100       Sigma  Chemical,  St.  Louis,  USA 
(C3OH32N4O8; MW: 624.0 g/mol) 
Trizma
®hydrochloride    Sigma-Aldrich,  Taufkirchen,  Germany 
(C4H11NO3.HCl; MW: 157.6 g/mol) 
0.05%  Trypsin/0.02%  EDTA     Biochrom AG, Berlin, Germany 
Tween
®20  (polysorbate)     Merck-Schuchardt,  Hohenbrunn, 
       G e r m a n y  
Vectashield (mounting medium)      Vector Laboratories, Peterborough, 
       U K  
Xylene        Merck,  Darmstadt,  Germany 
(C6H4(CH3)2; MW: 106.2 g/mol) 
 
 
 
3.1.2 Antibodies, Enzymes, Protein Standard, DNA-oligonucleotides, Kits 
 
Primary antibodies: see sections 3.3.8 and 3.3.15; Tables 12 and 14 
Secondary antibodies: see section 3.3.8 and 3.3.15; Tables 13 and 15 
 
DNA  Oligonucleotides:     Promega, Mannheim, Germany 
specific for NF-κB        
NF IgH-1comp  5’-AGT TGA GGG GAC TTT CCC AGG -3’ 
NF IgH-2comp  5’-TCA ACT CCC CTG AAA GGG TCC -3’ 
 
Enzymes:  
Streptavidin-HRP      Dako  Cytomation,  Glostrup, 
       D e n m a r k  
T4 Polynucleotide Kinase (T4 PNK)     Fermentas, St. Leon-Rot, Germany 
 
Radioactive nucleotide: 
dATP labelled with γ[
32P] (3000 Ci/mmol)    Hartmann Analytic,Braunschweig, 
       G e r m a n y  60 
Kits: 
Radioimmunoassay  kit     Diagnostic Systems Laboratories, 
Webster, Texas, USA 
Mouse Cytokine Luminex
TM multiplex kit    Biosource Europe, S.A. Nivelles, 
(IL-1β, IL-6, IL-10, IL-12, TNF-α)   Belgium 
   
Western blotting luminol reagent kit    Santa-Cruz  Biotechnology,  CA, 
       U S A  
RNeasy  Mini  kit      QIAGEN,  Hilden,  Germany 
RNase-free  DNase  set    QIAGEN,  Hilden,  Germany 
OneStep  RT-PCR  kit      QIAGEN,  Hilden,  Germany 
 
Water was generally of Millipore-purified or distilled quality, purchased from University 
Pharmacy Dusseldorf, Frankfurt (Germany) and Bristol (UK).  
 
 
3.1.3 Equipments 
Weighing balances (analytical and precision)  Sartorius, Göttingen, Germany 
β-counter  LS  1801      Beckman,  Frankfurt,  Germany 
Centrifuge 5417R and 5810R      Eppendorf, Hamburg, Germany 
Digital pH meter 646         Carl Zeiss, Oberkochen, Germany 
Drying  oven       Fisher  Scientific,  Pittsburgh,  PA 
Electronic ballast for mercury vapour    Leistungselektronik Jena GmbH, 
compressed-arc  lamp      Jena,  Germany 
Electrophoresis power supply- EPS 1001   Amersham  Pharmacia  Biotech, 
       P i s c a t a w a y ,   N J ,   U S A  
Electrophoresis  equipment     Bio-Rad,  Munich,  Germany 
Film processor AGFA/CURIX 60      Agfa, Mortsel, Belgium 
Galaxy mini centrifuge        VWR International, Darmstadt, 
       G e r m a n y  61 
Gel  dryer  583       Bio-Rad,  Munich,  Germany 
Heater        neoLab,  Heidelberg,  Germany 
Jerome industry phototype P99135 camera    Digital Video Camera, Austin, 
       T X ,   U S A  
Leica  DM  LB  microscope     Leica  Microsystems,  Wetzlar, 
       G e r m a n y  
 
Leica DC300F digital camera      Leica Microsystems, Wetzlar, 
       G e r m a n y  
Luminex  100  system      Luminex Corporation, Austin, TX, USA 
Mini-PROTEAN 3 system        Bio-Rad, Munich, Germany 
Microtome  HM330      Microm  GmbH,  Heidelberg, 
       G e r m a n y  
Nikon eclipse TE300 inverted microscope     Nikon, Tokyo, Japan 
μQuant microplate Spectrophotometer    Bio-Tek, Winooski, Vermont, 
       U S A  
Spindrive orbital shaker platform    Scienceware,  Pequannock, 
       New  Jersey,  USA 
Variomag  magnetic  stirrers     H + P Labortechnik, Oberschleiß- 
       h e i m ,   G e r m a n y  
Vortex  mixer       neoLab
®, Heidelberg, Germany 
Water  bath       Memmert  GmbH  &  Co.  KG, 
       Schwabach,  Germany 
 
 
3.1.4 Materials 
Centrifuge tubes (15, 50 ml)     Falcon,  Heidelberg,  Germany 
Cover slips (various sizes)        Fisher Scientific, Pittsburgh, PA 
Cryo  vials       Nunc,  Wiesbaden,  Germany 
Gel  blotting  papers      Schleicher  &  Schuell,  Dassel, 
       G e r m a n y  62 
Hybond ECL nitrocellulose membrane    Amersham Biosciences, Bucking- 
       h a m s h i r e ,   U K  
Hyperfilm™  ECL      Amersham  Biosciences,  Bucking- 
high performance chemiluminescence film    hamshire, UK 
Hyperfilm MP   (X-ray film)        Amersham Biosciences, Bucking- 
       h a m s h i r e ,   U K  
Intensifying  screens      Eastman  Kodak,  Rochester,  NJ, 
       U S A  
KODAK READYMATIC dental chemicals   Eastman Kodak, Rochester, NJ, 
(developer  and  fixer)      USA 
Microscope  slides      Engelbrecht, Edermünde, Germany 
Microtest tubes (0.5, 1.5, 2 ml)    Eppendorf,  Hamburg,  Germany 
Multi-well cell culture plates    Nunc,  Wiesbaden,  Germany 
Pipettes       Sarstedt,  Nümbrecht,  Germany 
Sterile micropore filters        Millipore, Eschborn, Germany 
Transparency films          Ahrend, Dreiech bei Frankfurt am  
       M a i n ,   G e r m a n y  
Whatman  paper  filters    Schleicher  &  Schuell,  Dassel, 
       G e r m a n y  
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3.2 Principle of Methods Applied 
This chapter outlines the principle methods underlying the experiments performed in this 
study. 
 
3.2.1 PCR 
The purpose of a polymerase chain reaction (PCR) is to make a huge number of copies of a 
gene. PCR is based on the enzymatic amplification of a fragment of DNA that is flanked by 
two 'primers', short oligonucleotides that hybridize to the opposite strands of the target 
sequence and then prime synthesis of the complementary DNA sequence by DNA 
polymerase. The chain reaction is a three-step process, denaturation, annealing and extension, 
which is repeated in several cycles. At each stage of the process, the number of copies is 
doubled from two to four, to eight, and so on. The reactions are controlled by changing the 
temperature using a special heat-stable Taq polymerase.  
 
 
1. Denaturation (at 94 °C): 
During the denaturation, the double strand melts open to single stranded DNA, all enzymatic 
reactions stop (e.g. the extension from a previous cycle).  
 
2. Annealing (at 54 °C): 
The primers are jiggling around, caused by the Brownian motion. Ionic bonds are constantly 
formed and broken between the single stranded primer and the single stranded template. The 
more stable bonds last a little bit longer (primers that fit exactly), and on that little piece of 
double stranded DNA (template and primer) the polymerase can attach and starts copying the 
template. Once there are a few bases built in, the ionic bond between the template and the 
primer is so strong that it does not break anymore.  
 
3. Extension (at 72 °C): 
72 °C is the ideal working temperature for the polymerase. The primers where there are a few 
bases built in already have a stronger ionic attraction to the template, more than the forces 
breaking these attractions. Primers that are in positions with no exact match become free 
again due to the higher temperature and so do not form a part of the extended fragment. The 64 
bases (complementary to the template) are coupled to the primer on the 3' side (the 
polymerase adds deoxyribonucleotide triphosphates from 5' to 3', reading the template from 3' 
to 5' side, bases are added complementary to the template)  
 
 
 
3.2.2 Bradford Assay (Quantification of Proteins) 
The Bradford assay is a rapid and accurate method used to determine the total protein 
concentration of a sample. This assay uses the dye Coomassie brilliant blue G-250, and is 
based on the immediate absorbance shift from 465-595 nm when Coomassie brilliant blue G-
250 binds to proteins in an acidic solution. The dye exists in a red and blue form. The red 
form is the predominant dye in solution and it converts to blue when its negative charge binds 
to the positive charges on protein. The binding of protein to the anionic form of the 
Coomassie dye results in an absorbance shift to 595 nm. The protein stabilizes the anionic 
form of the dye by hydrophobic and ionic interactions with arginine residues, and to a lesser 
extent histidine, lysine, tyrosine, tryptophan and phenylalanine residues. The absorption is 
proportional to the amount of protein present (Bradford 1976;Stoscheck 1990). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Chemical structure of Coomassie
® Brilliant blue G-250. 
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Because the colour response is non-linear over a wide range of protein concentration, a 
standard curve must be run with each assay (Bradford 1976). Standard curves are commonly 
prepared using bovine serum albumin. A standard curve provides a reference for measuring 
the amount of protein in a solution of unknown concentration. It is constructed by measuring 
the absorption of several known concentrations of protein. Then a sample will be tested for its 
absorbance in the assay and its concentration will be determined from the standard curve. 
 
 
 
3.2.3 Western Blotting (Immunoblotting) 
Western blotting is a common technique for protein detection and the word blotting means the 
transferring of biological samples from a gel to a membrane and the detection of them on the 
surface of the membrane. The specificity of the antibody/antigen-interaction used to identify a 
specific protein in a complex protein mixture provides qualitative data about that protein. 
During a western blotting procedure, electrophoresis of a gel results in macromolecules being 
separated. Then, the separated molecules are transferred on to a second matrix, e.g. 
nitrocellulose membrane. The next step involves the blocking of the membrane to stop non-
specific binding of antibodies to the surface of the membrane. The transferred protein is 
complexed with an enzyme-labelled antibody; an appropriate substrate is then added to the 
enzyme. This complex makes a detectable product on the membrane. One of the common 
substrate is chemiluminescence, which when combined with the enzyme complex produces 
light. The light can be captured using film that is designed for chemiluminescent detection. 
Whatever substrate is used, the intensity of the signal should correlate with the abundance of 
the antigen on the blotting membrane (Krebs et al. 2006). 
 
 
 
3.2.4 EMSA 
Electrophoretic mobility shift assay (EMSA) is used to investigate DNA/protein-interactions 
such as binding of transcription factors to their DNA binding sites. In principle, radioactivity-
labelled DNA fragments containing binding sites specific for the transcription factor in 
question are incubated with a test sample, in which the presence or amount of DNA-binding 66 
activity is determined. This mixture of components is then subjected to gel electrophoresis. 
The unbound DNA fragments will migrate relatively far away from the electrophoresis start 
site, whereas DNA/protein-complexes that may have formed during the incubation period will 
remain closest to the start site due to their larger size. Subsequently, autoradiography 
visualizes those complexes that contain radioactivity-labelled constituents. In order to confirm 
that the bands observed are specific and result from binding to a characterised DNA-site, 
competition assays may be performed. Unlabelled oligo-nucleotides with the specific DNA 
site are added to the sample, prior to the addition of the radioactivity-labelled 
oligonucleotides. The unlabelled specific oligonucleotides are added in molar excess over the 
labelled specific oligonucleotides and compete for binding. The observed band is weaker or 
not detectable at all, depending on the factor of molar ratio. Therefore concluding that the 
bands observed are indeed cause by a molecule that possesses a DNA-binding activity 
specific for the characterized oligonucleotide base sequence, but does not bind to other DNA. 
 
 
 
3.2.5 RIA 
The radioimmunoassay (RIA) is based on the competition between an unlabelled antigen and 
a fixed concentration of labelled antigen, which is called a tracer and usually labelled with 
I
125-isotope for a limited and constant number of binding sites on the specific antibody. The 
amount of tracer bound to the antibody will decrease as the concentration of unlabelled 
antigen increases. This can be measured after separating bound antibody from the free tracer 
and counting the bound fraction, the free fraction or both. A standard curve is set up with 
increasing amounts of known antigen and from this curve the amount of antigen in the 
unknown samples can be calculated. 
RIA is not limited to mediators of the immune systems, but can also be extended to other 
systems in which there is a specific reactor or binding substance. This could be for example a 
specific binding protein, enzyme or receptor. This assay is also suitable for measurement of 
hormones, vitamins, drugs and other substances present in biological fluids like serum or 
plasma. 
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3.2.6 Haematoxylin Staining 
Haematoxylin is a natural colour that is obtained from the logwood tree Haemotoxylon. There 
are several variations of the haematoxylin solution. The final colour of haematoxylin is blue. 
Haematoxylin can stain tissue only in acidic pH conditions. This staining makes it possible to 
visualize morphologic differences within tissues. Eosin is the most common colour which is 
used with haematoxylin. The intensity of eosin depending on its formula as well as the 
fixative varies very widely. Eosin stains cytoplasm pink to red; and also red blood cells to red. 
The contrast between these two colours makes it easy to see the difference between various 
parts of tissue. 
 
 
 
3.2.7 Immunohistochemistry 
Immunohistochemistry is a technique for the identification of specific tissue components by 
means of a specific antigen/antibody-reaction tagged with a visible label. Immuno-
histochemistry makes it possible to visualize the distribution and localization of specific 
cellular components (antigens) within a cell or tissue. The term immunohistochemistry is 
often used interchangeably with immunocytochemistry and immunostaining. 
 
 
Fixation of tissue and cells 
For immunohistochemical analysis, it is essential that the morphology of the tissues or cells is 
retained and that the antigenic sites (epitopes) are accessible. Tissue sections are typically 
immersed into a fixative solution. Fixation is necessary to prevent artifactual diffusion of 
soluble tissue components, to arrest enzymatic activity, to avoid decomposition of the 
structure and to protect the tissue against the deleterious effects involved in the 
immunohistochemical process. 
Fixatives help to preserve tissue by preventing autolysis caused by lysosomal enzymes and 
bacterial or fungal growth. Fixatives can often cross-link the tissue, making it difficult for the 
immunoassay reagents to penetrate it. Each fixative procedure must to be optimized to 
minimize this problem, without altering the antigen or disturbing the endogenous location and 
the cellular detail of the tissue. There are a lot of different fixatives, for e.g. formaldehyde, 68 
paraformaldehyde, glutaraldehyde, mercuric chloride, acetic acid-zinc chloride or 
precipitating  fixatives like ethanol, methanol and acetone. The suitability of a fixative 
depends on the tissue or antigen studied. 
 
 
Inhibition of endogenous tissue components 
Tissue can contain materials that react with the various reagents used to develop an 
immunohistochemical stain. Cellular components, such as enzymes and the vitamin biotin can 
result in unwanted signals, falsely indicating the presence of an antigen. The 
immunoperoxidase method of signal detection is commonly used for the immunostaining of 
tissue. Final analysis of this staining method is complicated by the presence of endogenous 
peroxidase and ‘pseudoperoxidase’ activity in tissue. Peroxidase can react with H2O2 to 
reduce substrates, resulting in non-specific staining of tissue or false positives. The most 
common methods to inhibit or destroy endogenous peroxidase activity after tissue fixation are 
treatment with H2O2 (0.3%) alone or with methanol. 
 
 
Blocking of non-specific sites (background staining) 
Blocking the reactive sites in tissue is essential for the development of an immuno-
histochemical reaction. Normal serum is the most popular blocking agent for 
immunohistochemical staining. The principle is that non-immune serum from the host species 
of the secondary antibody is applied to the tissue at the beginning of the procedure and will 
adhere to protein-binding sites either by non-specific adsorption or by binding of specific, but 
unwanted serum antibodies to antigens. 
 
 
Labelled Streptavidin-Biotin 
There are numerous immunohistochemical techniques that may be used to localize antigens. 
The selection of a suitable method should be based on parameters, such as the type of 
specimen under investigation and the degree of sensitivity required. In this study, the labelled 
streptavidin-biotin method was processed. Streptavidin derived from Streptomyces avidinii is 
a recent substitution to avidin. Unlike avidin, streptavidin molecule is uncharged, and 
therefore electrostatic binding to tissue is eliminated. In addition, streptavidin does not 69 
contain carbohydrate groups which might bind to tissue lectins, resulting in a degree of 
background staining. 
Labelled streptavidin-biotin is technically similar to the standard avidin-biotin complex-
method. The first layer is unlabelled primary antibody, which reacts with tissue antigen. The 
second layer is biotinylated secondary antibody, which reacts with the primary antibody. This 
secondary antibody must be directed against the IgG of the animal species in which the 
primary antibody has been raised. The third layer is enzyme-streptavidin conjugates 
horseradish peroxidase (HRP)-streptavidin or alkaline phosphatase-streptavidin to replace the 
complex of avidin-biotin peroxidase. The enzyme is then visualized by application of the 
substrate chromogen which produces a colorimetric end product. Labelled streptavidin-biotin 
method is about 5-10 times more sensitive than the standard avidin-biotin-complex method. 
 
 
Immunohistochemical substrates 
Immunoenzymatic staining of tissue results in the reaction of a soluble substrate with an 
enzyme to produce an insoluble, coloured product. When a substrate is added, the intensity of 
the colour produced should correlate to the concentration of the primary antibody and the 
respective tissue antigen. Many enzymes are used for this application, but the most common 
selection is HRP (isolated from the root of the horseradish plant) and calf intestinal alkaline 
phosphatase. HRP has an iron-containing haeme group (haematin) as its active site and in 
solution is coloured brown. The haematin of HRP first forms a complex with H2O2 and then 
causes it to decompose resulting in water and atomic oxygen. HRP activity in the presence of 
an electron donor first results in the formation of an enzyme-substrate complex then in the 
oxidation of the electron donor. The electron donor provides the force in continuing catalysis 
of H2O2, while its absence effectively stops the reaction. 
There are several electron donors that when oxidized become coloured products and are 
therefore called chromogens. 3,3’-diaminobenzidine is the most common electron donor in 
immunohistochemistry. Diaminobenzidine produces a brown end product, which is highly 
insoluble in alcohol and other organic solvents. 
 
 
Controls 
Special controls must be carried out in order to test the protocols and for the specificity of the 
antibody being used.  70 
A positive control is to test for a protocol or procedure used. It is ideal to use a sample of 
tissue where the target antigen is present, and therefore can be used as a positive control. If 
the tissue shows negative staining, the protocol needs to be checked until a good positive 
staining is obtained. 
A negative control is to test for the specificity of the antibody involved. Therefore, in the 
absence of the primary antibody or replacement of this by normal serum (derived from the 
same species as the primary antibody) no staining should occur. This control is easy to 
achieve and can be used routinely in immunohistochemical staining. 
 
 
 
3.2.8 Luciferase Assay  
The use of the firefly beetle Photinus pyralis luciferase gene in molecular biology has offered 
a method for utilizing light production in research. Luciferase interacts with the substrate 
luciferin and produces a light emission, peaking at 562 nm. The main flash reaction is 
finished within approximately 20 s. Therefore, luciferase determination needs rapid mixing 
and measurement of light emission. Light emission is measured most sensitively with 
luminometers in microtiter plates using scintillation counters or photographic films. This form 
of luminescence can provide a sensitive non-radioactive assay. Luciferase can be produced 
from different vectors and in various organisms as a reporter of gene regulation. Luciferase 
assays are one of the best non-toxic, rapid and sensitive methods to measure gene expression. 
The assay is based on the detection of luciferase activity which correlates with transcription 
due to DNA regulatory elements in genes, mutations within those elements as well as 
responses to extracellular and intracellular signals. 
 
 
 
3.2.9 ELISA 
Enzyme-linked immunosorbent assay (ELISA) employs the quantitative sandwich enzyme 
immuno technique. The antigen is detected by selective monoclonal antibodies, which interact 
with two different binding sites (epitopes). A specific antibody is coated on the surface of a 71 
microtiter plate as the capture (immobilized) antibody. A secondary HRP-conjugated 
antibody serves as the detection antibody in the assay. 
The antibodies in concert with the appropriate antigen form an antibody-antigen-antibody 
complex (sandwich-complex). The peroxidase then catalyzes the conversion of the 
chromogen substrate (e.g. tetramethylbenzidine) into a coloured product, which is detected by 
means of spectrophotometry. The intensity of the colour generated is directly proportional to 
the concentration of the presents in a sample. Sample values are then determined from the 
standard curve. 
 
 
 
3.2.10 Luminex xMAP
TM Technology 
The Luminex xMAP
TM technology employs microspheres. Each bead can be covered with a 
reagent specific to a particular bioassay, allowing the detection of specific analytes from a 
sample. Within the Luminex analyzer, lasers provoke the internal dyes that detect each 
microsphere particle. Many readings are made on each bead set, further validating the results. 
In this way, Luminex xMAP
TM technology allows multiplexing of up to 100 unique assays 
within a single sample, rapidly and precisely. This technique has ideal speed and sensitivity 
for cytokine measurements. Its sensitivity is comparable with traditional ELISA-based 
systems, but with additional advantages including an expanded dynamic range and smaller 
sample size. 72 
3.3 Experimental Part  
 
This chapter contains detailed descriptions of the experiments performed in this study as well 
as the contents of the reagents used.  
 
3.3.1 Animals  
TLR-2, TLR-4 and TLR-9 deficient (TLR-2
-/-, TLR-4
-/- and TLR-9
-/-) mice were generated by 
homologous recombination. TLR-2
-/- mice were provided by Tularik Inc. (South San 
Francisco, CA); TLR-4
-/- and TLR-9
-/- mice were kindly provided by Akira (Osaka 
University, Osaka, Japan) (Hoshino et al. 1999;Hemmi et al. 2000). TLR-2
-/-, TLR-4
-/- and 
TLR-9
-/- mice, plus their respective controls (wild-type = WT; C57BL/6 mice) were kept at 24 
°C, 55% humidity, 12 h day-night rhythm and received a standard diet and water ad libitum. 
Male or female mice that were 12-16 weeks old (20-30 g) were used for the experiments.All 
procedures were carried out in accordance with the Association for Assessment and 
Accreditation of Laboratory Animal Care (AAALAC) International guidelines and Guide for 
the Care and Use of Laboratory Animals (Department of Health and Human Services, 
National Institutes of Health, Publication no. 86-23) and were approved by the German 
government ethical and research boards.  
 
 
 
3.3.2 Animal Interventions  
 
TLR-2 
WT and TLR-2
-/- mice were randomized in 24 different treatment groups (n = 4-8/group) and 
treated intraperitoneally (i.p.) with saline (sal; 1 ml/kg), LPS (1 mg/kg; Escherichia coli, 
serotype 0.111:B4) or LTA (1 mg/kg; Staphylococcus aureus). After a period ranging from 30 
min to 24 h, mice were killed by terminal anaesthesia using pentobarbital, provided by the 
University Pharmacy of Dusseldorf, Germany. Plasma samples and the adrenal glands were 
taken and frozen at -20 °C or snap frozen and stored at -80 °C respectively until assayed. 
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Table 8: Summary of treatment groups in the TLR-2 study.  
 
 
TLR-4 
WT and TLR-4
-/- mice were treated i.p. with sal (1 ml/kg), crude ‘commercialized’ (c)LPS (1 
mg/kg; Escherichia coli, serotype 0.111:B4) or pure (p)LPS (1 mg/kg; Escherichia coli, F515 
LPS SB III, 66), a highly purified preparation kindly provided by Prof. U. Zähringer 
(Research Centre Borstel, Borstel, Germany). After 1, 6 and 24 h, mice were sacrificed by 
terminal pentobarbital anaesthesia. Plasma and the adrenal glands were taken and frozen at -
20 °C or snap frozen and stored at -80 °C respectively until assayed. 
 
Treatment (i.p.)  1 h   6 h   24 h 
saline (1 ml/kg)  WT or TLR-4
-/-  WT or TLR-4
-/-  WT or TLR-4
-/- 
cLPS (1 mg/kg)  WT or TLR-4
-/-  WT or TLR-4
-/-  WT or TLR-4
-/- 
pLPS (1 mg/kg)  WT or TLR-4
-/-  WT or TLR-4
-/-  WT or TLR-4
-/- 
 
Table 9: Summary of treatment groups in the TLR-4 study.  
 
 
TLR-9 
WT and TLR-9
-/- mice were i.p. sensitized with a hepatocyte-specific inhibitor of RNA 
synthesis D-galactosamine (D-GalN; 1 mg/kg). D-GalN sensitization was used to reduce the 
amount of bacterial DNA or CpG-ODN (Hemmi et al. 2000;Wang et al. 2006). Thirty 
minutes later, animals received i.p. either 1 ml/kg of sal or 1 nmol/g CpG-ODN (containing a 
“CG-motif”: 5’-TCC ATG ACG TTC CTG ATG CT) for a period of 15 min to 6 h. After 
each time period, animals were killed by an overdose of pentobarbital. Adrenal glands, spleen 
and plasma samples were taken and frozen at -20 °C or snap frozen and stored at -80 °C 
respectively until assayed. 
 
 
Treatment (i.p.)  30, 60, 90, 120 min  6 h  24 h 
saline (1 ml/kg)  WT only  WT or TLR-2
-/-  WT or TLR-2
-/- 
LPS (1 mg/kg)  WT only  WT or TLR-2
-/-  WT or TLR-2
-/- 
LTA (1 mg/kg)  WT only  WT or TLR-2
-/-  WT or TLR-2
-/- 74 
 
Table 10: Summary of treatment groups in the TLR-9 study.  
 
 
 
3.3.3 Human Adrenal Tissue 
Foetal (12-week) and adult human adrenal tissue were obtained from the adrenal tissue bank 
approved by the ethical committee of the University of Dresden, Germany. 
 
 
 
3.3.4 Isolation of RNA 
Total RNA from tissue or cells was isolated using RNeasy Mini kit including a DNase 
digestion step (RNase-free DNase set; Qiagen) according to the manufacturer's instructions. 
For reverse transcription reaction (RT), 1 μg of RNA was incubated at 37 °C for 1 h in buffer 
containing 200 U of M-MLV reverse polymerase, oligo(dT)15 primers mix and dNTPs. RNA 
concentration
 was determined by absorbance at 260 nm. Until further processing, RNA was 
dissolved in 30 µl of RNase-free water and stored at -80 °C.  
 
 
 
3.3.5 RT-PCR 
The first-strand cDNA was synthesized using an Omniscript kit (Qiagen). Primers were 
designed by using the Primer3 software synthesised by MWG Biotechnology (Ebersberg, 
Germany) (see Tab. 11). All RT-PCR tests were run under the following conditions: initial 
denaturation at 94 °C for 60 s followed by 40 cycles of amplification with the denaturation 
step at 94 °C for 45 s, the annealing step for 60 s at 54 °C and the elongation step at 72 °C for 
90 s or 30 cycles of 30 s at 94 °C, 30 s at 56 °C and 2 min extension at 72 °C. β-actin as a 
housekeeping gene was used to ensure the purity of the cDNA. The RT-PCR products were 
Treatment (i.p.)  15, 30, 45,60 min  2 h  6 h 
saline (1 ml/kg)  WT only  WT or TLR-9
-/-  WT or TLR-9
-/- 
CpG-ODN (1 nmol/g)  WT only  WT or TLR-9
-/-  WT or TLR-9
-/- 75 
separated in 2% (wt/vol) agarose gels and visualized with ethidium bromide. Quantitative 
analysis of TLR mRNA levels was performed by determination of the optical density using 
Scion Image software (Scion Corporation, Maryland, USA) and normalized to β-actin mRNA 
expression levels. 
 
 
Gene Forward  Reverse  Product 
size (bp) 
mTLR-2 5’-AGCTCTTTGGCTCTTCTG-3’  5’-AGAACTGGGGGATATGC-3’  950 
mTLR-4 5’-GCATGGCTTACACCACCTCT-3’  5’-GTGCTGAAAATCCAGGTGCT-3’  970 
mTLR-9  5’-TGC AGG AGC TGA ACA TGA AC-3’  5’-TAG AAG CAG GGG TGC TCA GT-3’  297 
mβ-actin 5’-GTGGGGCGCCCCAGGCACCA-3’  5’-CTCCTTAATGTCACGCACGAT-3’ 540 
mβ-actin  5’-TGT TAC CAA CTG GGA CGA CA-3’  5’-TCT CAG CTG TGG TGG TGA AG-3’  392 
 
Table 11: Summary of primers. 
 
 
 
3.3.6 Protein Preparation of Tissue for Western Blotting  
Protein extraction buffer (Lysis buffer):  
NaCl                  150 mM  
Tris-HCl  (pH  7.4)      50  mM   
Ethylenediaminetetraacetic acid (EDTA)    1 mM  
Phenylmethylsulphonyl fluoride (PMSF)    1 mM  
Triton X-100               1%  
Sodium deoxycholate            1%  
Sodium dodecyl sulfate (SDS)      0.1%  
Leupeptin                 5 µg/ml  
Aprotinin A               5 µg/ml  
 
The protease inhibitors leupeptin, aprotinin and PMSF were freshly added just before use. 
The lysis procedure was performed on ice.  
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Tissue (adrenal glands) was homogenized in 4 volumes of ice-cold protein extraction buffer, 
after being disrupted with a clean scalpel. The crude homogenate was then transferred to a 
microcentrifuge tube. After 20 min incubation on ice, the homogenate was centrifuged at 
20000 x g for 20 min at 4 °C. The supernatant was removed and frozen at -80 °C until 
assayed. The total protein present in each sample was determined by the Bradford 
colorimetric assay. 
 
 
 
 
3.3.7 Protein Quantification (Bradford Assay) 
Protein concentration of samples for Western blotting or EMSA was measured using the 
method described by Bradford in a colorimetric assay. The unknown samples and the blank 
(consists of buffer with no protein) were diluted 1:10 or 1:25 in distilled water. For protein 
standards, a serial dilution of bovine serum albumin (BSA) was prepared. The BSA standard 
solutions ranged from 0.1-1.0 mg/ml. This assay was performed in 96-well plates and in 
duplicate for each sample and standard solution. 10 µl of the protein standards, the unknown 
samples and the blank were added to separate wells in the 96-well plate and mixed with 200 
µl of the protein dye reagent (Bradford reagent). After incubation at room temperature (RT) 
for 5 min, the absorbance was measured at λ = 595 nm in a microplate reader. Protein 
concentrations in the samples were determined with KC4™ data analysis software using a 
standard curve.  
 
 
 
3.3.8 Western Blotting  
Stock solutions  
Tris (hydroxymethyl)-aminomethane (Sigma 7-9
®; 1.875 M):  
Sigma 7-9
®       45.4  g         
distilled  water       150.0  ml 
was adjusted to pH 8.8 with 6 N HCl and  to a total volume of 200 ml with distilled water.  
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Sigma 7-9
® (0.625 M):  
Sigma 7-9
®       15.1  g         
distilled  water       150.0  ml 
was adjusted to pH 6.8 with 6 N HCl and  to a total volume of 200 ml with distilled water.  
Ammonium persulfate (APS; 10%):  
100 mg APS were dissolved in 1.0 ml of distilled water.  
 
Tris-HCl (0.5 M):  
Tris-HCl         15.76  g     
distilled  water       150.0  ml 
was adjusted to pH 6.8 with 5 N NaOH and to a total volume of 200 ml.  
 
 
Buffers  
Separating gel buffer (200 ml):  
1 g (0.5%) SDS was dissolved in 1.875 M Sigma 7-9
® (pH 8.8) stock solution and stored at 
RT.  
 
Stacking gel buffer (200 ml):  
1 g (0.5%) SDS was dissolved in 0.625 M Sigma 7-9
® (pH 6.8) stock solution and stored at 
RT.  
 
Sample buffer (10 ml):  
0.5 mM Tris-HCl (pH 6.8)           1.0 ml (final concentration: 50 mM)  
Glycerol                 2.0 ml (20%)  
SDS                  0.1 g (1%)  
Bromphenol blue              5 mg (0.05%)  
distilled water              6.0 ml  
β-Mercaptoethanol             1.0 ml  (10%)  
β-Mercaptoethanol was added to sample buffer prior to use.  
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Running buffer (1000 ml):  
Sigma 7-9
®                 6.1 g (50 mM)  
Glycine                 28.8 g (0.384 M)  
SDS                  1.0 g (0.1%)  
All reagents were dissolved in distilled water.  
 
Transfer buffer (1000 ml):  
Sigma 7-9
®                 6.0 g (25 mM)  
Glycine                 14.4 g (0.192 M)  
Methanol                 200.0 ml (20%)  
distilled water              800.0 ml  
 
 
Solutions  
Phosphate buffered saline (PBS) solution (1000 ml):  
5 PBS tablets were dissolved in distilled water.  
 
TPBS solution (400 ml):  
PBS                  399.0 ml  
Tween
® 20               1.0 ml  
 
Blocking solution (200 ml):  
PBS                  200.0 ml  
Skim milk                 10.0 g (5%)  
Tween
® 20               0.5 ml  
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Antibodies  
The primary and secondary antibodies used in Western blotting are listed in Tables 12 and 13, 
respectively.  
 
Antibody Isotype  (Ig) Dilution  Source 
Anti-β-actin (monoclonal, mouse)  IgG1  1:3000  Sigma-Aldrich, St. Louis, USA 
Anti-mouse TLR2 (polyclonal, goat)  IgG  1:1000  Santa Cruz, Heidelberg, 
Germany 
Anti-mouse TLR4 (polyclonal, goat)  IgG  1:1000  Santa Cruz, Heidelberg, 
Germany 
Anti-human TLR2 (polyclonal, goat)  IgG  1:500  Santa Cruz, Heidelberg, 
Germany 
Anti-human TLR4 (polyclonal, rabbit)  IgG  1:500  Santa Cruz, Heidelberg, 
Germany 
Anti-mouse TLR9/CD289 (polyclonal, rabbit)  IgG  1:1000  Imgenex Corp., San Diego, 
CA,USA 
 
Table 12: Primary antibodies used in Western blotting analysis.  
 
 
Antibody-HRP conjugated Dilution  Source 
Goat anti-mouse IgG-HRP  1:3000  Santa Cruz, Heidelberg, Germany 
Rabbit anti-goat IgG-HRP  1:3000  Santa Cruz, Heidelberg, Germany 
Donkey anti-rabbit IgG-HRP  1:3000  Santa Cruz, Heidelberg, Germany 
Goat anti-rabbit IgG-HRP  1:5000  Imgenex Corp., San Diego, CA, USA 
 
Table 13: Secondary antibodies used in Western blotting analysis. HRP, horseradish peroxidase.  
 
 
 
Preparation of Gels  
Separating gel (7.5%; 20 ml):  
Acrylamide/Bis (30%)            5.0 ml  
Separating gel buffer              4.0 ml  
distilled water              10.9 ml  
APS (10%)                100 µl  
Tetramethylethylenediamine (TEMED)    20 µl  
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Stacking gel (4%; 10 ml)):  
Acrylamide/Bis (30%)            1.3 ml  
Stacking gel buffer              2.0 ml  
distilled water              6.6 ml  
APS (10%)                50 µl  
TEMED                 10 µl  
 
 
The separating and stacking gels were prepared by mixing the respective reagents. Both 
monomer solutions were degassed under vacuum (in a 50 ml falcon tube) for at least 5 min. 
Then 10% APS and TEMED were gently added to the solutions immediately before pouring 
each gel.  
First the gel cassette sandwich (Mini-PROTEAN cell 3) was assembled as recommended by 
the manufacturer. A comb was placed into the assembled gel cassette, and the glass plate was 
marked 1 cm below the comb to indicate the level to which the separating gel was to be 
poured. The comb was removed after marking. The separating gel solution filled (with a 
pipette) between the glass plate sandwich, until the mark was reached. Immediately, the 
solution was overlaid with water to remove air bubbles and to obtain an even interface 
between gels. Then the separating gel was allowed to polymerize for 45 min. The water on 
top of the separating gel was removed and the area above the gel was dried carefully with 
filter paper. The stacking gel was prepared just before use and then poured on top of the 
separating gel. The desired comb was inserted between the glass plate sandwiches, being 
careful not to trap bubbles under the teeth. The stacking gel was allowed to polymerize for 
30-45 min.  
 
 
SDS-PAGE and Membrane Transfer  
Aliquots of cell lysates or tissue homogenates, equivalent to 40 µg proteins, were diluted in 
equal amounts of sample buffer and heated for 5 min at 95 °C. The samples were then loaded 
into each lane and separated by SDS-PAGE 7.5% polyacrylamide gels (1.5 mm). In the first 
lane, 7 µl of rainbow marker (Kaleidoscope Prestained Standards) were loaded. Gels were run 
at 100 V (constant voltage) for 1 h. After electrophoresis proteins were transferred to 
nitrocellulose membranes (Hybond ECL Nitrocellulose membrane) by semi-dry-
electroblotting. Transfer conditions were 1 h at a voltage of 100 V. When finished, the 81 
nitrocellulose membranes were immersed in blocking solution and blocked overnight at 4 °C 
or for 2 h at RT on a shaker platform.  
 
 
Antibodies and Detection  
The membranes were washed 3 x 5 min with tween 20/PBS (TPBS). This and all other 
incubation steps were performed at RT on a shaker platform. The membranes were then 
incubated with the appropriate specific primary antibody in blocking solution for 1 h (see 
Tab. 12). After 3 x 5 min washes in TPBS, the nitrocellulose membranes were incubated with 
HRP-conjugated secondary antibody in blocking solution for 1 h as listed in Table 13. Finally, 
the membranes were washed with TPBS (3 x 5 min) and once in PBS for 5 min. 
Immunoreactive proteins were detected by enhanced chemiluminescence using the ECL 
detection system (Western blotting luminol reagent kit) and subsequent autoradiography. All 
steps of immunodetection were performed in the dark. Equal volumes of ECL solution A and 
B were mixed (1:1) and added to the membranes for 1 min. Membranes were placed in a film 
developer cassette and covered with transparent cover sheets. Film (Hyperfilm™ ECL) was 
placed on top and the cassette was closed. The film was developed for 5-20 min, respectively.  
 
 
3.3.9 Nuclear Extraction for EMSA  
EMSA totex high salt buffer:  
4-(2-hydroxyethyl)-1-piperazine-    20  mM 
ethanesulfonic acid (HEPES; pH 7.9) 
NaCl                  350 mM  
MgCl2                 1  mM   
EDTA                 0.5  mM   
Ethylene glycol tetraacetic acid (EGTA)    0.1 mM  
Dithiothreitol  (DTT)      0.5  mM   
PMSF                  1 mM  
Glycerol                 20%   
Nonidet P-40               1%  
Aprotinin                 2 µg/ml  
Leupeptin                 2 µg/ml  82 
Leupeptin, aprotinin, DTT and PMSF as protease inhibitors were freshly added just before 
use. All procedures were performed on ice.  
 
 
Nuclear extracts of tissues (adrenal glands) were prepared in a high salt buffer (50-100 µl). 
After homogenisation by slicing tissue into very small pieces or vigorous vortexing of the 
cells, the samples were incubated on ice for 15 min and then centrifuged at 18000 x g for 20 
min at 4 °C. The supernatants were frozen and the protein content of the supernatants was 
determined by Bradford assay.  
 
 
 
3.3.10 EMSA  
 
Radiolabelling of Oligonucleotides  
10x Klenow buffer (annealing buffer):  
Tris-HCl (pH 7.5)               500 mM  
NaCl                  100 mM  
MgCl2                100  mM   
Polynucleotide kinase reaction buffer (PNK buffer; 10x):  
(as purchased from the supplier)  
Tris-HCl (pH 7.6)               500 mM  
MgCl2                 100  mM   
DTT                  50 mM  
Spermidine                 1 mM  
EDTA                 1  mM   
 
Sodium/Tris/EDTA buffer (STE buffer):  
NaCl                  100 mM  
Tris-HCl (pH 8)                10 mM  
EDTA (pH 8)               1 mM  
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The DNA-oligonucleotides containing an NF-κB binding motif were synthesised by MWTG 
Biotech (Ebersberg, Germany). They were purchased single-stranded with the following 
sequence  
5’- AGC TTC AGA GGG GAC TTT CCG AGA GGT CGA -3’ or  
5’- TCG ACC TCT CGG AAA GTC CCC TCT GAA GCT -3’. 
These single-strand oligonucleotides were annealed with a complementary strand by heating 
50 µg of either strand in 900 µl Millipore water and 100 µl Klenow buffer (10x) at 95 °C for 5 
min and allowed to cool down at RT. They were then stored at -20 °C.  
 
The oligonucleotides were radiolabelled with 
32P, using [γ 
32P]-adenosine triphosphate ([γ 
32P]-ATP) and T4 polynucleotide kinase. This enzyme is prepared from a cloned pseT gene of 
bacteriophage T4, which is carried by Escherichia coli cells. T4 polynucleotide kinase 
catalyzes the transfer of the γ-phosphate from ATP to the 5’-hydroxylated terminus of DNAs 
(or RNAs). Thus, when the γ-phosphate group of the ATP was added in the reaction, 
containing a β-emitting 
32P-isotype, the DNA oligonucleotide was labelled radioactively. 1.5 
µl of nucleotide (equivalent to 25-50 ng), 5 µl of [γ 
32P]-ATP (50 µCi), 1.5 µl (10-15 Units) 
T4 PNK and 10 µl millipore water were incubated in polynucleotide kinase reaction buffer 
(10x) at 37 °C for 30 min. The reaction was stopped by the addition of sodium/tris/EDTA 
buffer (40 µl). The vial was kept on ice immediately. The radiolabelled oligonucleotides were 
separated from unincorporated [γ 
32P]-ATP with QIAquick nucleotide removal kit. 10 
volumes of binding buffer were added to 1 volume of the reaction sample and mixed. A 
QIAquick spin column was placed in a provided 2-ml collection tube. To bind DNA, the 
sample was applied to the QIAquick column and centrifuged for 1 min at 3800 x g. Then, the 
column was transferred into a clean tube, and the tube containing the radioactive flow-through 
was discarded appropriately. Thereafter, the column was washed by adding 500 µl of binding 
buffer and centrifuged for 1 min at 3800 x g. The wash procedure was repeated. The flow-
through was discarded, and the QIAquick column was placed back in the same tube, which 
should been empty. It was centrifuged for an additional 1 min at ≥ 10000 x g and the column 
was placed in a clean 1.5-ml microcentrifuge tube. To elute DNA, 75 µl of distilled water was 
added to the centre of the QIAquick membrane subsequently. The column was then allowed 
to stand for 1 min before centrifugation. The labelled oligonucleotides were collected in a 
microcentrifuge tube and stored at -20 °C. 2 µl of elute were mixed with 1 ml of water in a 
flat-bottomed plastic vial. The radioactivity in the samples was determined in a β-counter.  
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Electrophoresis and Autoradiography  
Gel shift marker (10 ml):  
Xylincyanol               40 mg (final concentration: 0.4%)  
Bromphenol blue               40 mg (0.4%)  
Ficoll 400                 2.5 g (25%)  
distilled water                ad 10.0 ml  
 
Gel shift buffer (20 ml):  
HEPES (1 M)                 1.0 ml (final concentration: 0.05 M)  
EDTA (0.5 M)                0.2 ml (5 mM)  
MgCl2 (1 M)                  0.5 ml (25 mM)  
Glycerol (87%)                11.5 ml (50%)  
Bromphenol blue (1%, pH 7.8)        1.0 ml  
distilled water              5.8 ml  
 
Binding reaction pre-mix:  
Sample  volume        9.5  µl   
Gelshift buffer              4.0 µl  
DTT (1 M)                0.1 µl  
PMSF (200 mM)                0.2 µl  
Poly  deoxyinosinic-deoxycytidylic      1.0  µl 
(dI-dC; 1 mg/ml) 
Bovine serum albumin (BSA; 1 mg/ml)    2.0 µl  
distilled water              2.2 µl  
 
The pre-mix was prepared as a master-mix for all samples and an additional one. Thereafter, 
the labelled probe ([
32P]-NF-κB oligonucleotide) was added to this binding reaction pre-mix, 
followed by incubation (15 min at RT). The amount of radiolabelled oligonucleotides used 
was determined by their radioactivity. An amount yielding 10000 cpm was used in the assays.  
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Tris-Borate-EDTA buffer (10x TBE buffer):  
Tris                  108.0 g  
Boric acid                 55.0 g  
EDTA                 7.4 g  
distilled water                ad 1000 ml  
 
Electrophoresis buffer (0.25 TBE buffer):  
prepared by a 1:40 dilution of 10x TBE stock solution in distilled water.  
10x TBE                 25.0 ml  
distilled water                 975.0 ml  
 
4.5% Polyacrylamide gels (4.5%; 200 ml):  
distilled water               94.5 ml  
Acrylamide 4K-Solution (40%, 19:1)    13.5 ml  
10x TBE                  3.0 ml  
Glycerol (87%)               9.0 ml  
APS (20%)                400 µl  
TEMED                  80 µl  
The non-denaturing polyacrylamide gels were cast the day before the experiment and kept in 
a cooling room.  
 
 
Binding reactions were prepared by combining the following in 1.5 ml micro-reaction tubes:  
 
Binding reaction mixture (19 µl):  
Nuclear extract               9.5 µl  
(diluted with distilled water to 9.5 µl)  
Binding reaction pre-mix             9.5 µl  
 
 
After 15 min of incubation at RT, all samples were loaded into the lanes of the pre-run poly-
acrylamide gel (220 V for 20 min) and 7 µl of the gel shift marker were loaded into the first 
lane to track the position of unbound probe. The gels were run with 0.25x TBE buffer for 3 h 
at 220 V until the bromphenol blue marker reached the mark of 12 cm from loading site. At 86 
the end of electrophoresis, gels were carefully removed from the glass plates and transferred 
onto filter papers (Whatman papers). The gels were covered with aluminium foil and dried 
under vacuum (gel dryer) for 2 h at 80 °C. Then a radiographic film (Hyperfilm MP) was 
exposed to the dried gels, while kept at -70 °C for 4-6 h or overnight, and developed in a film 
processor.  
 
 
 
3.3.11 Purity of LPS Preparation (Luciferase Assay)  
To determine the purity of our LPS preparations, we used a TLR-specific NF-kB reporter 
gene assay (Hemmi et al. 2000;Opitz et al. 2001). Human embryonic kidney 293 (HEK293) 
cells stably expressing CD14 were cultured in Dulbecco's modified Eagle's medium, 
supplemented with 10% heat-inactivated foetal calf serum, 2 mM glutamine and 50 µg/ml of 
each penicillin and streptomycin. Cells were plated into 12-well triplicate plates with 1 x 10
5 
cells per well. Transfection was performed using FuGENE 6 reagent with an NF-kB-
controlled luciferase construct (120 ng), Rous sarcoma virus  β-galactosidase (40 ng) and 
expression plasmids for human TLR-2 or TLR-4 plus MD2 (40 ng each). 24 h after 
transfection, cells were stimulated with purified pLPS or crude cLPS preparation (0, 1, 10, 
100 ng/ml). After a further 20 h of incubation, the activities of luciferase and β-galactosidase 
(which was used as a marker for transfection efficiency) were determined in cell extracts 
using a chemiluminescence based assay (Roche Diagnostics GmbH, Mannheim, Germany). 
Luciferase activities were calculated and normalized to the β-galactosidase control. 
 
 
 
3.3.12 Tissue Preparation & Morphometric Analysis of Adrenal Glands 
Tissue Embedding 
PBS: 
Solution A: 35.61 g of Na2HPO4 x 1 H2O was dissolved in 1000 ml distilled water. 
Solution B: 27.60 g of NaH2PO4 x 1 H2O was dissolved in 1000 ml distilled water. 
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PBS (0.01 M): 
Solution  A       40.0  ml 
Solution  B       10.0  ml 
NaCl        9.0  g 
was adjusted to pH 7.3-7.4 and to a total volume of 1000 ml with distilled water. 
 
Paraformaldehyde (4%): 
Paraformaldehyde      80.0  g 
distilled  water       800.0  ml 
 
 
Adrenal glands were fixed in 4% paraformaldehyde for 24 h at 4 °C. To remove any water 
before embedding in paraffin, dehydration was performed by soaking the tissue in a series of 
increasing alcohol concentrations. In this step, the tissues were incubated three times in 70%, 
80%, 90% and 100% alcohol for 30 min at RT. Alcohol was removed from the tissue by 
incubating in xylol overnight. Thereafter, the tissues were incubated next in paraffin for 1 h 
and then in new paraffin overnight at 60 °C. Before embedding, the paraffin was changed four 
times. Finally, the adrenal gland was put in an embedding mould and melted paraffin was 
poured into the mould to form a block. The mould was left on a cold plate, until the tissue-
paraffin block was set and removed from the mould. Blocks were stored at 4 °C. 
 
 
Tissue Sectioning 
The blocks were fixed firmly in a microtome and then sliced at a thickness of 5-8 µm. The 
sections were put on a surface of water (warmed at 45 °C) and allowed to spread out before 
placed on to slides. The slides were dried overnight at 45 °C and stored at RT until ready for 
staining. 
 
 
Haematoxylin staining 
Cross-sections of mouse adrenal gland were deparaffinized by incubating slides in xylol for 2 
x 5 min and rehydrated by incubating in descending ethanol concentrations (100%, 90%, 
70%, 50% ethanol and distilled H2O). After rehydration, the sections were incubated in 
haematoxylin for 1 min, which resulted in a blue colour. The colour reaction was stopped by 88 
incubating the slides in distilled H2O for 1 min. All following incubation steps were done in a 
humid environment at RT to prevent the tissue sections from drying out during the staining 
process. Finally, the sections were dehydrated by incubating then in increasing concentrations 
of ethanol (50%, 70%, 90% and 100%). Sections were then incubated twice in Roti
®-Histol 
(xylol substitute) for 1 min and mounted immediately with Entellan, a permanent mounting 
medium.  
 
 
 
3.3.13 Morphometric Analysis  
To determine the size of adrenal sections a computer-supported imaging system connected to 
a light microscope (Eclipse TE300 microscope, Nikon, LUCIA G Software, Nikon, Jerome 
Industry Phototype P99135 camera, (Austin, TX) was used. The area of tissue sections was 
measured in triplicates. The four largest sections were evaluated to give an approximation of 
the largest diameter in each gland.  
 
 
 
3.3.14 Electron Microscopy for Functional Analysis of Adrenal Glands 
Electron Microscopy was done in collaboration with Prof. S.R. Borstein, Department of 
Medicine, University of Dresden, Carl Gustav Carus, Dresden, Germany. Adrenal glands 
were fixed in phosphate buffer (0.1 M; pH 7.3) with 2% formaldehyde and glutaraldehyde. 
Adrenal slices were post-fixed for 90 min (2% OsO4 in 0.1 M cacodylate buffer, pH 7.3), 
dehydrated in ethanol, and embedded in epoxy resin. Ultra-thin sections were stained with 
uranyl acetate and lead citrate and examined at 80 kV in a Phillips CM 10 electron 
microscope (Eindhoven, The Netherlands).  
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3.3.15 Immunostainings 
Antibodies:  
The primary and secondary antibodies used in immunostainings are listed in Tables 14 and 
15, respectively.  
Antibody Isotype  (Ig) Dilution  Source 
Anti-mouse TLR9/CD289 (polyclonal, rabbit)  IgG 
1:100 ( in IHC) 
1:200 (in ICC) 
Imgenex Corp., 
San Diego, CA, USA 
Anti-mouse IL-1R (polyclonal, goat)  IgG  1:100  Santa Cruz, 
Heidelberg, Germany 
Anti-mouse IL-6 (polyclonal, rabbit)  IgG  1:100 
Chemicon,  
Temecula, USA 
Anti-mouse TNF-α (polyclonal, goat)  IgG  1:100 
R&D Systems 
Europe, Abingdon, 
UK 
 
Table 14: Primary antibodies used in immunostainings.  
 
 
Secondary antibody  Dilution  Source 
Goat anti-rabbit IgG, biotinylated  1:300  Dako Cytomation, Glostrup, 
Denmark 
Rabbit anti-goat IgG, biotinylated  1:300  Dako Cytomation, Glostrup, 
Denmark 
Goat anti-rabbit IgG (H+L), Cy3-conjugated 
1:250 (in IHC) 
1:1000 (in ICC) 
Jackson ImmunoResearch, 
Cambridgeshire, UK 
 
Table 15: Secondary antibodies used in immunostainings.  
 
 
 
Solutions : 
Triton X-100 (0.3%) in PBS:  
Triton X-100               0.3 ml  
PBS (0.01 M)               99.7 ml  
H2O2 (0.3%): 
H2O2 (30%)               50 µl  
0.3% Triton X-100/PBS            4950 µl  
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Normal serum (3%):   
Normal serum (goat or rabbit)        150 µl  
0.3% Triton X-100/PBS            4850 µl  
 
DAB (stock; 4 mg/ml):  
20 mg DAB were dissolved in 5 ml distilled water, aliquoted and stored at -20 °C.  
 
DAB (0.2 mg/ml; 5 ml)  
DAB (4 mg/ml)                500 µl  
PBS (0.01 M)               4500 µl  
For activating DAB, 5 µl of 1% H2O2 (33.3 µl of 30% H2O2 in 966.7 µl dH2O) was added to 
each ml DAB solution before use. 
 
 
Mouse adrenal gland cross-sections were deparaffinized by incubating slides twice in xylol 
for 5 min and rehydrated by incubating in descending ethanol concentrations (100%, 90%, 
70%, 50% ethanol and dH2O). After rehydration, the sections were washed in PBS for 5 min. 
Then the endogenous peroxidase activity was quenched by incubating the specimens for 30 
min with 0.3% H2O2 in a humidity chamber. All following incubation steps were done in a 
humid environment at RT to prevent the tissue sections from drying out during the staining 
process. Sections were washed in PBS for 5 min, and then incubated with a blocking solution 
containing 3% normal serum (goat or rabbit serum; as they are the same species in which the 
secondary antibodies were raised) for 30 min. Thereafter, the specimens were incubated with 
the appropriate characterized primary antibody (Tab. 14) overnight at 4 °C. The primary 
antibody was diluted with 0.3% Triton X-100/PBS. The tissue sections were rinsed for 5 min 
in PBS and subsequently incubated with the respective biotinylated secondary antibody (Tab. 
15) for 1 h. The sections were washed in PBS once again, followed by 30 min incubation with 
HRP-labelled streptavidin (1-2 drops solution per section). After washing in PBS, staining 
was completed by incubating with the substrate-chromogen, DAB (0.2 mg/ml) for 10 min. 
This resulted in a brown-coloured precipitate at the antigen site. Colour reaction was stopped 
by incubating the slides in PBS for 3 min. Sections were counterstained for 1 min in 
haematoxylin and washed 3 times in distilled water. Finally, the sections were dehydrated by 
incubating with increasing concentrations of ethanol (50%, 70%, 90% and 100%). Sections 
were then incubated (2x) in Roti
®-Histol (xylol substitute) for 2 min and mounted 91 
immediately with Entellan, a permanent mounting medium. Immunostaining of the sections 
was examined using a light or fluorescence microscope.  
 
 
 
3.3.16 Determination of Plasma Corticosterone and ACTH by RIA 
Plasma levels of corticosterone and ACTH were determined by RIA in collaboration with the 
Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine University, 
Düsseldorf, Germany and Department of Medicine, University of Dresden, Carl Gustav 
Carus, Dresden, Germany, and according to the instructions of the manufacturer (Diagnostic 
Systems Laboratories, Webster, Texas, USA).  
A standard curve was determined for each assay; 200 µl of standards, controls and samples 
were added to appropriate tubes and assayed in duplicates. Standards and controls were 
supplied by the manufacturer and present in each kit. To non-specific binding tubes, 300 µl of 
non-specific standard (buffer) was added. Immediately, 100 µl of the specific anti-serum 
(antibody) was added to all tubes except non-specific binding and ‘Total Count’ tubes. After 
incubation at 2-8 °C for 4 h, 100 µl of [
125I]-labelled ACTH reagent or [
125I]-labelled 
corticosterone reagent was added to all tubes. The tubes were vortexed and incubated for 16-
24 h at 2-8 °C. Then, 1 ml of precipitating reagent (mixed before use) was added to all tubes, 
except ‘Total Count’ tubes. Tubes were vortexed and incubated for 15-20 min at RT. Then, all 
the tubes were centrifuged for 15 min at 1500 x g at 4 °C. The tubes were then poured off by 
simultaneous inversion with a sponge rack, which drained into the radioactive waste. The 
tubes were drained on absorbent material for 30 s and then gently blotted to remove any drops 
before returning to their upright position, as failure to blot tubes adequately may result in poor 
replication and inaccurate values. Tubes were then counted for 1 min in a γ-counter. 
 
 
 
3.3.17 The Levels of IL-1β, IL-6 and TNF-α  
The plasma levels of IL-1β, IL-6 and TNF-α were determined by using ELISA kits according 
to the manufacturer’s instructions.  
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Sample Collection and Storage  
Blood samples were allowed to clot for 2 h at RT or overnight at 2-8 °C before centrifuging 
for 20 min at approximately 2000 x g. Serum was then removed and assayed immediately or 
aliquoted and stored at -20 °C. Plasma was collected by using heparin as an anticoagulant and 
centrifuged for 20 min at 2000 x g within 30 min of collection. It was assayed immediately or 
aliquoted and stored at -20 °C or below.  
 
 
Reagent Preparation  
All reagents were brought to RT before use.  
Kit control:  
The kit’s control was reconstituted with 1 ml distilled water.  
 
Wash buffer:  
To prepare wash buffer for one plate, 25 ml of concentrated wash buffer was diluted with 600 
ml of distilled water.  
 
Substrate solution:  
Colour A and B was mixed together in equal volumes within 15 min of use. The solution has 
to be protected from light. 100 µl of the resultant mixture was required per well.  
 
Standards:  
The standard was reconstituted with 5 ml of buffered protein solution, with preservatives 
(Calibrator Diluent RD5T) to produce a stock solution of 500 pg/ml. The standard was 
allowed to sit for 5 min with gentle mixing prior to making dilutions to ensure complete 
reconstitution. The serial 1:2 dilutions of the standard were made (250, 125, 62.5, 31.2, 15.6, 
7.8, 0 pg/ml).  
 
 
Assay Procedure  
All reagents and samples were brought to RT before use. Samples, controls and standards 
were assayed in duplicates. Assay diluent (RD1-14; 50 µl) was added to each well. In the next 
step, 50 µl of standards, samples or controls was added to the appropriate well of a 96-well 
plate. The wells were mixed by gently tapping the plate for 1 min. The plate was then covered 93 
with the adhesive strip provided before incubating for 2 h at RT. Solution from the wells was 
then thoroughly aspirated or decanted. Each plate was washed 4 times with wash buffer (400 
µl). After the last wash, any remaining wash buffer was removed by aspiration or decanting. 
The plate was inverted and blotted with a clean paper towel. After removing any unbound 
substances, 100 µl of a polyclonal antibody (specific for mouse IL-1β, IL-6 or TNF-α) 
conjugated to HRP was pipetted into each well. After 2 h of incubation at RT, the plate was 
aspirated and washed as previously described. Next, 100 µl of substrate solution was added to 
each well and the plate was incubated for 30 min at RT in the dark. Finally, 100 µl of stop 
solution was pipetted to each well and the plate was gently tapped to ensure thorough mixing. 
The solution changed from blue to yellow. The optical density was determined within 30 min 
by using a microplate reader set at a wavelength of 450 nm. 
 
 
 
3.3.18 Determination of Plasma Cytokines by Luminex™ Microbead Assay  
The plasma levels of cytokines (granulocyte macrophage-colony stimulation factor (GM-
CSF), IL-1β, 2, 4, 5, 6, 10, 12, IFN-γ and TNF-α) were determined by using the Luminex™ 
microbead assay according to the manufacturer’s instruction (BioSource Europe S.A. 
Belgium).  
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3.4 Analysis  
All illustrations using EMSA, Western blots and immunohistochemical staining were done by 
using Adobe Photoshop Version CS2 (Adobe Systems Inc., San Jose, USA).  
 
Quantitative analysis of NF-κB activation as well as TLR-2 and TLR-9 expression were 
performed by determination of optical density using Scion Image Version Alpha 4.0.3.2 
(Scion Corporation, Federick, Maryland, USA).  
 
The cytokine multiplex assays were analyzed with StarStation software Version 1.1 (Applied 
Cytometry Systems, Sheffield, UK). 
 
 
 
 
3.5 Statistics  
Results are expressed as mean ± standard error mean (SEM). Statistical significance was 
calculated by a Student’s t-test, one sample t-test or an ANOVA followed by Bonferroni’s or 
Dunnett’s posttests where appropriate by using GraphPad Prism
® Version 5.2 (GraphPad 
Software, San Diego, CA, USA). Statistical significance was considered at P<0.05. 95 
4 Results  
4.1 TLR-2 Study 
4.1.1 TLR-2 Expression in Adrenal Glands 
To determine whether TLR-2 exists in WT and TLR-2
-/- mice, adrenal glands of both mouse 
groups were analyzed by Western blotting. Adrenal glands of WT mice expressed TLR-2 as 
demonstrated, however this protein was absent in TLR-2
-/-animals (Fig. 10). 
 
 
 
 
 
 
 
Figure 10: Expression of TLR-2 in adrenal glands by Western blotting analysis. A representative blot showing TLR-2 
expression in adrenal glands of WT but not TLR-2
-/- mice (n = 3/group). β-actin is used as house keeping protein. 
 
 
4.1.2 Structure and Function of Adrenal Glands in TLR-2
-/- Mice  
4.1.2.1 Determination of Adrenal Gland Size  
The adrenal size was determined to see if there were any differences between TLR-2
-/- mice 
and their counterpart control animals. Morphometric analysis revealed that the adrenal gland 
was significant larger in TLR-2
-/- mice (21.3 ± 1.9 mm
2) than in WT animals (11.5 ± 3 mm
2; 
Fig. 11B). As demonstrated in Fig. 11A, this increase was primarily due to the enlargement of 
the adrenal cortex and not the adrenal medulla. 
 
 
 
 
 
 
 
 
Figure 11: Enlargement of the adrenal gland in TLR-2
-/- mice. (A) Measurement of adrenal size in WT (n = 5) and  
TLR-2
-/- mice (n = 3) by morphometric analysis. (B) A graph of the adrenal surface of WT and TLR-2
-/- mice. Data are 
presented as mean ± SEM. Statistical significance was determined by a Student’s t-test. ; P< 0.05. 
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4.1.2.2 Alterations in Adrenal Structure of TLR-2
-/- Mice 
Due to the facts that the adrenal glands were markedly enlarged in TLR-2
-/- mice, it is of 
interest to investigate potential ultrastructural modifications of the afrenal glands in these 
animals. Electron micrographs of adrenal gland sections showed at the ultrastructural level 
that the adrenocortical cells of TLR-2
-/- mice exhibited marked morphological alterations (Fig. 
12A-D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Adrenal structure in WT and TLR-2
-/- mice. (A) Electronmicrographs of adrenocortical cells in the zona 
fasciculata in WT mice. Cytoplasm is filled with characteristic round mitochondria with tubulo-vesicular internal membranes 
(MIT), ample smooth endoplasmatic reticulums and liposomes (LIP). (B-D) Electronmicrographs of adrenocortical cells in 
the zona fasciculata in TLR-2
-/- mice. Increase in plasma membrane folding with intracytoplasmic invaginations (arrows; bar 
= 1 µm; g). The electron-dense membranes form stratifications or girlande-like structures (bar = 0.5 µm). (D) Plasma 
membranes enveloping nerve endings (NE) (A-B). There are ample liposomes (LIP) storing cholesterol in both TLR-2
-/- and 
WT mice (bar = 1 µm). The characteristic tubulovesicular mitochondria (MIT) of the steroid-producing cells in WT animals 
appear more elongated with tubular internal membranes bridging the mitochondrial matrix (MIT) in TLR-2
-/- mice.  
 
 
In control animals (WT), the most prominent organelles in steroid-producing adrenocortical 
cells were round mitochondria with characteristic tubulo-vesicular internal membranes and 
numerous lipid-storing droplets constituting the substrates for steroidogenesis (Fig. 12A). In 
MIT 
NUC 
LIP
MIT
MIT 
MIT 
MIT 
LIP
LIP 
NUC 
NE
WT TLR-2
-/-
TLR-2
-/- TLR-2
-/- 
A B 
C D 97 
TLR-2
-/- mice, there was a decrease in the number of mitochondria with a transformation of 
vesicular internal membranes to more tubular structures bridging the inner matrix (Fig. 12B). 
The most conspicuous changes, however, occurred at the cell membranes of adrenocortical 
cells in TLR-2
-/- mice. While normal adrenocortical cells have the capacity to form filopodia 
under stimulation, changes in the plasma membrane of adrenocortical cells of TLR-2
-/- mice 
were distinct and occurred under basal conditions (Fig. 12B-D). There were extensive 
interdigitations and in-folds engulfing cytoplasm, intracytoplasmic organelles or extracellular 
structures including nerve endings (Fig. 12D). In part, the abundant folding of the membrane 
appeared to form stratifications or vesicularization of membranes providing a complex 
labyrinth formed by interdigitating processes (Fig. 12D). 
 
 
4.1.2.3 Alterations of Adrenal Function in TLR-2
-/-Mice  
Alterations of adrenal morphology in TLR-2
-/- mice (Fig. 12) indicate that the absence of the 
TLR-2 may lead to alterations in adrenal function. To test this hypothesis, plasma 
corticosterone and ACTH levels in WT and TLR-2
-/- mice were measured by RIA. Our results 
showed that the adrenal corticosterone release in TLR-2
-/- versus WT mice was significantly 
decreased (Fig. 13A). In contrast, plasma levels of ACTH were elevated in TLR-2
-/- animals 
(Fig. 13B) suggesting a potential primary impairment of the HPA-axis at the level of the 
adrenal gland.  
 
 
 
 
 
 
 
Figure 13: Plasma corticosterone and ACTH in WT and TLR-2
-/- mice. Plasma from WT and TLR-2
-/- mice (n = 6-
8/group) was taken and (A) corticosterone and (B) ACTH concentrations were measured by RIA. Data are presented as 
mean ± SEM of 6-8 experiments assayed in duplicates. Statistical significance was determined by Student’s t-
test.; P<0.05.  
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4.1.3 Effects of LPS or LTA on TLR-2 Expression in the Adrenal Gland  
As demonstrated in previous experiments (Fig. 10), there was a basal expression of TLR-2 
protein in the adrenal gland. The next step was to investigate the expression pattern of TLR-2 
by determining its responsiveness to LPS or LTA at different time points. The time course of 
TLR-2 expression in adrenal glands of WT mice was analyzed by Western blot analysis. 
Animals were pretreated i.p. with saline (sal; 1 ml/kg), LPS (1 mg/kg) or LTA (1 mg/kg) for 
0.5, 1, 1.5, 2, 6, or 24 h. As shown in Fig. 14, exposure to both LPS and LTA led to a time-
dependent increase in TLR-2 protein expression, with maximum induction at 6 h and 
remaining significantly upregulated at 24 h.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Effects of LPS or LTA treatment on TLR-2 expression in the adrenal gland. WT mice were challenged with 
(A) LPS (1 mg/kg; i.p.) or (B) LTA (1 mg/kg; i.p.) and saline (sal; 1 ml/kg; i.p.). After 0.5, 1, 1.5, 2, 6 or 24 h, protein 
extracts (40 µg) were subjected to immunoblotting. β-actin is shown as evidence of equal loading. (C) Densitometric analysis 
of TLR-2 protein expression in WT mice. Data are presented as mean ± SEM (n = 4/group).Statistical significance was 
determined by one-way ANOVA and Dunnet’s post-test (sal versus each time point).; P<0.05.  
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4.1.4 Plasma Levels of Corticosterone and ACTH after LPS or LTA 
Treatment 
To investigate the role of TLR-2 in the adrenal stress response to bacterial cell wall fragments 
such as LPS or LTA, WT and TLR-2
-/- mice were pretreated with saline (sal; 1 ml/kg), LPS (1 
mg/kg; Escherichia coli, serotype 0.111:B4) or LTA (1 mg/kg; Staphylococcus aureus) by i.p. 
injection for 6 or 24 h. Thereafter, plasma concentrations of corticosterone and ACTH were 
determined by RIA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Plasma corticosterone and ACTH response after 6 h LPS or LTA challenges. WT and TLR-2
-/- mice were 
challenged with saline (sal; 1 ml/kg; i.p.) or LPS (1 mg/kg; i.p.) and plasma corticosterone (A) and ACTH (B) levels were 
measured after 6 h. WT and TLR-2
-/- mice were challenged with saline (sal; 1 ml/kg; i.p.) or LTA (1 mg/kg; i.p.) and plasma 
corticosterone (C) and ACTH (D) levels were measured after 6 h. Data are presented as mean ± SEM of 6-8 experiments 
assayed in duplicates (n = 6-8/group). Statistical significance was determined by Student’s t-test.; P<0.05. 
 
 
We demonstrated that in WT mice following 6 h of LPS exposure, adrenal corticosterone 
release increased by three-fold as compared to saline treatment. This notable increase of 
plasma corticosterone after LPS was significantly higher in WT animals than in TLR-2
-/- 
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mice, where a two-fold increase in corticosterone after LPS was observed as compared to 
saline treatment only (Fig. 15A). Similarly, a significant increase in plasma levels of ACTH 
was observed in WT animals following LPS treatment. In contrast, ACTH levels in TLR-2
-/- 
mice did not change after LPS treatment (Fig. 15B). Pretreatment with LTA for 6 h did not 
affect plasma corticosterone levels in WT mice (Fig. 15C). Conversely, TLR-2
-/- animals 
exhibited a marked reduction in plasma corticosterone levels 6 h after LTA treatment (Fig. 
15C). Furthermore, LTA had no significant effect on ACTH levels, neither in WT nor in 
TLR-2
-/- mice (Fig. 15D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Plasma corticosterone and ACTH response after 24 h LPS or LTA challenges. WT and TLR-2
-/- mice were 
challenged with saline (sal; 1 ml/kg; i.p.) or LPS (1 mg/kg; i.p.) and plasma corticosterone (A) and ACTH (B) levels were 
measured after 24 h. WT and TLR-2
-/- mice were challenged with saline (sal; 1 ml/kg; i.p.) or LTA (1 mg/kg; i.p.) and plasma 
corticosterone (C) and ACTH (D) levels were measured after 24 h. Data are presented as mean ± SEM of 6-8 experiments 
assayed in duplicates (n = 6-8/group). Statistical significance was determined by Student’s t-test.; P<0.05. 
 
 
In WT animals, plasma levels of corticosterone after 24 h of LPS treatment were comparable 
to saline treatment. In TLR-2
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LPS was comparable to saline controls. However, it is interesting to note that in TLR-2
-/- 
mice, LPS treatment significant attenuated corticosterone levels when compared to LPS 
treatment in WT mice (Fig. 16A). Plasma ACTH levels did not differ between groups after 24 
h treatment with LPS (Fig. 16B). Surprisingly, LTA pretreatment caused a significant 
reduction of plasma corticosterone levels in WT mice by ~40%, whereas in TLR-2
-/- mice, 
levels in saline and LTA treated animals were comparable (Fig. 16C). The adrenal ACTH 
response to LTA was not significantly different in WT or TLR-2
-/- following 24 h of LTA 
treatment (Fig. 16D). 
 
 
4.1.5 Adrenal Cellular Stress Response to LPS or LTA Challenges  
Steroidogenesis takes place in mitochondria and the smooth endoplasmic reticulum in the 
steroid-producing cells. On the ultrastructural level, there was a marked increase in the 
number of mitochondria as well as in vesicularization in the adrenocortical cells of WT 
animals 24 h following LPS challenge (Fig. 17A). This increase in mitochondria, smooth 
endoplasmic reticulum and vesicularization of mitochondrial membranes is consistent with 
the increase in steroidogenesis. At the same time, the number of liposomes declined in 
accordance with the utilization of stored cholesterol pools as a substrate for glucocorticoid 
synthesis (Fig 17A). This process of increased SER, mitochondrial membranes and reduced 
liposomes was markedly less pronounced in TLR-2
-/- mice, commensurate with their impaired 
steroid release (Fig 17B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Adrenal structure in WT and TLR-2
-/-  mice following LPS stimulation. (A) Electronmicrographs of 
adrenocortical cells in the zona fasciculata in WT mice. Marked increase in mitochondria (MIT) filling the entire cytoplasm 
24 h after LPS injection with a decline in liposomes (LIP). There is an increase in intercellular endothelial cells in direct 
contact with adrenocortical cells and an intracytoplasmic accumulation of lysosomes. (B) Electronmicrographs of 
adrenocortical cells of TLR-2
-/- mice in the zona fasciculata. Increase in mitochondria is less pronounced following LPS 
treatment. NUC, nucleus 
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4.1.6 Adrenal NF-κB Activation by LPS or LTA Challenges  
Activation of TLRs often results in the induction of the transcription factor NF-κB (Takeda 
2005). Once induced, it translocates into the nucleus, where it binds to DNA and activates the 
induction of different genes. To confirm the important role of TLR-2 in adrenal response to 
LPS- or LTA-induced stress, NF-κB activation was determined by electrophoretic mobility 
shift assay (EMSA). This technique was performed with adrenal nuclear extracts from WT 
and TLR-2
-/- mice. Animals were exposed to saline (sal, 1 ml/kg), LPS (1 mg/kg) or LTA (1 
mg/kg) for 6 h. DNA-binding activity of NF-κB was analyzed by using a 
32P-labelled NF-κB 
specific oligonucleotide. The intensity of the bands (indicated by an arrow) reflects the 
amount of DNA-binding activity of NF-κB to its binding site in the nuclear extracts (Fig. 
18A). 
As shown in Fig. 18A, there was a low-level of background DNA-binding activity of NF-κB 
in saline-treated animals (WT mice). However, exposure to LPS as well as LTA led to a 
strong induction of NF-κB-DNA-binding activity in adrenal nuclear extracts, which was 
significantly higher than in saline controls (Fig. 18B). In contrast, DNA-binding activity of 
NF-κB was considerably impaired in TLR-2
-/- mice. In addition, the response of adrenal cells 
to a LTA challenge was blunted, while LPS-mediated activation of adrenal NF-κB was 
preserved in TLR-2
-/- mice (Fig. 18A, B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Activation of NF-κB in adrenal glands after LPS or LTA treatment. NF-κB activation was determined by 
EMSA in adrenal nuclear extracts from WT and TLR-2
-/- animals (n = 5-8/group) after 6 h of treatment with saline (sal; 1 
ml/kg; i.p.), LPS (1 mg/kg; i.p.) or LTA (1 mg/kg; i.p.). (A) Representative autoradiograph, NF-κB/DNA complex is 
indicated by the arrow, a non-specific DNA complex is marked by a circle. (B) Densitometric analysis, data were normalized 
to the intensity of the non-specific DNA complex and expressed as x-fold induction of WT saline-treated animals. Data are 
presented as mean ± SEM. Statistical significance was determined by Student’s t-test. ; P<0.05. 
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4.1.7 Plasma Levels of Various Cytokines in WT and TLR-2
-/- 
DNA-binding of activated NF-κB regulates gene transcription and expression of several 
proteins. The target genes include cytokines (e.g. IL-1, 2, 6, 8, 12, 18 and TNF-α), 
immunoreceptors and acute phase proteins. Therefore, the next step of this study was to 
analyze the production of proinflammatory cytokines, such as TNF-α, IL-1 and IL-6 in 
response to TLR-ligands, i.e. LPS and LTA. Mice (WT and TLR-2
-/-) were pretreated as 
indicated with saline (sal, 1 ml/kg), LPS (1 mg/kg) or LTA (1 mg/kg) for 6 or 24 h and 
plasma cytokine levels were determined by ELISA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Plasma levels of cytokines in response to LPS or LTA treatment. Plasma levels of (A) IL-1, (B) TNF-α and 
(C) IL-6 after 6 h or (D) IL-6 after 24 h treatment with saline (sal; 1 ml/kg; i.p.), LPS (1 mg/kg; i.p.) or LTA (1 mg/kg; i.p.) 
in WT and TLR-2
-/- mice (n = 5-8/group). Data are presented as mean ± SEM of 5-8 experiments assayed in duplicates. 
Statistical significance was determined by Student’s t-test. ; P<0.05. 
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WT mice showed a significant increase in the plasma levels of IL-1 (3-fold), TNF-α (2-fold) 
and IL-6 (1,000-fold) after 6 h exposure to LPS (Fig. 19A-C). Plasma levels of IL-1 and TNF-
α returned to baseline concentrations after 24 h LPS treatment (data not shown), whereas 
plasma levels of IL-6 remained elevated in WT mice (Fig. 19D). The cytokine response (IL-1 
and TNF-α) to LPS treatment (6 h) was significantly impaired in TLR-2
-/- mice (Fig. 19A-C) 
However, LPS challenge caused an increase in plasma levels of IL-6 in TLR-2
-/- mice, which 
was similar to the increase observed in WT animals (Fig. 19C). However, at 24 h after LPS 
administration, IL-6 levels were significantly reduced in TLR-2
-/- mice when compared to WT 
mice (Fig. 19D). LTA challenge for 6 h or 24 h did not affect the plasma concentrations of IL-
1, IL-6 or TNF-α neither in WT nor in TLR-2
-/- mice (Fig. 19).  
 
 
To support the association between TLR-2-deficiency and the impaired response of the 
inflammatory cytokines, we determined the local expression of the cytokines TNF-α, IL-1 and 
IL-6 on the adrenal gland. After saline or LPS treatment (24 h), immunohistochemical 
staining of adrenal cortices of WT and TLR-2
-/- mice was performed (Fig. 20). 
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Figure 20: Detection of IL-1, IL-6 and TNF-α expression in adrenal cortices by immuno-histochemical staining. WT or 
TLR-2
-/- were treated with saline (sal, 1 ml/kg; i.p.) or LPS (1 mg/kg; i.p.) for 24 h. Adrenal cortices were analyzed for 
immunoreactivity of IL-1 protein (A, D, G; 40x magnification), IL-6 protein (B, E, H; 100x magnification) and TNF-α 
protein (C, F, H; 100x magnification). 
 
 
As shown in Fig. 20, there was only weak staining for IL-1, IL-6 and TNF-α on zona 
fasciculata cells of the adrenal cortex of WT mice following saline treatment (Fig. 20A-C). 
After LPS treatment (24 h), there was a marked increase in the expression of all three 
cytokine proteins, the most prominent staining was for TNF-α (Fig. 20D-F). In contrast, the 
expression of IL-1, IL-6 and TNF-α protein in TLR-2
-/- animals following LPS-treatment was 
observably reduced (Fig. 20G-I). 
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4.2 TLR-4 Study 
4.2.1 TLR-4 Expression in Adrenal Glands  
We investigated whether TLR-4 is expressed in the adrenal glands of WT mice. Western blot 
analysis revealed that TLR-4 is expressed in these glands as demonstrated in Fig. 21. 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Expression of TLR-4 in adrenal glands by Western blotting analysis. A representative blot showing TLR-4 
expression in adrenal glands of WT mice (n = 3). β-actin is used as house keeping protein. 
 
 
4.2.2 Structure and Function of Adrenal Glands in TLR-4
-/- Mice  
4.2.2.1 Determination of Adrenal Gland Size  
Like in TLR-2 study, the adrenal size was determined by morphometric analysis to see if 
there were any differences between TLR-4
-/- mice and their counterpart control animals. As 
demonstrated in Fig. 22A, the adrenal gland was significant larger in TLR-4
-/- mice (272,000 
± 14,000 pixels
2) than in WT animals (221,000 ± 17,000 pixels
2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Enlargement of the adrenal gland in TLR-4
-/- mice. (A) Measurement of adrenal size in WT and TLR-4
-/- mice 
(n = 8/group) by morphometric analysis. (B) A graph of the adrenal surface of WT and TLR-4
-/- mice. Data are presented as 
mean ± SEM. Statistical significance was determined by a Student’s t-test. ; P< 0.05. 
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4.2.2.2 Alterations in Adrenal Structure of TLR-4
-/-Mice 
Seeing that the adrenal glands were markedly enlarged in TLR-4
-/- mice, it is of interest to 
investigate potential ultrastructural modifications of the afrenal glands in these animals. At 
the ultrastructural level, the most pronounced differences of WT and TLR-4
-/- animals were 
seen in the mitochondrial structure (Fig. 23A-B). The steroid-producing adrenocortical cells 
of WT mice revealed round mitochondria with characteristic tubovesicular cristae and 
electron-opaque granules (Fig. 23A). In contrast, mitochondria of TLR-4
-/- adrenocortical 
cells showed a reorganization of the cristae to lamellar or even circular structures, bridging 
the inner matrix of the mitochondria (Fig. 23B). In addition, lipid-storing droplets constituting 
the substrates for steroidogenesis were abundant in adrenocortical cells of WT mice, but they 
were conspicuously reduced in TLR-4
-/- mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Adrenal structure in WT and TLR-4
-/- mice. (A) Electronmicrographs of adrenocortical cells in the inner zona 
fasciculata in WT mice. The cytoplasm is filled with characteristic round mitochondria (MIT) with tubulovesicular cristae, 
ample smooth endoplasmic reticulum, and liposomes (LIP). (B) Electron micrographs of adrenocortical cells of TLR-4
-/- mice 
in the zona fasciculata. Mitochondria of the steroid-producing cells appear increased and more elongated with lamellar and 
even circular internal membranes bridging the mitochondrial matrix. NUC, nucleus. 
 
 
 
4.2.2.3 Alterations of Adrenal Function in TLR-4
-/-Mice  
To examine if morphological modifications of adrenal gland in TLR-4
-/- mice could lead to 
functional modifications, plasma levels of corticosterone and ACTH were determined by RIA 
in WT and TLR-4
-/- mice. The results showed that adrenal corticosterone release in TLR-4
-/- 
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mice was significantly higher than in WT mice (Fig. 24A). In contrast, plasma levels of 
ACTH were similar in both groups (Fig. 24B).  
 
 
Figure 24: Plasma corticosterone and ACTH in WT and TLR-4
-/- mice. Plasma from WT and TLR-4
-/- mice (n = 8/group) 
was taken and (A) corticosterone and (B) ACTH concentrations were measured by RIA. Data are presented as mean ± SEM 
of 8 experiments assayed in duplicates. Statistical significance was determined by Student’s t-test. ; P<0.05.  
 
 
 
4.2.3 Purity of LPS Preparations 
To investigate whether TLR-4 plays a role in the adrenal stress response during inflammation, 
we used a low-dose of LPS that reflects the clinical condition of SIRS. Sometimes, 
commercial preparations of LPS contain TLR-2 agonists and effects could have been due to 
the activation of TLR-2 as well as TLR-4. To exclude this possibility, we first compared the 
agonist activity of TLR-2 and TLR-4 in the crude and pure LPS preparations (cLPS and 
pLPS) we obtained for this study. 
 
 
 
 
 
 
 
 
 
WT TLR-4
-/- 0
100
200
300
400
500

C
o
r
t
i
c
o
s
t
e
r
o
n
e
 
(
n
g
/
m
l
)
WT TLR-4
-/- 0
50
100
150
A
C
T
H
 
(
p
g
/
m
l
)
0
5000
10000
15000
20000
cLPS (ng/ml) pLPS (ng/ml)
control 1 10 100 1 10 100




T
L
R
-
4
 
a
c
t
i
v
a
t
i
o
n
(
r
e
l
a
t
i
v
e
 
l
i
g
h
t
 
u
n
i
t
s
)
A B 
A 109 
 
 
 
 
 
 
 
 
 
Figure 25: Purity of LPS preparations by luciferase assay. Human embryonic kidney 293 cells were transfected with 
either TLR-2 or TLR-4. (A) Effects of crude or pure LPS (cLPS or pLPS; 1-100 ng/ml) on NF-κB-driven luciferase activity 
in comparison to untreated control in TLR-4 transfected cells (n = 3). (B) Effects of cLPS and pLPS (1-100 ng/ml) on 
luciferase activity in comparison to untreated control in TLR-2 transfected cells (n = 3). Luciferase activity was normalized 
to the β-galactosidase control and is presented as relative light units. Data are presented as mean ± SEM. Statistical 
significance was determined by one-way ANOVA and Bonferroni`s post-test (versus control). ; P<0.05.  
 
 
In TLR-4 transfected HEK293 cells, both cLPS (at all three concentrations) and pLPS (only at 
the highest concentration) increase significantly TLR-4 activation (NF-κB driven luciferase 
activity) (Fig. 25A), whereas only cLPS but not pLPS increased NF-κB activity in TLR-2 
transfected cells. pLPS had no effect on luciferase activity even at the highest concentration 
(100 ng/ml) in TLR-2 transfected cells (Fig. 25B). These results demonstrate that the pLPS 
preparation was free of TLR-2 ligands. In contrast, the cLPS preparation activated both TLR-
2 and TLR-4, demonstrating that this preparation was contaminated with TLR-2 agonist.  
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4.2.4 Effects of cLPS and pLPS on Plasma Corticosterone and ACTH 
To determine the effects of LPS on the adrenal stress response, plasma concentrations of 
corticosterone and ACTH were measured by RIA, taken from WT and TLR-4
-/- mice pre-
treated with saline (1 ml/kg), cLPS (1 mg/kg) or pLPS (1 mg/kg) for 6 or 24 h.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Plasma corticosterone and ACTH response to cLPS and pLPS challenges. Plasma levels of (A) 
corticosterone and (B) ACTH were determined after 6 or 24 h of treatment with saline (sal; 1ml/kg; i.p.), cLPS (1 mg/kg; i.p.) 
or pLPS (1 mg/kg; i.p.) in WT or TLR-4
-/- mice (n = 7-8/group). Data are presented as mean ± SEM. Statistical significance 
was determined by one-way ANOVA and Bonferroni`s post-test (versus saline). ; P<0.05.  
 
 
As shown in Fig. 26A, in WT mice corticosterone release increased significantly after both 6 
h cLPS and pLPS treatment. After 24 h, plasma levels were similar to saline-treated controls 
in cLPS treated animals. In mice treated with pLPS, corticosterone plasma levels appeared to 
be raised, but were not more significant. In TLR-4
-/- mice, cLPS and pLPS had no effect on 
corticosterone release at any time point. This could have been due to the fact that plasma 
levels of corticosterone were already elevated in saline-treated TLR-4
-/- mice (3-fold higher 
versus WT animals). As demonstrated in Fig. 26B for plasma ACTH, at 6 h there was an 
increase with cLPS, but not pLPS in WT mice (P<0.05). However, at 24 h, plasma levels of 
ACTH were similar to saline-treated animals. In TLR-4
-/- animals, both cLPS and pLPS had 
no effect.  
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4.2.5 Adrenal NF-κB Activation by cLPS or pLPS Challenges 
To confirm NF-κB is involved in TLR-4 signalling during the adrenal stress response to LPS, 
we determined its activation by EMSA in adrenals. The intensity of the bands reflects the 
amount of DNA-binding activity of NF-κB to its binding site in the nuclear extracts (Fig. 
27A). In the adrenal glands of WT mice, cLPS and pLPS treatment led to a strong induction 
of NF-κB-DNA binding protein complex after 1 h, but this effect was markedly impaired in 
TLR-4
-/- animals (Fig. 27B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Activation of NF-κB in adrenal glands after cLPS or pLPS treatment. NF-κB activation was determined by 
EMSA in adrenal nuclear extracts from WT and TLR-4
-/- animals (n = 5-8/group) after treatment with saline (sal; 1 ml/kg; 
i.p.), cLPS (1 mg/kg; i.p.) or pLPS (1mg/kg; i.p.). (A) Representative autoradiograph, NF-κB/DNA complex is indicated by 
the arrow, a non-specific DNA complex is marked by a circle. (B) Densitometric analysis of EMSA. Data were normalized to 
the intensity of the non-specific DNA complex and expressed as x-fold induction of WT saline-treated animals. Data are 
presented as mean ± SEM. Statistical significance was determined by one-way ANOVA and Bonferroni’s post-test for each 
animal group (versus saline). ; P<0.05. 
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4.2.6 Plasma Levels of Various Cytokines in WT and TLR-4
-/- Mice 
Cytokines regulate the hormonal release and glucocorticoid output of the HPA-axis. Thus, the 
next step of this study was to analyze the systemic response of cytokines IL-1β, 6, 10, 12 and 
TNF-α after cLPS and pLPS treatment in WT and TLR-4
-/- mice. 
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Figure 28: Plasma levels of cytokines in response to cLPS or pLPS treatment. Determination of plasma cytokines (A) IL-
1β, (B) IL-6, (C) IL-12, (D) TNF-α, and (E) IL-10 in WT and TLR-4
-/- mice (n = 5-8/group). Animals were treated with 
saline (sal; 1ml/kg; i.p.), cLPS (1 mg/kg; i.p.) or pLPS (1 mg/kg;i.p.) for 6 or 24 h. Data are presented as mean ± SEM. 
Statistical significance was determined by one-way ANOVA and Bonferroni’s post-test for each animal group. ; P<0.05. 
 
 
All plasma cytokines were increased in WT mice after a 6 h cLPS challenge. These results 
indicate an inflammatory response with cLPS, but the same could not be seen in pLPS-treated 
animals. After 6 h of cLPS treatment, IL-1β was increased approximately by 3-fold, IL-6 by 
200-fold, IL-12 by 80-fold and TNF-α by 10-fold in comparison with saline- treated animals 
(Fig. 28A-D). The same result was shown with IL-10 (an anti-inflammatory cytokine): cLPS 
increased the plasma levels of this cytokine significantly (50-fold) after 6 h, in comparison to 
WT controls (Fig. 28E). After 24 h of pLPS treatment, plasma levels of all cytokines returned 
to the baseline and after cLPS treatment, plasma levels of all cytokine except IL-10 returned 
to the baseline after 24h. Plasma IL-10 was already high, but was not significant. In TLR-4
-/- 
mice, neither cLPS nor pLPS had any effects on the plasma cytokines studied. Plasma levels 
of IL-1β were increased after pLPS treatment, but values were not of statistical significance.
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4.3 TLR-9 Study 
4.3.1 TLR-9 Expression in Adrenal Glands 
In this study, we showed for the first time that murine adrenal glands expressed TLR-9 both at 
mRNA and protein level, as demonstrated by RT-PCR (Fig. 29A) and Western blot analysis 
(Fig. 29B). However, TLR-9 protein was absent in TLR-9
-/- mice. Furthermore, both 
immunohistochemical and immunofluorescence staining for TLR-9 in the adrenal gland of 
untreated WT mice revealed that TLR-9 was expressed in the adrenal cortex, but not in the 
adrenal medulla. No staining was observed in negative controls where no specific TLR-9 
antibody was used (Fig. 29C). As illustrated in Fig. 29D-E, the cortical zona fasciculata 
exhibited prominent staining for TLR-9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Expression of TLR-9 in the adrenal glands by (A) RT-PCR, (B) Western blotting analysis, (C-D) 
immunohistochemical and (E) immunofluorescence staining. Representative PCR gel (A) and western blot (B) 
respectively show TLR-9 expression in adrenal glands of WT but not TLR-9
-/- mice. β-actin is used as house keeping protein. 
Depicted are the following groups: (1) spleen and (2) adrenal glands of WT mice and (3) adrenal glands of TLR-9
-/- mice (n = 
4/group). Spleen of WT mice served as positive control for the expression of TLR-9. The TLR-9 expression in the adrenal 
gland was visualized by (C-D) immuno-histochemical and (E) immuno-fluorescence staining. (C) Adrenal gland sections 
without the specific TLR-9 staining as negative control. (D-E) Sections stained by anti-mouse TLR-9 antibody revealed the 
expression of TLR-9 in adrenal cortex, particularly in zona fasciculata, but not in adrenal medulla. Overview, 10x 
magnification; sectionings of zona fasciculata, 100x magnification. Reproductive results were obtained in 3 independent 
experiments.  
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4.3.2 Structure and Function of Adrenal Glands in TLR-9
-/- Mice  
4.3.2.1 Determination of Adrenal Gland Size  
Like in TLR-2 and TLR-4 studies, the adrenal size was determined by morphometric analysis 
to see if there were any differences between TLR-9
-/- mice and their counterpart control 
animals. Morphometric analysis of the adrenal gland displayed no difference in adrenal size 
between WT and TLR-9
-/- mice as shown in Fig. 30A-B. 
 
 
 
 
 
 
 
 
Figure 30: Size of the adrenal gland in WT and TLR-9
-/- mice. (A) Measurement of adrenal size in WT and TLR-9
-/- mice 
(n = 4-8/group) by morphometric analysis. (B) A graph of the adrenal surface of WT and TLR-9
-/- mice. Data are presented as 
mean ± SEM.  
 
 
4.3.2.2 Alterations of Adrenal Function in TLR-9
-/-Mice  
Plasma corticosterone and ACTH levels in untreated WT and TLR-9
-/- mice were measured 
by RIA. The results indicate comparably corticosterone and ACTH plasma levels in both 
animal groups (Fig. 31A-B). 
 
 
 
 
 
 
 
 
Figure 31: Plasma corticosterone and ACTH in WT and TLR-9
-/- mice. Plasma from WT and TLR-9
-/- mice 
(n = 4-8/group) was taken and (A) corticosterone and (B) ACTH concentrations were measured by RIA. Data are 
presented as mean ± SEM of 4-8 experiments assayed in duplicates.  
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4.3.3 Effects of CpG-ODN on TLR-9 Expression in the Adrenal Gland  
As showed in previous experiments (Fig. 29), there was a basal expression of TLR-9 in the 
adrenal gland. The next step was to investigate the expression pattern of this protein by 
determining their responsiveness to its appropriate ligand CpG-ODN at different time points. 
WT mice were challenged with CpG-ODN (30 min after sensitization with D-GalN) and 
sacrificed at several time points (15-360 min). In control experiments, D-GalN alone did not 
induce an inflammatory response (data not shown). Using RT-PCR and Western blot analysis, 
TLR-9 expression was studied. Fig. 32A depicts a typical autoradiograph where adrenal 
glands were analyzed using RT-PCR. TLR-9 band intensities were normalized to β-actin 
levels in the same sample. When compared to control, CpG-ODN challenge did not influence 
levels of TLR-9 mRNA over time (Fig. 32B). Similar results were obtained in Western blot 
analysis (Fig. 32C-D), demonstrating no significant change in TLR-9 protein expression 
pattern following CpG-ODN challenge. 
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Figure 32: Effects of CpG-ODN on TLR-9 expression in the adrenal gland. D-GalN-sensitized (1 mg/kg; i.p.) WT mice 
were challenged with CpG-ODN (1 nmol/g; i.p.) for various time points as indicated (n = 8-10/group). (A) Using RT-PCR, 
adrenal glands were analyzed for TLR-9 expression. β-actin was used as a reference gene. (B) Quantification of 
autoradiographs. Band intensities were normalized to β-actin in the same samples. (C) Typical example of a Western blot 
showing TLR-9 protein expression. β-actin was used as a loading control. (D) Band intensities were normalized to β-actin 
expression in the same samples. Data are presented as mean ± SEM. 
 
 
 
4.3.4 Plasma Levels of Corticosterone and ACTH after CpG-ODN 
Treatment  
To investigate further the role of TLR-9 in the adrenal stress response to CpG-ODN, plasma 
levels of corticosterone and ACTH were determined by RIA. Under physiological conditions 
(control), the plasma levels of corticosterone (Fig. 33A) and ACTH (Fig. 33B) were similar in 
WT and TLR-9
-/- mice. Following a CpG-ODN challenge, WT mice exhibited a three-fold 
increase in plasma corticosterone after 2 h and returned back to baseline values after 6 h. In 
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contrast, CpG-ODN-mediated effects were abolished in TLR-9
-/- mice (Fig. 33A). CpG-ODN 
had little or no effect on ACTH plasma levels in WT animals. Similarly, no changes in plasma 
ACTH were observed after CpG-ODN treatment in TLR-9
-/- mice (Fig. 33B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Plasma corticosterone and ACTH response to CpG-ODN challenge. Plasma levels of (A) corticosterone and 
(B) ACTH in D-GalN-sensitized (1 mg/kg; i.p.) WT and TLR-9
-/- mice (n = 6-9/group) under control physiological 
conditions or after CpG-ODN challenge for 2 or 6 h (1 nmol/g; i.p.). Data are presented as mean ± SEM. Statistical 
significance was determined by one-way ANOVA and Bonferroni’s post-test for each group (versus control). ; P<0.05. 
 
 
 
control
CpG-ODN 2h
CpG-ODN 6h
control
CpG-ODN 2h
CpG-ODN 6h
0
100
200
WT TLR-9
-/-
A
C
T
H
 
(
p
g
/
m
l
)
control
CpG-ODN 2h
CpG-ODN 6h
control
CpG-ODN 2h
CpG-ODN 6h
0
200
400
600
800
WT TLR-9
-/-

C
o
r
t
i
c
o
s
t
e
r
o
n
e
 
(
n
g
/
m
l
)
A 
B 119 
4.3.5 Adrenal NF-κB Activation after CpG-ODN Treatment  
To investigate the role of NF-κB in TLR-9 signalling during the adrenal stress response to 
CpG-ODN, we determined its activation by EMSA in adrenals. We determined NF-κB 
activity in adrenal glands following a CpG-ODN challenge. As depicted in Fig. 34A 
(autoradiograph) and B (densitometry), CpG-ODN after 2 or 6 h had no detectable effect on 
NF-κB activity in WT or TLR-9
-/- mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Activation of NF-κB in the adrenal glands in WT and TLR-9
-/- mice after CpG-ODN treatment. NF-κB 
activation was determined by EMSA in adrenal nuclear extracts from D-GalN-sensitized (1 mg/kg; i.p.) WT and TLR-9
-/- 
mice (n = 7/group) following 2 or 6 h challenge of CpG-ODN (1 nmol/g; i.p.). (A) Representative autoradiograph, NF-
κB/DNA complex is indicated by the arrow, a non-specific DNA complex is marked by a circle. (B) Densitometric analysis 
of EMSA. Data were normalized to the intensity of the non-specific DNA complex and expressed as x-fold induction of WT 
control. Data are presented as mean ± SEM.  
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In another set of experiments, WT mice were challenged with CpG-ODN for various time 
points (15-360 min). When compared to control, no significant alterations of NF-κB activity 
were detected; Fig. 35A (autoradiograph) and B (densitometry). However, there was a 30% 
increase of NF-κB-DNA binding activity after 30 min which was of no statistical significance 
(P<0.0538). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Activation of NF-κB in the adrenal glands in WT mice after CpG-ODN treatment. NF-κB activation was 
determined by EMSA in adrenal nuclear extracts from D-GalN-sensitized (1 mg/kg; i.p.) WT mice after CpG-ODN challenge 
(1 nmol/g; i.p.) for various time points as indicated (n = 4-7/group). (C) Representative autoradiograph, NF-κB/DNA 
complex is indicated by the arrow, a non-specific DNA complex is marked by a circle. (D) Densitometric analysis of EMSA. 
Data were normalized to the intensity of the non-specific DNA complex and expressed as x-fold induction of WT control. 
Data is presented as mean ± SEM.  
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4.3.6 Determination of Various Cytokines in WT and TLR-9
-/- 
We next focused on the plasma activity of various cytokines in WT and TLR-9
-/- mice. The 
animals were either challenged with saline or CpG-ODN for 15-360 min. As shown in Tab. 
16, under control physiological conditions control WT and control TLR-9
-/- mice exhibited 
similar levels of cytokines, such as GM-CSF, IL-5, 6, 12, IFN-γ and TNF-α. In contrast, a 
CpG-ODN challenge (120 min) in WT mice caused a marked and significant increase in all 
cytokines (except IL-1β and IL-2) ranging from 5- to 213-fold. Plasma levels of IL-6 (213-
fold), IL-10 (37-fold), IL-12 (29-fold) IFN-γ (100-fold) and TNF-α (30-fold) were elevated in 
particular as compared with controls. After 360 min, levels of GM-CSF, IL-5, 6, 10, 12 and 
IFN-γ remained significantly increased. In contrast, a CpG-ODN mediated effects in WT 
mice were abolished in TLR-9
-/- mice. Only IL-6 levels rose within 120 min, but 31-fold less 
than in WT animals. In addition, IL-6 levels were back to baseline after 360 min in TLR-9
-/- 
mice and still up-regulated in WT mice. 
 
We further investigated the effects of CpG-ODN challenge on plasma cytokine expression in 
WT mice at different time points (15-360 min). As summarized in Tab. 16, all cytokines were 
significantly up-regulated between 45 and 60 min (IL-1β approximately by 61-fold, IL-6 by 
232-fold, IL-10 by 99-fold, IL-12 by 39-fold, GM-CSF by 6-fold and TNF-α by 288-fold), 
and plasma levels of IL-2, 5, 10, 12 and GM-CSF remained significantly high at 360 min. In 
contrast, IL-1β, 4, 6 and TNF-α levels declined to baseline already after 120 min.  
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Table 16: Plasma levels of cytokines in WT and TLR-9
-/- mice in response to CpG-ODN treatment. D-GalN-sensitized (1 mg/kg; i.p.) WT and TLR-9
-/- mice (n = 4-10/group) were 
challenged with CpG-ODN (1 nmol/g; i.p.) for various time points as indicated. Experiments were performed in duplicate. Data are presented as mean±SEM and were analyzed by one-way 
ANOVA for each time point vs. the control of WT or TLR-9
-/- mice (* P < 0.05); Student’s t-test for each time point of WT vs. TLR-9
-/- mice (
+ P < 0.05).  
GM-CSF, granulocyte-macrophage colony-stimulating factor; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; n.d., not detectable.
Cytokine 
(pg/ml)  WT TLR-9
-/- 
  control  CpG-ODN 
15 min 
CpG-ODN 
30 min 
CpG-ODN 
45 min 
CpG-ODN 
60 min 
CpG-ODN 
120 min 
CpG-ODN 
360 min  control  CpG-ODN 
120 min 
CpG-ODN 
360 min 
GM-CSF  10±2 3±1  6±1  37±7* 63±3* 46±12* 46±30*  23±12 29±6 19±10 
IL-1β  6±2 7±3  26±9  311±68*
  366±18*  7±2 0.7±0.7 n.d. 
  0.5±0.5
+  n.d. 
IL-2  45±12 n.d.  62±42*  n.d.  134± 6*
  94±31* 79±18* 13±5
+  22±4 38±13 
IL-4  1.0±0.3 1.0±  0.7 3.0±0.8 5.0±0.9  14±1*
  18±11*  n.d. n.d. n.d. 
  n.d. 
IL-5  9±2 11±3 8±3 16±2  50±4* 90±24* 105±38*  11± 3  61±19  62±42 
IL-6  11±2 16±4  58±23  901±211* 2552±250* 2349±125* 168±76*  5±2  75±19*
,+  24±8 
IL-10  5±1 11±3  25±8  419±134* 495±56* 186±65* 186±63*  n.d. n.d.    n.d. 
IL-12  180±15 201±26 191±21  1068±328* 6982±500* 5302±1687* 4411±1431*  174±60  190±71
+ 173±21
+ 
IFN-γ  0.1±0.1 n.d.  n.d. 0.1±0.1  2.0±0.2  10±3* 14±5*  0.1±0.1  0.3±0.2
+ 0.2±0.2
+ 
TNF-α  8±2 80±33  205±47  2103±522* 2301±174* 243±78*  44±13 2±1  4±2
+  13±8 123 
4.3.7 Expression of TLR-9 in Human Adrenal Glands 
After characterizing the expression of TLR-9 in murine adrenal glands, it was of great interest 
to determine the expression of this receptor in the human adrenal gland. Here, we demonstrate 
for the first time by immunostaining the existence of TLR-9 in human adrenal glands. Normal 
human foetal and adult adrenal glands revealed TLR-9 expression in the adrenal cortex, but 
not in the adrenal medulla. As depicted in Fig. 36A, there was no detectable staining for TLR-
9 detectable when the adrenal sections were stained without the specific TLR-9 antibody 
(negative control). Like in mouse adrenal glands, there was a staining of TLR-9 in zona 
fasciculata of both foetal (Fig. 36B) and adult (Fig. 36C) adrenal glands indicating 
constitutive expression of TLR-9.  
 
 
 
 
 
 
 
 
 
Figure 36: Expression of TLR-9 in human adrenal glands. (A) Negative control, (B) TLR-9 positive staining in foetal and 
(C) adult adrenal glands in the adrenal cortex (particularly in zona fasciculata, but not in adrenal medulla). Overview, 10x 
magnification; sectionings of zona fasciculata, 40x magnification. Results were obtained in 3 independent experiments. 
x10  40x  x10  x10  40x  40x 
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5 Discussion  
5.1 TLR-2 Study  
In this study, we have demonstrated that TLR-2 is expressed in murine adrenal glands under 
basal conditions. Treatment of animals with a non-lethal dose of LPS or LTA (over a 24 h 
period) leads to time-dependent increases of TLR-2 expression. Several studies have reported 
that TLR-2 mediates LPS-responsiveness (Kirschning et al. 1998;Matsuguchi et al. 
2000;Yang et al. 1998). However, the transcriptional regulation of TLR-2 in response to 
gram-negative bacteria has not been fully elucidated. Increased TLR-2 expression in response 
to LPS has been observed in brain, heart, lung, liver and skeletal muscle (Lang et al. 
2003;Matsumura et al. 2000). LPS induces transcription of NF-κB, which leads to expression 
of inflammatory gene products, including cytokines (Mackman et al. 1991;Vincenti et al. 
1992). Matsuguchi and colleagues demonstrated that an elevation in LPS-mediated TLR-2 
mRNA was significantly impaired when NF-κB activation was inhibited by curcumin 
(Matsuguchi et al. 2000). These observations suggest that LPS-induced up-regulation of TLR-
2 expression is mediated by NF-κB activation. Furthermore, a study from Oshikawa and co-
workers hypothesized that TLR-2 up-regulation in alveolar macrophages following bacterial 
respiratory infections (e.g. LPS) may render the lung responsive to TLR-2 ligands. In 
addition, its up-regulation may contribute to the accelerated macrophage response seen at 
subsequent stages of infection, both of which may enhance the innate immunity against 
pathogens (Oshikawa and Sugiyama 2003). It is possible that after its own activation, TLR-4 
promotes the activation of other TLRs and thus improves the host’s defence against 
pathogens. In fact, it has been shown in adiopocytes activation of TLR-4 with LPS also 
results in induction of TLR-2 expression (Lin et al. 2000). Therefore in our study, LPS could 
have altered the expression of TLR-2 through a downstream mechanism, warranting further 
study. One further possible explanation could be that our LPS preparation could have been 
contaminated with TLR-2 ligands (Hirschfeld et al. 2000;Lee et al. 2002).  
 
Furthermore, we show that TLR-2 was present in human adrenal NCI-H295 cells. This work 
was completed by the finding that TLR-2 is also expressed in human glands (Bornstein et al. 
2004b). The presence of TLR-2 in adrenal glands may suggest a role for this receptor in the 
HPA-axis. Absence of TLR-2 in mice results in an enlargement of the adrenal gland, which is 
correlated to the elevation of plasma ACTH in TLR-2
-/- mice. Only the adrenal cortex of TLR-125 
2
-/- animals showed increased adrenal gland size, which may due to the prolonged release of 
ACTH from the pituitary, presumably to cope with a greater need for glucocorticoid 
production in adrenal cortex (Simpson and Waterman 1988). At the same time, the 
corticosterone levels in TLR-2
-/- mice were reduced, which suggest a possible impairment of 
the HPA-axis at the level of the adrenal gland and even during basal conditions. Our 
ultrastructural analysis of adrenocortical cells indicates that TLR-2
-/- mice also have marked 
changes at the level of the plasma membrane with unusual interdigitations and infoldings of 
cell membranes. 
Adrenal glands have an astonishing ability to adapt to physiological stressors or diseases, with 
extensive hypervascularization, zonal transformations, cellular hyperplasia and rapid hormone 
release (Bornstein et al. 1992). Glucocorticoids (e.g. cortisol, corticosterone) are powerful 
anti-inflammatory compounds that have the ability to inhibit all stages of the inflammatory 
response. Thus, they play an important role in the modulation and suppression of the acute 
stress response (Munck et al. 1984). Glucocorticoids produce their effect by binding to 
glucocorticoid receptors inside the cell and forming a complex, which then moves to the 
nucleus, where it can directly or indirectly regulate the transcription of anti-inflammatory 
genes (Karin 1998). But it seems highly unlikely that the widespread anti-inflammatory 
actions of glucocorticoids can be explained by increased transcription of a small number of 
anti-inflammatory genes, such as annexin-1, IL-10 and IκBα (inhibitor of NF-κB). However, 
therapeutic doses of inhaled glucocorticoids do not increase annexin-1 concentrations in 
bronchoalveolar lavage fluid (Hall et al. 1999), and an increase in IκBα does not occur in 
most cell types (Heck et al. 1997).  
 
Under basal conditions, impairment of adrenal structure and function in TLR-2
-/- mice was 
only minimal and did not compromise the viability of the animals. However, an appropriate 
adrenal glucocorticoid response to inflammatory stimuli is critical for the organism to cope 
with disease. Therefore, we evaluated the adrenal stress response following activation of the 
HPA-axis by bacterial ligands, including LPS and LTA. Despite the fact that glucocorticoids 
induce gene transcription, the major anti-inflammatory effects of glucocorticoids are through 
suppression of inflammatory and immune genes, including cytokines such as TNF-α, IL-1β 
and IL-6 (Besedovsky and Del 1996;Wilckens and De 1997). The inhibitory effect of 
glucocorticoids appears to be due to the interaction between the activated glucocorticoid 
receptors and the transcription factors like NF-κB and activator protein-1, which mediate the 
expression of these inflammatory genes (Karin 1998;Konig et al. 1992;Ma et al. 126 
2004;Scheinman et al. 1995;Yang-Yen et al. 1990). It has been known that there are cross-
talks between the immune and endocrine system during acute infection, which is vital for 
homeostasis. Recent evidence indicates that after an inflammatory stimulus, the release of 
inflammatory cytokines (IL-1β, IL-6 and TNF-α) from immune cells or fibroblasts is impaired 
in TLR-2
-/- mice (Darville et al. 2003;Kurt-Jones et al. 2004). It is well established that LPS is 
a potent activator of the HPA-axis (Beishuizen and Thijs 2003;Takemura et al. 1997). 
Therefore, we investigated the effect of LPS on the adrenal response. Interestingly, in the 
absence of TLR-2, the systemic response to LPS resulted in an impaired release of IL-1. 
Plasma levels of IL-6 and TNF-α were elevated after LPS treatment, although somewhat 
attenuated in TLR-2
-/- animals. This finding was further supported by the fact that local 
adrenal expression of all three cytokines was significantly less after LPS stimulation when 
compared to WT animals. 
 
Impaired IL-1 response in TLR-2
-/- animals after exposure to LPS indicates an impairment of 
the HPA-axis, as it is a principal pro-inflammatory cytokine required for innate immunity 
(Suzuki et al. 2002). IL-1 can activate the HPA-axis at the central as well as the peripheral 
level (Chrousos 1995;Gonzalez-Hernandez et al. 1995). It has been reported that IL-1β has 
the ability to induce corticosterone in two ways: First, the cytokine can enter into the central 
nervous system and stimulate the HPA-axis, resulting in the release of ACTH and 
corticosterone (Parsadaniantz et al. 2000). Second, IL-1β can trigger adrenal corticosterone, 
either directly via IL-1 receptor (Mazzocchi et al. 1998;Nagano et al. 2000) or indirectly with 
the local release of catecholamines (Gwosdow 1995). These pathways may function 
independently of CRH (Sapolsky et al. 1987) or ACTH (Parsadaniantz et al. 2000) and thus 
be independent of the HPA-axis. Since LPS induces the synthesis and secretion of IL-1 (Laye 
et al. 2000), it has been proposed that IL-1 is the primary endogenous cytokine in the response 
to LPS. However, no significant alterations in plasma ACTH or corticosterone have been 
observed with the use of IL-1-receptor antagonist following LPS exposure (Dunn 2000). 
Hence, a blunted IL-1 response after LPS treatment in TLR-2
-/- mice may not be the primary 
mechanism responsible for the impaired adrenal release of glucocorticoids.  
Like IL-1, TNF-α is also an immune mediator which stimulates the HPA-axis during stress, 
increasing glucocorticoids and thus causing a decrease in the immune response. However, 
cytokines also suppress the HPA-axis. For instance TNF-α impairs ACTH release following 
CRH stimulation (Bateman et al. 1989;Gaillard et al. 1990). A number of clinical studies have 
reported low ACTH levels in patients with severe sepsis and SIRS (Bateman et al. 127 
1989;Richards et al. 1999;Soni et al. 1995). Furthermore, TNF-α has been demonstrated to 
inhibit adrenal gland function (Jaattela et al. 1991;Zhu and Solomon 1992). It reduces adrenal 
cortisol synthesis by inhibiting the stimulatory action of ACTH on adrenal cells (Jaattela et al. 
1990;Jaattela et al. 1991). Similarly, TNF-α has been shown to have a direct inhibitory effect 
on adrenal cells. Therefore, an impaired TNF-α response would then be expected to lead to an 
increase in corticosterone levels in TLR-2
-/- mice rather than a blunted response that was 
observed in this study.  
IL-6 is a potent stimulator of the HPA-axis during immune activation. After systemic immune 
induction by LPS, IL-6 enhances corticosterone release in mice in a CRH-independent way 
(Bethin et al. 2000). In the present study, we demonstrated that IL-6 is expressed in the 
adrenal cortex. Furthermore, Path and colleagues have shown that IL-6 receptor is present on 
the human adrenal gland and in adrenal cell cultures (Path et al. 1997). As the IL-6 receptor is 
expressed on adrenocortical cells, IL-6 may act directly on glucocorticoid synthesis via its 
receptor. There is increasing evidence that regulation of adrenal steroidogenesis may happen 
independently of the CRH/ACTH-axis (Chrousos 1995). Several studies have pointed out that 
diurnal variations in adrenal steroidogenesis do not seem to be directly related to plasma 
ACTH (Fehm et al. 1984a;Fehm et al. 1984b). After long-term administration of IL-6, plasma 
ACTH levels decrease, whereas cortisol levels remain high (Mastorakos et al. 1993;Spath-
Schwalbe et al. 1994). Glucocorticoids are able to inhibit cytokine-induced ACTH release by 
acting at the hypothalamic level (Cambronero et al. 1989). Therefore, impairment of ACTH 
after an enduring challenge of IL-6 may be the result of inhibiting cortisol feedback 
mechanisms. The data in this study may also suggest a direct effect of IL-6 on the adrenal 
cortex.  
 
In conclusion, there is an impairment of both systemic and local cytokine secretion, which 
would explain the significant attenuation of the HPA-axis in TLR-2
-/- mice upon exposure to 
bacterial ligands. Nevertheless, we cannot exclude the fact that some of the effects observed 
in our study after LPS challenges are due to a contamination with lipopeptides. Recently, 
several studies reported contaminations of commercial LPS preparations with lipopeptides or 
lipoproteins (Hirschfeld et al. 2000;Lee et al. 2002;Tapping et al. 2000). It was demonstrated 
that modified phenol extraction of LPS eliminated TLR-2 mediated activity, and thus they 
concluded that components other than LPS were responsible for TLR-2 signalling (Hirschfeld 
et al. 2000;Tapping et al. 2000). Furthermore, Lee and colleagues investigated two 
lipoproteins isolated from Escherichia coli, lip12 and lip19, which were responsible for TLR-128 
2 mediated cell activation despite being major components in a LPS preparation (Lee et al. 
2002).  
The same investigations were performed by treating animals with LTA, a classic ligand for 
TLR-2 and a cell wall component of gram-positive bacteria. A significant impairment in 
adrenal glucocorticoid release after LTA stimulation was observed. Interestingly, this ligand 
significantly suppressed plasma corticosterone in TLR-2
-/- mice 6 h after administration, in 
contrast to 24 h in WT animals. For future experiments, a higher dose of LTA should be used 
and therefore may elicit more prominent effects. In the current experiments, because there 
was no significant impairment at the pituitary level, the impaired glucocorticoid response 
suggests a direct action at the level of the adrenal gland.  
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5.2 TLR-4 Study  
In the present study, we show for the first time that TLR-4 is expressed in adrenal glands of 
WT mice. Under normal physiological conditions, the adrenal gland is bigger in TLR-4
-/- 
mice than in WT animals, which is due to the enlargement of the adrenal cortex. The 
enlargement of the adrenal glands in TLR-4
-/- mice could represent a compensatory 
mechanism to maintain basal corticosterone release despite impaired adrenocortical function. 
One could also debate that the altered structure of the adrenal glands reflects the enhanced 
synthesis and release of corticosterone in TLR-4
-/- mice. Nevertheless, it is possible that 
increased cytokine levels in TLR-4
-/- mice stimulate directly the adrenal cortex to liberate 
corticosterone. 
At the ultra-structural level of the adrenal gland, intact steroidogenesis requires a defined 
spatial and conformational arrangement of mitochondria and their cristae, enabling optimal 
electron transfer and cytochrome P450 activity. The mitochondrial cristae of steroid 
producing cells are organized in a tubulovesicular pattern. However, electron microscopy 
revealed that in TLR-4
-/-  mice, adrenocortical cells exhibit mitochondria with lamellar 
membranes or central dilatations. Adrenocortical cells of TLR-4
-/- mice show a marked 
reduction of liposomes, which may result in a rapid exhaustion of the adrenal lipid reserves 
upon a massive stress stimulus like endotoxemia. Thus, these ultra-structural changes may 
provide an explanation for the innate defect of steroidogenesis in TLR-4
-/- mice and their 
inability to respond adequately to external stimuli. 
Furthermore, under physiological conditions the basal plasma corticosterone was significantly 
higher in TLR-4
-/- mice, whereas ACTH levels were similar in both animal groups, WT and 
TLR-4
-/-. The elevated corticosterone levels indicate that these adrenals were being driven by 
some stimuli. Negative feedback of the elevated levels of corticosterone caused ACTH levels 
returned to nearly normal. However in TLR-2
-/- mice, where an enlarged adrenal cortex was 
observed, corticosterone levels were suppressed (see chapter TLR-2 study). On the other 
hand, increased basal corticosterone levels in TLR-4
-/- mice may also be due to increased 
basal levels of IL-12 and TNF-α. 
 
The functional role of TLR-4 in murine adrenal glands was studied during inflammation. To 
mimic the clinical conditions of SIRS, a low-dose of LPS (1 mg/kg) was used. Crude LPS 
preparations are often contaminated with TLR-2 ligands such as lipopeptides (Hirschfeld et 
al. 2000;Lee et al. 2002). Therefore, it is possible that earlier observations reported using 130 
crude LPS preparations may have been due to the activation of TLR-2 and TLR-4 signalling. 
To exclude these doubts, we used two different LPS preparations and compared their effects 
on the adrenal response in WT and TLR-4
-/- mice. By using a chemiluminescence assay, we 
demonstrated that the purified pLPS preparation only activated TLR-4, whereas the crude 
LPS preparation stimulated both receptors, TLR-4 and TLR-2. These results indicated that 
cLPS was indeed contaminated with TLR-2 ligands and therefore not specific for TLR-4.  
 
In WT animals, both preparations of LPS elicited a significant effect on plasma corticosterone 
levels within the first 6 h, however, no effect was observed in TLR-4
-/- mice. In these mice, an 
inadequate response of corticosterone to pLPS might due to the absence of TLR-4 signalling. 
After treatment with cLPS, the lack of response to adrenal corticosterone could also have 
been due to the abolished activation of IL-1β, IL-6 and TNF-α. These cytokines are released 
by peripheral immune cells in response to an endotoxin exposure, and through the activation 
of the HPA-axis, they regulate the corticosterone liberation (van der Meer et al. 1995;van der 
Meer et al. 1996). Another possible explanation for the unresponsiveness to LPS could 
ascribe to the fact that plasma corticosterone is already elevated in saline-treated TLR-4
-/- 
animals, so that corticosterone release is already exhausted even before stimulation with LPS. 
In contrast to corticosterone, basal ACTH remained unaltered in TLR-4
-/- mice. Furthermore, 
unlike cLPS, pLPS did not affect pituitary ACTH release in WT animals, suggesting that a 
low dose of pLPS elicits its effects directly on the adrenal gland through the activation of 
TLR-4. At the pituitary level, cLPS-induced effects on ACTH release could have been 
mediated by TLR-4 and TLR-2, and thus confirm the contamination of the cLPS preparation 
with TLR-2 agonists.  
 
Over the past few years, it has become evident that the adrenal gland is the main effector 
organ of the HPA-axis, and a major site for both the synthesis and action of numerous 
cytokines (Bornstein and Chrousos 1999). Various studies suggest that IL-6, either alone or in 
combination with other cytokines, is involved in many responses observed after LPS 
administration, including the activation of the HPA-axis (Lenczowski et al. 1997). Peripheral 
LPS may alter pituitary function indirectly by stimulating the secretion of hypothalamic 
hormones and neurotransmitters, which in turn modulate the secretion of pituitary hormones. 
Moreover, LPS may directly induce cytokines in the pituitary where they could act as 
autocrine or paracrine signals (Whiteside et al. 1999). It has been shown that immune 
activation of the adrenal gland by LPS is thought to occur by cytokine stimulation of CRH 131 
production in the hypothalamus, which in turn stimulates the secretion of ACTH from the 
pituitary (Beishuizen and Thijs 2003;Gadek-Michalska and Bugajski 2004;Watanobe and 
Yoneda 2003). Binding of LPS directly to adrenal cells has been also reported (Enriquez de et 
al. 2000). Furthermore, another study has shown that LPS can act directly on human adrenal 
cells, and this direct effect leads to the stimulation of cortisol secretion (Vakharia et al. 2002). 
Cytokines secreted by bacterial endotoxin-activated immune cells stimulate the HPA-axis, 
especially IL-1, IL-6 and TNF-α (Perlstein et al. 1993;Rivier et al. 1989). Immune cells 
including macrophages, monocytes, dendritic cells, mast cells and lymphocytes are located 
within the adrenal cortex. Macrophages are mostly located in the inner adrenocortical zone 
and express TNF-α (Gonzalez-Hernandez et al. 1996), IL-1β (Gonzalez-Hernandez et al. 
1995) and IL-6 (Path et al. 1997). These cytokines influence adrenal function by exerting 
stimulatory or inhibitory effects (Judd 1998;Marx et al. 1998). Similarly, LPS-stimulated 
macrophages stimulate or inhibit glucocorticoid biosynthesis by human adrenocortical cells 
and may participate in a local immune-adrenal regulation. Adrenocortical cells themselves 
synthesize several cytokines. The distribution of the expression of these cytokines varies in a 
species-specific manner. In rats, high amounts of cytokines have been detected in the zona 
glomerulosa (Judd 1998), whereas in humans the main site of cytokine production is the inner 
zona reticularis (Gonzalez-Hernandez et al. 1994;Gonzalez-Hernandez et al. 1995;Gonzalez-
Hernandez et al. 1996). In mice, studies indicate that potent activators of hormone synthesis 
like ACTH in the adrenal cortex induce IL-6 secretion, whereas TNF-α release is inhibited by 
ACTH (Judd 1998). The discovery of inhibitory factor expression in the rat adrenal may 
provide an explanation for the ability of adrenal lymphocytes to secrete these inflammatory 
cytokines in the presence of local glucocorticoids (Bacher et al. 1997). Most of the cytokines 
shown to be produced in the adrenal cortex are able to exert direct effects on adrenocortical 
cells (Judd 1998;Marx et al. 1998). These include effects on growth and differentiation of the 
adrenocortical cells. In particular the inflammatory cytokines TNF-α, IL-1β and IL-6, all 
seem to play a role in local immune-adrenal regulation. In vivo, IL-1β induced corticosteroid 
biosynthesis independently of ACTH and caused glucocorticoid secretion in 
hypophysectomized rats (Andreis et al. 1991), perfused rat adrenals (Roh et al. 1987) and 
dispersed human adrenal cells (Whitcomb et al. 1988). Recombinant human IL-6 also 
increased the secretion of cortisol and adrenal androgens in humans both via ACTH and 
directly (Path et al. 1997). TNF-α inhibited the secretion of aldosterone from rat adrenal cells 132 
(Natarajan et al. 1989), whereas in human foetal adrenal cells, it decreased both basal and 
ACTH-stimulated cortisol production.  
These findings suggest a key role for the adrenal gland and cytokines in the regulation of the 
HPA-axis. Therefore, the next step was to determine plasma levels of different cytokines 
under normal and pathological conditions. As mentioned, basal plasma levels of IL-1β, IL-12 
and TNF-α are elevated in TLR-4
-/- mice. However, elevation of these cytokines did not 
change the basal release of ACTH from the pituitary. In rats, IL-1β, IL-12 and TNF-α are 
expressed in the pituitary and adrenal gland after stimulation with a crude LPS preparation 
(Chen et al. 2005). Therefore, it is not surprising that after 6 h of cLPS stimulation, all plasma 
cytokines were raised in WT mice indicating an inflammatory response. Additionally, IL-10, 
which is recognized as a regulator of the HPA-axis (Smith et al. 1999), was elevated after a 
cLPS stimulus in WT animals. In contrast, pLPS had no effect in WT mice indicating that 
TLR-2 signalling contribute to the activation of these cytokines. This is supported by the 
previous study with TLR-2, demonstrating that plasma levels of IL-1β and TNF-α are 
decreased in TLR-2
-/- mice, but not completely suppressed after cLPS stimulation (see chapter 
TLR-2 study).  
LPS is known as an activator of NF-κB, which leads to expression of different inflammatory 
genes such as cytokines (Vincenti et al. 1992). Bauer et al. (2005) demonstrated that NF-κB 
activity was markedly decreased in TLR-4
-/- mice in comparison with WT mice in response to 
an antioxidant (butylated hydroxytoluene). Furthermore, another study on TLR-4 in cardiac 
myocytes has shown that NF-κB was upregulated after LPS administration in WT control 
mice in comparison with non-functional TLR-4 mice (Baumgarten et al. 2006). Therefore, to 
confirm the role of TLR-4 signalling in adrenal stress response to LPS, NF-κB activation was 
also determined in this study. Our results show that pLPS and cLPS caused an induction of 
NF-κB activity in WT mice after 1 h, which was markedly impaired in TLR-4
-/- mice. These 
results are consistent with previous findings, revealing an impairment of NF-κB induction 
after LPS treatment in TLR-4
-/- mice. 
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5.3 TLR-9 Study 
Here, we demonstrate for the first time that TLR-9 mRNA and protein are present in the 
murine adrenal gland. In order to study TLR-9 expression in vivo, tissue samples from 
healthy, non-treated animals (normal leukocyte blood count) were taken. Since histology of 
the adrenal gland revealed only a small number of leukocytes present in this organ, it can be 
excluded that adrenal TLR-9 mRNA and protein determined by PCR and Western Blot 
analysis was leukocyte-derived. TLR-9 was also detected in the human adrenal cortex. These 
findings are in line with a previous report that TLR-9 mRNA is expressed in human adrenal 
glands (Nishimura and Naito 2005). Additionally, it has been shown that TLR-9 is present in 
different organs, e.g. spleen, kidney, liver, lung and brain (Martin-Armas et al. 2006;Ono et 
al. 2004) and in various human tissue (Droemann et al. 2005;Nishimura and Naito 2005). 
However, the role and function of TLR-9 in the adrenal gland has not been studied. 
Furthermore, we looked into adrenal morphology and function in WT and TLR-9
-/- mice 
under control physiological conditions. Here, neither adrenal size nor plasma corticosterone 
or ACTH differed between animals. This is in contrast to our previous findings, where TLR-2 
or TLR-4 deficient mice demonstrated marked differences in the above parameters when 
compared to WT animals (see chapters TLR-2 and TLR-4 studies). Although baseline 
function was abnormal in TLR-2 and TLR-4 mice, this did not influence the phenotypes of 
each strain. Therefore, we were interested in studying the role of TLR-9 in mice under 
conditions of inflammation, where appropriate adrenal function is very important for 
combating disease. 
 
In a SIRS model, we investigated the effects of systemic inflammation using the TLR-9 
agonist CpG-ODN on the HPA-axis in WT and TLR-9
-/- mice. CpG-ODN caused a three-fold 
increase in levels of corticosterone in WT mice, comparable to the effects of LPS in a similar 
model (see chapter TLR-4 study). CpG-ODN-induced effect was absent in TLR-9
-/- mice 
indicating that TLR-9 contributed either directly or indirectly to this hormonal response.  
CpG-ODN had no effect on plasma levels of ACTH, either in WT or in TLR-9
-/- mice. 
Although this fits with the lack of expression of TLR-9 in the murine pituitary gland (Ono et 
al. 2004) we cannot exclude a small indirect (IL-6 driven) stimulatory effect in WT mice. The 
HPA-axis can be influenced by both pituitary (ACTH) and extra-pituitary mechanisms 
(Gloddek et al. 2001b;Suzuki et al. 1986a;Gloddek et al. 2001a;Suzuki et al. 1986b). For 
example, LPS increases ACTH and corticosterone plasma levels (Watanobe and Yoneda 134 
2003) as well as the release of various cytokines. The latter fact mediates the production of 
CRH in the hypothalamus. In turn, CRH stimulates the release of ACTH from the pituitary 
gland, which then increases glucocorticoid synthesis in the adrenal gland (Reincke et al. 
1993). Based on our in vivo results, one could argue that corticosterone production was 
mediated by an extra-pituitary mechanism. 
 
CpG-ODN challenge did not affect the expression of TLR-9 mRNA and protein in adrenal 
glands of WT mice. One of the reasons could be the dose of CpG-ODN administered (1 
nmol/g). Several studies on the distribution of phosphorothioate oligodeoxynucleotides in 
rodents have shown that the majority of intravenously injected phosphorothioate 
oligodeoxynucleotides (96%) are cleared from the circulation as a result of rapid 
redistribution over the body fluid (Rifai et al. 1996). It has been demonstrated that 4 min after 
injection, 50% of 
125I-CpGs were eliminated from the blood stream with a very high uptake in 
liver and kidney (Butler et al. 1997;Martin-Armas et al. 2006;Peng et al. 2001;Rifai et al. 
1996). These data suggest that the amount of CpG-ODN reaching the mouse adrenal gland is 
probably too low to affect the expression of TLR-9. 
 
CpG-ODN treatment was associated with high plasma levels of corticosterone and various 
cytokines in mice. We profiled the cytokine expression (following a CpG-ODN challenge) in 
the mouse every 15 min for the first hour and than at 2 and 6 h, thereafter. Interestingly, most 
cytokines were already significantly up-regulated after 45-60 min (see time-course in Table 
16). Inflammatory cytokines, such as IL-1, IL-6 and TNF-α have been identified as important 
modulators of HPA-axis function (Bornstein and Chrousos 1999;Chrousos 1995). Plasma 
levels of these three cytokines were increased by more than 10-fold compared to baseline 
supporting the concept of cytokine-mediated high glucocorticoid output and a change from 
neuron-endocrine to immune-endocrine function (Bornstein et al. 2004a). There is good 
evidence that CpG-ODN leads in vitro as well as in vivo to stimulation of immune competent 
cells resulting in the release of various cytokines (Anitescu et al. 1997;Hong et al. 
2004;Kadowaki et al. 2001;Sparwasser et al. 1997;Stacey et al. 1996). In a model of CpG-
DNA induced liver injury (D-GalN-sensitized mice), the pro-inflammatory cytokines IL-1β, 
IL-6, IL-12 and TNF-α were generated within 1 h (Yi et al. 2006). However after 4 h, levels 
of these cytokines returned back to baseline. These findings correspond to our observation in 
WT mice (see Table 16). Cytokine levels were significantly increased between 45-60 min. 
After 2 h, levels of IL-1β, IL-6 and TNF-α declined to baseline, and only levels of IL-12 135 
remained high. We cannot exclude whether the cytokine profile measured in this study was at 
least in part due to CpG-ODN-induced liver injury. 
 
TLR-9 is somehow involved in the adrenal stress response following a CpG-ODN challenge. 
Absence of TLR-9 abolishes the corticosterone and cytokine response supporting the concept 
that CpG-ODN mediates its effects on adrenal cells via TLR-9. However, this does not appear 
to compromise the phenotype of TLR-9
-/- mice. Whether this effect is mediated directly (via 
adrenal TLR-9), indirectly (via blood-derived TLR-9 and consequently cytokine release) or 
by a combination of both pathways, remains open for further study. However, we have at least 
strong evidence for a direct effect (30% increases in adrenal NF-κB activity after 30 min, 
significant plasma cytokine response after 45 min and significant corticosterone levels were 
detectable at 120 min). Taken together with our previous findings, TLR-9 activation 
contributes to an endocrine stress system response. 136 
6 Perspective 
According to the present findings, TLR-2, TLR-4 and TLR-9 are expressed in murine as well 
as in human adrenal glands. The presence of these TLRs in this endocrine organ suggests a 
potential role in HPA-axis function. Thus, they may constitute an important link between the 
innate immune and endocrine systems at two different levels, central as well as peripheral, 
particularly during inflammatory conditions. Our study with TLR-deficient mice shows that 
the absence of TLR-2 and TLR-4, but not TLR-9 leads to altered adrenal morphology. These 
alterations do not appear to compromise the phenotype of TLR-2
-/- and TLR-4
-/- mice. 
Moreover, TLR-2, 4 and 9 deficient animals were not able to respond adequately to 
inflammatory stress induced by their potential ligands LPS, LTA or CpG-ODN, respectively. 
These impaired adrenal stress responses appear to be associated with decreases in systemic 
and intra-adrenal cytokine expressions. In conclusion, TLR-2, TLR-4 and TLR-9 are shown 
to be key players in the immuno-endocrine interactions during inflammatory conditions. 
 
Mutations in the innate immune system are not a rare event and may be the fundamental 
mechanism for an impaired adrenal stress response in patients with sepsis. Several studies 
which are relevant to TLR signalling showed that there is an important link between TLRs 
and human diseases. These studies demonstrate that manipulation of TLR pathways could 
have therapeutic potential for conditions such as hepatitis B and C, anthrax, influenza, HIV, 
allergic rhinitis, asthma, sepsis and various forms of cancer (reviewed by Kanzler et al. 2007). 
Currently, several TLR-based therapeutic agents are developed, e.g. TLR antagonists which 
are structural analogs of TLR-agonists but unable to induce signalling. Other possible 
approaches are antibodies directed against TLRs or small molecule antagonists selected from 
compound libraries. TLR antagonists appear quite promising for a number of inflammatory 
and autoimmune diseases. Two lipid A analogs which act as potent antagonists of TLR-4 
have advanced into clinical trials for sepsis. 
 
Based on the present study, it is of particular interest to clarify whether patients with TLR 
polymorphisms, in particular TLR-2, TLR-4 and TLR-9 polymorphism, have an impaired 
HPA-axis during stress. This could change the current therapy of sepsis, when patient’s 
genotypic profile is known. In summary, understanding of the relationships between TLR 
signalling pathways, related polymorphisms and severe diseases is of particular interest for 
development of new encouraging therapies. 137 
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